Rapid tyrosine phosphorylation of key cellular proteins is a crucial event in the transduction of activation signals to T-lymphocytes.	6	14	AMINO_ACID
Even a moderate increase in the cellular cysteine supply elevates the intracellular glutathione (GSH) and glutathione disulfide (GSSG) levels and potentiates immunological functions of lymphocytes in vitro.	41	49	AMINO_ACID
We have examined the effects of N-acetyl-L-cysteine (NAC), a well-characterized, thiol-containing antioxidant, on agonist-induced monocytic cell adhesion to endothelial cells (EC).	32	51	AMINO_ACID
We have examined the effects of N-acetyl-L-cysteine (NAC), a well-characterized, thiol-containing antioxidant, on agonist-induced monocytic cell adhesion to endothelial cells (EC).	53	56	AMINO_ACID
Ligand-induced tyrosine phosphorylation of the STATs promotes their homodimer and heterodimer formation and subsequent nuclear translocation.	15	23	AMINO_ACID
Activation of cytoplasmic tyrosine kinases is an important aspect of signal transduction mediated by integrins.	26	34	AMINO_ACID
N-acetyl-L-cysteine (NAC) is an antioxidant molecule endowed with immunomodulatory properties.	0	19	AMINO_ACID
N-acetyl-L-cysteine (NAC) is an antioxidant molecule endowed with immunomodulatory properties.	21	24	AMINO_ACID
To investigate the effect of NAC on the induction phase of T cell responses, we analyzed its action on human dendritic cells (DC) derived from adherent PBMC cultured with IL-4 and granulocyte-macrophage CSF.	29	32	AMINO_ACID
Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries	156	182	ANALYTICAL_METHOD
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	15	52	ANALYTICAL_METHOD
"009, logistic regression), when comparing \""best\"" and \""worst\"" risk groups"	5	24	ANALYTICAL_METHOD
Results were assessed by Cox model for survival and by logistic regression for response and toxicity	25	34	ANALYTICAL_METHOD
Results were assessed by Cox model for survival and by logistic regression for response and toxicity	55	74	ANALYTICAL_METHOD
Logistic regression was applied to assess CYP2C19 polymorphism as an effect modifier of cyclophosphamide	0	19	ANALYTICAL_METHOD
These models were evaluated within the PLATO software package using pair wise logistic regression models	68	104	ANALYTICAL_METHOD
Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with regular use of NSAIDs and with relevant polymorphisms on ovarian cancer risk	0	31	ANALYTICAL_METHOD
Multivariable unconditional logistic regression estimated the association of NSAID use across stratum of each genotype	0	47	ANALYTICAL_METHOD
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	9	40	ANALYTICAL_METHOD
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	63	100	ANALYTICAL_METHOD
With the wrapper-based feature selection approach, we employed multilayer feedforward neural network (MFNN) and logistic regression as a basis for comparisons	112	131	ANALYTICAL_METHOD
Our data revealed that the MFNN models were superior to the logistic regression model	27	38	ANALYTICAL_METHOD
Our data revealed that the MFNN models were superior to the logistic regression model	60	85	ANALYTICAL_METHOD
Our logistic regression analyses indicated the probability that 76% patients carrying combination of four SNPs will not show favorable response to AAP therapy	4	23	ANALYTICAL_METHOD
A multiple linear regression model revealed that the ABCC3 -211C/T polymorphism was not independently associated with ADP-induced MPA measurements; a multiple logistic regression model revealed that carrying the ABCC3 -211C allele was not associated with the risk of developing an ST event in clopidogrel-treated patients not harbouring CYP2C19*2, *3 and *17 variants	2	28	ANALYTICAL_METHOD
Seven candidate polymorphisms (rs3842 and rs1045642 in ABCB1, rs212091 and rs3743527 in ABCC1, rs3745274 in CYP2B6, rs628031 in SLC22A1 and rs1517618 in SLCO3A1) were evaluated if they were associated with virological failure through logistic regression analysis	234	253	ANALYTICAL_METHOD
Logistic regression including appropriate covariates was performed	0	19	ANALYTICAL_METHOD
1 or less in the univariate analysis were included in a multiple regression analysis (logistic regression for adverse reactions)	56	75	ANALYTICAL_METHOD
1 or less in the univariate analysis were included in a multiple regression analysis (logistic regression for adverse reactions)	86	105	ANALYTICAL_METHOD
6% in the evaluation by means of logistic regression	33	52	ANALYTICAL_METHOD
A multivariate analysis by logistic regression confirmed its significant contribution (p = 0	2	23	ANALYTICAL_METHOD
A multivariate analysis by logistic regression confirmed its significant contribution (p = 0	27	46	ANALYTICAL_METHOD
Multivariate logistic regression revealed that five SNPs (rs11209026 in IL23R, rs10782001 in FBXL19, rs3087243 in CTLA4, rs651630 in SLC12A8 and rs1800453 in TAP1) were associated with paradoxical reactions	0	32	ANALYTICAL_METHOD
Quality control of genome-wide data was performed according to standard criteria and linear/logistic regression models were used as appropriate under an additive hypothesis	85	111	ANALYTICAL_METHOD
Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months	0	28	ANALYTICAL_METHOD
Multiple logistic regression and Cox regression analysis were performed to assess the association of these SNPs with the primary endpoint, which was a composite of transient ischemic attack (TIA), stroke, myocardial infarction, or death within 12 months	33	47	ANALYTICAL_METHOD
A sensitivity analysis of a secondary composite endpoint of TIA, stroke, or death demonstrated a significant trend in multiple logistic regression analysis of CYP2C19 variants, with lower odds of secondary endpoint in patients carrying at least 1 LOF allele (*2, *3, *8) than in wild-type homozygotes (OR 0	127	146	ANALYTICAL_METHOD
Logistic regression model adjusted for sex, risk and treatment phase revealed that ITPA rs1127354 homozygous mutated patients showed an increased risk of severe GI and NEU	0	19	ANALYTICAL_METHOD
Logistic regression was used to test for association between these polymorphisms and treatment response	0	19	ANALYTICAL_METHOD
Multivariate logistic regression analysis revealed that the ABCB1 3435C>T polymorphism and cisplatin dose were significant predictors of CR	0	32	ANALYTICAL_METHOD
In a binary logistic regression analysis the odds ratio (OR) was 8	5	31	ANALYTICAL_METHOD
Association with toxicities was evaluated retrospectively using logistic regression analysis	64	83	ANALYTICAL_METHOD
A non-conditional logistic regression was used to identify the factors associated with hepatotoxicity	2	37	ANALYTICAL_METHOD
Multivariate logistic regression analysis was used to structure a nomogram	0	32	ANALYTICAL_METHOD
Univariate and multivariate statistical analysis by logistic regression revealed 10 SNPs associated with severe adverse reactions to capecitabine (P<0	52	71	ANALYTICAL_METHOD
The relation of SOCS1-1478 CA/del polymorphism to PCOS status and insulin resistance was analysed via logistic regression analysis	102	121	ANALYTICAL_METHOD
Odds ratios for HLA alleles and KIR types and HLA*KIR interactions using conditional logistic regressions were determined in the overall population and by race/ethnicity	73	105	ANALYTICAL_METHOD
The genetic associations were tested using logistic regression analyses	43	62	ANALYTICAL_METHOD
Logistic regression analysis showed that the dose of metoprolol and the genotypes of <i>CYP2D6</i> were predictors of heart rate\u00a0<70\u00a0beats/min in these patients	0	19	ANALYTICAL_METHOD
Linear regression was performed for baseline weight and BMI <i>z</i>, while change in BMI <i>z</i> was assessed using random effects ordered logistic regression	0	17	ANALYTICAL_METHOD
Linear regression was performed for baseline weight and BMI <i>z</i>, while change in BMI <i>z</i> was assessed using random effects ordered logistic regression	118	161	ANALYTICAL_METHOD
Next, binary logistic regression was applied to evaluate the association of the PGSs to SSRIs treatment response in a discovery sample (ISPC, N\u2009=\u2009865), and in a replication cohort (STAR*D, N\u2009=\u20091,878)	6	32	ANALYTICAL_METHOD
<b>Conclusions:</b> This study did identify associations between <i>CHRM2</i> variations and TD; the results of logistic regression analysis with covariates suggest that the association is, however, likely to be secondary to other concomitant factors	112	131	ANALYTICAL_METHOD
2) and clinical conditions in relation to severe (III-IV) adverse drug reactions (ADRs), stepwise forward multivariate logistic regression analyses were performed	119	138	ANALYTICAL_METHOD
Moreover, the multinomial logistic regression analysis showed that SNP genotypes within the <i>SLC22A1</i>, <i>SLC22A2</i>, and <i>SLC22A3</i> genes, body mass index (BMI) and age of diagnosis were significantly associated with glycemic control (<i>p</i> < 0	26	45	ANALYTICAL_METHOD
Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively	0	23	ANALYTICAL_METHOD
Cox proportional hazard and logistic regression were used to estimate risk predictors of toxicity and reduced RDI, respectively	28	47	ANALYTICAL_METHOD
The three top scoring SNPs (rs12248560, rs878567, rs17710780) were subsequently combined into an unweighted GRS, which was included in linear and logistic regression models using the CES-D score, occurrence of a major depressive episode (MDE) during follow-up and regular antidepressant treatment during the 6 months preceding follow-up assessment as outcomes	146	165	ANALYTICAL_METHOD
Linear and logistic regression analyses were used to assess predictors of withdrawal symptomatology	11	30	ANALYTICAL_METHOD
Logistic regression analysis showed that high SAMe-TT<sub>2</sub>R<sub>2</sub> score was the only statistically significant predicting factor of poor INR control (odds ratio (OR) 5	0	19	ANALYTICAL_METHOD
Cox and logistic regression models with Elastic net penalty were employed	0	3	ANALYTICAL_METHOD
Cox and logistic regression models with Elastic net penalty were employed	8	27	ANALYTICAL_METHOD
In a logistic regression analysis, higher CYP2C19 activity (OR (95% CI): 4	5	24	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	15	31	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	54	76	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	83	105	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	113	135	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	144	163	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	170	186	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	194	234	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	243	266	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	277	296	ANALYTICAL_METHOD
We used a logistic regression model to identify patient variables that predicted successful enrollment after subjects were contacted and evaluated the reasons that clinical trial eligible subjects refused enrollment	9	29	ANALYTICAL_METHOD
Multivariable logistic regression analysis showed the minor alleles of these three SNPs were associated with lower odds for MRONJ	0	33	ANALYTICAL_METHOD
Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments	166	171	ANALYTICAL_METHOD
Our data revealed that the ensemble predictive algorithm with feature selection (using fewer biomarkers) performed comparably to other predictive algorithms (such as MFNNs and logistic regression) to derive the perplexing relationship between biomarkers and the status of antidepressant treatments	176	196	ANALYTICAL_METHOD
The association between genotypes, alleles and blood pressure response to treatment was determined by conducting multivariate logistic regression model analysis	113	145	ANALYTICAL_METHOD
<b>Methods:</b> We genotyped thirteen tagging and functional SNPs of <i>ABCG2</i> in 1004 patients, and assessed their association with response, toxicity and survival using unconditional logistic regression and Cox proportional hazards regression analyses respectively	188	207	ANALYTICAL_METHOD
<b>Methods:</b> We genotyped thirteen tagging and functional SNPs of <i>ABCG2</i> in 1004 patients, and assessed their association with response, toxicity and survival using unconditional logistic regression and Cox proportional hazards regression analyses respectively	212	247	ANALYTICAL_METHOD
In simulation data with added noises or CFs and in pharmacogenomic data, RePhine demonstrated an improved performance in comparison with three commonly used methods (including Pearson correlation analysis, logistic regression model, and gene set enrichment analysis)	176	195	ANALYTICAL_METHOD
In simulation data with added noises or CFs and in pharmacogenomic data, RePhine demonstrated an improved performance in comparison with three commonly used methods (including Pearson correlation analysis, logistic regression model, and gene set enrichment analysis)	206	225	ANALYTICAL_METHOD
We genotyped 16 polymorphisms in genes for enzymes involved in the folate-methionine pathway and in methotrexate transport, and analysed their association with treatment efficacy and toxicity using classification and regression tree analysis and logistic regression	246	265	ANALYTICAL_METHOD
We constructed the predictive model using logistic regression	42	61	ANALYTICAL_METHOD
Multiple logistic regression was then performed to identify the factors associated with rapid CKD progression	0	28	ANALYTICAL_METHOD
Logistic regression models were used to examine the relationship between chronic pain and clinical and demographic factors	0	19	ANALYTICAL_METHOD
Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression	164	184	ANALYTICAL_METHOD
Five variables (hematocrit, risk classification, dose, SLC19A1 rs2838958, sex) and three variables (SLC19A1 rs2838958, sex, dose) were statistically significant in univariable analysis and, separately, multivariate logistic regression	203	235	ANALYTICAL_METHOD
Logistic regressions were performed between PRSs and non-response or non-remission in six European clinical samples, adjusting for age, sex, baseline symptom severity, recruitment sites, and population stratification	0	20	ANALYTICAL_METHOD
Multivariable logistic regression analyzed the association between one or more gene-x-drug interactions with 90-day readmission	0	33	ANALYTICAL_METHOD
Responses were assessed using multivariable logistic regression	30	63	ANALYTICAL_METHOD
Logistic regression was used for analysis	0	19	ANALYTICAL_METHOD
Multivariable logistic regression analysis was employed to investigate the independent risk factors for bleeding and to develop a risk scoring system	0	33	ANALYTICAL_METHOD
Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes	12	31	ANALYTICAL_METHOD
Employing a logistic regression model with false discovery rate penalization and Kaplan-Meier analyses, we observed significant association between survival rates and metabolizer genes	81	102	ANALYTICAL_METHOD
Logistic regression model was used to analyze the correlation between the <i>CYP2D6</i> phenotype and incidence of adverse events, which were assessed over a 12-week period	0	19	ANALYTICAL_METHOD
In logistic regression model, the overall incidence of adverse events was 1	3	22	ANALYTICAL_METHOD
Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model	79	112	ANALYTICAL_METHOD
Two logistic regression models accounted for two diplotypes in OCT1 and ABCB1, including statistically significant covariates	4	23	ANALYTICAL_METHOD
Our multinomial logistic regression results may benefit future predictive analyses in diabetic populations	4	36	ANALYTICAL_METHOD
Univariate logistic regression demonstrated body mass index (BMI), concomitant use of protease inhibitor (PI), hyperlipidemia, and homozygous C/C SNP rs1059751 of <i>ABCC4</i> gene as predisposing factors of RTD	0	30	ANALYTICAL_METHOD
Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression	60	79	ANALYTICAL_METHOD
Genotypes and failure of anti-TNF drugs were analyzed using Kaplan-Meier curves and Cox logistic regression	84	107	ANALYTICAL_METHOD
Multiple logistic regression analysis identified DRD2 -141C deletion [odds ratio (OR)\u2005=\u20051	0	28	ANALYTICAL_METHOD
Negative binomial regression and logistic regression were used	0	28	ANALYTICAL_METHOD
Negative binomial regression and logistic regression were used	33	52	ANALYTICAL_METHOD
Race, income, employment status, and gene-x-drug interactions were robust in a multivariable logistic regression model	79	112	ANALYTICAL_METHOD
Logistic regression models were fitted to assess the impact of activity scores on symptom improvement and side effects	0	19	ANALYTICAL_METHOD
We conducted logistic regression models to examine the association of genetic variants with CAA/L during acute KD and with persistence >6 weeks using an additive model between cases and 238 controls with no CAA	13	32	ANALYTICAL_METHOD
Genetic association analyses were conducted using the additive model and multivariable logistic regression	0	19	ANALYTICAL_METHOD
Genetic association analyses were conducted using the additive model and multivariable logistic regression	54	68	ANALYTICAL_METHOD
Genetic association analyses were conducted using the additive model and multivariable logistic regression	73	106	ANALYTICAL_METHOD
The Japonica array provides better imputation performance for Japanese individuals than the existing commercially available SNP arrays with both the 1KJPN panel and the International 1000 genomes project panel	183	205	ANALYTICAL_METHOD
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	151	182	ANALYTICAL_METHOD
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	190	207	ANALYTICAL_METHOD
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	222	273	ANALYTICAL_METHOD
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	289	325	ANALYTICAL_METHOD
It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text	69	85	ANALYTICAL_METHOD
It can be replaced by or combined with more advanced methods such as machine learning or natural language processing approaches to further improve the performance of the drug-gene relationship extraction from free text	89	127	ANALYTICAL_METHOD
In this literature-based study, we compared the performances of eight machine learning techniques with those of MLR in a large, racially-diverse cohort	70	86	ANALYTICAL_METHOD
We initiate the study of privacy in pharmacogenetics, wherein machine learning models are used to guide medical treatments based on a patient's genotype and background	62	78	ANALYTICAL_METHOD
Very recently, machine learning regression has been used to investigate how well cancer cell line sensitivity to drugs is predicted depending on the type of molecular profile	15	42	ANALYTICAL_METHOD
R code to facilitate the construction of alternative machine learning models and their validation in the presented benchmark is available at http://ballester	53	69	ANALYTICAL_METHOD
With machine learning and integrated pharmacogenomics and metabolomics, we demonstrate that KA efficacy is not determined by the status of individual genes, but by the quantitative extent of the WE, leading to a therapeutic window in\u00a0vivo	5	21	ANALYTICAL_METHOD
Machine learning models showed that independent SNPs in this pathway predicted TRD with a mean sensitivity of 0	0	16	ANALYTICAL_METHOD
Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine	0	14	ANALYTICAL_METHOD
Deep learning encapsulates a family of machine learning algorithms that has transformed many important subfields of artificial intelligence over the last decade, and has demonstrated breakthrough performance improvements on a wide range of tasks in biomedicine	39	55	ANALYTICAL_METHOD
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	147	163	ANALYTICAL_METHOD
Among the identified small set of genes associated with reduced breast cancer incidence, laboratory experiments on one of the genes, CDC42, showed that its downregulation by metformin inhibited cancer cell migration and proliferation, thus validating the ability of machine learning approaches to identify biologically relevant candidates for laboratory experiments	266	282	ANALYTICAL_METHOD
During the last decade, the interest to apply machine learning algorithms to genomic data has increased in many bioinformatics applications	46	62	ANALYTICAL_METHOD
Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone	0	27	ANALYTICAL_METHOD
Supervised machine learning and feature selection were used to demonstrate that a set of 16 loci from 5 genes can predict t-MP with over 90% accuracy, depending on t-MP category and algorithm, which was significantly greater than predictions made by CYP2D6 alone	32	49	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	62	75	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	127	140	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	145	158	ANALYTICAL_METHOD
This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project	150	173	ANALYTICAL_METHOD
This article offers a perspective of the relations that exist between the fields of big data and biotechnology, including the related technologies of artificial intelligence and machine learning and describes how data integration, data exploitation, and process optimization correspond to three essential steps in any future biotechnology project	178	194	ANALYTICAL_METHOD
We set out to determine whether machine learning-based algorithms that included functionally validated pharmacogenomic biomarkers joined with clinical measures could predict selective serotonin reuptake inhibitor (SSRI) remission/response in patients with major depressive disorder (MDD)	32	48	ANALYTICAL_METHOD
These results demonstrate that machine learning can achieve accurate and, importantly, replicable prediction of SSRI therapy response using total baseline depression severity combined with pharmacogenomic biomarkers	31	47	ANALYTICAL_METHOD
Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning	161	184	ANALYTICAL_METHOD
Several topics where TBI research is at the leading edge are 1) the use of large-scale biobanks linked to electronic health records, 2) pharmacogenomics, and 3) artificial intelligence and machine learning	189	205	ANALYTICAL_METHOD
We demonstrate that deep neural networks outperform the current state in machine learning frameworks	20	40	ANALYTICAL_METHOD
We demonstrate that deep neural networks outperform the current state in machine learning frameworks	73	89	ANALYTICAL_METHOD
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	182	215	ANALYTICAL_METHOD
In this paper, we aim to provide a detailed evaluation of three categories of state-of-the-art common module identification techniques from a machine learning perspective, including non-negative matrix factorization (NMF), partial least squares (PLS) and network analyses	223	246	ANALYTICAL_METHOD
A way to generate predictive models for the remaining cases is with suitable machine learning algorithms that are yet to be applied to existing in vitro pharmacogenomics datasets	77	93	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	15	31	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	54	65	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	83	105	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	113	135	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	144	163	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	170	186	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	194	234	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	243	266	ANALYTICAL_METHOD
We apply eight machine learning techniques, including naive Bayes classifier (NB), support vector machine (SVM), elastic net regression (ENET), logistic regression (LR), lasso regression (LAR), multivariate adaptive regression splines (MARS), boosted regression tree (BRT) and random forest model (RF)	277	290	ANALYTICAL_METHOD
The capability of learning representations from structures directly without using any predefined structure descriptor is an important feature distinguishing deep learning from other machine learning methods and makes the traditional feature selection and reduction procedures unnecessary	182	198	ANALYTICAL_METHOD
In the wake of recent advances in machine learning research, the study of pharmacogenomics using predictive algorithms serves as a new paradigmatic application	34	50	ANALYTICAL_METHOD
In this work, our goal was to explore an ensemble machine learning approach which aims to predict probable antidepressant treatment response and remission in major depressive disorder (MDD)	41	66	ANALYTICAL_METHOD
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	30	46	ANALYTICAL_METHOD
We also compared our ensemble machine learning framework with other state-of-the-art models including multi-layer feedforward neural networks (MFNNs), logistic regression, support vector machine, C4	102	141	ANALYTICAL_METHOD
Many machine learning techniques have been demonstrated in this domain	5	21	ANALYTICAL_METHOD
Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning	227	238	ANALYTICAL_METHOD
Here, we explore the evidence for, and practical use of, a number of these emerging technologies, including the measurement and quantification of epigenetic changes, microbiome analysis and the use of cell-free DNA, along with data mining and machine learning	243	259	ANALYTICAL_METHOD
Furthermore, we performed a machine learning analysis and determined that Native American admixture and heart failure were strongly predictive of AF in PHR	28	44	ANALYTICAL_METHOD
Here, we leverage publicly available, whole genome sequencing data collected from global populations, evolutionary characteristics, and annotated protein features to construct a new in silico machine learning pharmacogenetic identification method called XGB-PGX	192	208	ANALYTICAL_METHOD
We used the anti-epileptic drug brivaracetam as a case study and combine a hybrid data/knowledge-driven feature extraction with machine learning to systematically integrate clinical and genetic data from a clinical discovery dataset (n\u2009=\u2009235 patients)	128	144	ANALYTICAL_METHOD
Hence, it provides a blueprint for how machine learning-based multimodal data integration can act as a driver in achieving the goals of precision medicine in fields such as neurology	39	55	ANALYTICAL_METHOD
Five machine learning algorithms combined with four resampling techniques were used to build optimal predictive model	5	21	ANALYTICAL_METHOD
By machine learning, we have developed and validated comprehensive models to predict the risk of neutropenia and fever	3	19	ANALYTICAL_METHOD
This study assesses the value of potentially functional single nucleotide polymorphisms (pfSNPs) and employs six machine learning algorithms to identify the combination of SNPs that best predict myalgia	113	129	ANALYTICAL_METHOD
Variants that were highly associated with myalgia from this and previous studies were extracted, assessed for potential functionality (pfSNPs) and incorporated into six machine learning models	169	185	ANALYTICAL_METHOD
The minimum combination of SNPs to achieve maximum sensitivity and specificity as determined by AUC, that predict atorvastatin-induced myalgia in most, if not all the six machine learning models was determined	171	187	ANALYTICAL_METHOD
pfSNPs were found to be more robust in predicting myalgia, outperforming non-pf SNPs in the majority of machine learning models tested	104	120	ANALYTICAL_METHOD
<b>Conclusion:</b> Combinations of pfSNPs that were consistently identified by different machine learning models to have high predictive performance have good potential to be clinically useful for predicting atorvastatin-induced myalgia once validated against an independent cohort of patients	89	105	ANALYTICAL_METHOD
This work proposes a machine learning approach to infer robust predictors of drug responses from patient genomic information	21	37	ANALYTICAL_METHOD
Graph structures have received increasing attention owing to their outstanding performance in machine learning	94	110	ANALYTICAL_METHOD
This study aimed to establish a predictive model to identify children with hematologic malignancy at high risk for delayed clearance of high-dose methotrexate (HD-MTX) based on machine learning	177	193	ANALYTICAL_METHOD
Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5	34	53	ANALYTICAL_METHOD
Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5	5	21	ANALYTICAL_METHOD
Five machine learning algorithms (cart classification and regression trees, na\u00efve Bayes, support vector machine, random forest, C5	58	74	ANALYTICAL_METHOD
When developed machine learning models were evaluated in the validation dataset, the C5	15	31	ANALYTICAL_METHOD
In addition, we preliminarily explored the machine learning-based methods for identifying mutation markers of anti-cancer drug sensitivity and produced optimistic results, which suggests that a reliable dataset may provide new insights and essential clues for future cancer pharmacogenomics studies	43	59	ANALYTICAL_METHOD
Machine learning methods have been employed to predict drug sensitivity based on the multiple omics data available for large panels of cancer cell lines	0	16	ANALYTICAL_METHOD
However, there are no comprehensive guidelines on how to properly train and validate such machine learning models for drug sensitivity prediction	90	106	ANALYTICAL_METHOD
However, there is no evidence that machine learning approaches combining multi-omics measures (e	35	51	ANALYTICAL_METHOD
Machine Learning (ML) is emerging as a particularly promising complementary approach to precision oncology	0	16	ANALYTICAL_METHOD
We compare the accuracy of stable warfarin dose prediction using linear and nonlinear machine learning models in a large cohort enriched for US Latinos and Latin Americans (ULLA)	76	102	ANALYTICAL_METHOD
Our tool also includes a machine learning random forest binary classifier that showed an accuracy of 73%	25	73	ANALYTICAL_METHOD
To identify the parameters that had the greatest importance for the prediction of the therapy response to metformin, we next built a set of machine learning models, based on the various combinations of genetic and phenotypic characteristics	140	156	ANALYTICAL_METHOD
Using machine learning (ML) techniques with pharmacogenomics data provides one pathway toward individualized prediction of therapeutic outcomes of antidepressants	6	22	ANALYTICAL_METHOD
Extensive in vitro cancer drug screening datasets have enabled scientists to identify biomarkers and develop machine learning models for predicting drug sensitivity	109	125	ANALYTICAL_METHOD
CREAMMIST provides easy-to-use statistics derived from the integrative dose-response curves for various downstream analyses such as identifying biomarkers, selecting drug concentrations for experiments, and training robust machine learning models	223	239	ANALYTICAL_METHOD
To overcome this hurdle, machine learning models have been extensively adapted in drug dose prediction	25	41	ANALYTICAL_METHOD
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	48	64	ANALYTICAL_METHOD
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	77	88	ANALYTICAL_METHOD
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	90	95	ANALYTICAL_METHOD
The results are further validated through three machine learning approaches: Elastic Net, LASSO, and Ridge	101	106	ANALYTICAL_METHOD
Based on the concept of precision pharmacy, we adpoted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children and elderly patients	152	168	ANALYTICAL_METHOD
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	31	38	ANALYTICAL_METHOD
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	43	65	ANALYTICAL_METHOD
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	133	149	ANALYTICAL_METHOD
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	172	190	ANALYTICAL_METHOD
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	209	251	ANALYTICAL_METHOD
The study proposes the uses of Firefly and Grey Wolf Optimization techniques for feature extraction, while comparing the traditional Machine Learning (ML), ensemble ML and Stacking Algorithm with the proposed Convolutional Temporal Deep Neural Network or CTDN	256	260	ANALYTICAL_METHOD
Based on these findings, data from patients treated with cannabis and genotyped for several candidate polymorphic genes (single-nucleotide polymorphism: SNP) were collected, integrated, and analyzed through a machine learning (ML) model to demonstrate that the reduction in pain intensity is closely related to gene polymorphisms	209	225	ANALYTICAL_METHOD
Genome-wide patterns of pharmacogenomic variation-6311 drug response-associated variants for <i>All of Us</i> and 5966 variants for <i>UKB</i>-were analyzed with machine learning classifiers to predict participants' self-identified race and ethnicity	162	178	ANALYTICAL_METHOD
Based on the concept of precision pharmacy, we adopted approaches including PK/PD, quantitative pharmacology, population pharmacokinetics, and big data machine learning to provide more personalized pharmacy services, which is mainly for special patients, such as critical patients, patients with interaction risk of multiple drugs, patients with liver and renal insufficiency, pregnant women, children, and elderly patients	152	168	ANALYTICAL_METHOD
A machine learning classifier method was used to discover classification rules for our dataset	2	18	ANALYTICAL_METHOD
PANCDR outperformed other machine learning models in predicting external test data	0	6	ANALYTICAL_METHOD
PANCDR outperformed other machine learning models in predicting external test data	26	42	ANALYTICAL_METHOD
Data science and machine learning play a crucial role in the processing and interpretation of results, using enormous databases and statistics to discover new and support current genotype-phenotype correlations	17	33	ANALYTICAL_METHOD
A machine learning model was trained to predict the genome-wide chromatin accessibility from transcriptome data using the paired expression and chromatin accessibility data collected from ENCODE and ROADMAP	2	18	ANALYTICAL_METHOD
An area of recent interest is the potential for machine learning (ML) applications within pharmacology	48	64	ANALYTICAL_METHOD
Two signatures for prognosis and EGFRi sensitivity were developed via machine learning	70	86	ANALYTICAL_METHOD
This study investigates how artificial intelligence (AI) and machine learning (ML) can address key challenges in integrating pharmacogenomics (PGx) into psychiatric care	61	77	ANALYTICAL_METHOD
(Genetics 1987; 117:343-351) and hierarchical clustering of haplotypes as described by Durrant et al	33	56	ANALYTICAL_METHOD
Results: Using unsupervised hierarchical clustering and a combination of candidate genotypes and clinical variables, we identified several distinct clusters of patients at high risk (36-38%) and low risk (10-17%) of respiratory depression; the relative risk of respiratory depression for high versus low risk clusters was 2	15	51	ANALYTICAL_METHOD
Hierarchical clustering of the common genes represented in both mRNA and protein datasets displayed two dominant patterns	0	23	ANALYTICAL_METHOD
Identification of groups of features is performed by hierarchical clustering	53	76	ANALYTICAL_METHOD
This chapter presents a workflow to interrogate multiple genomic inputs and individually assess their relationship with the phenotype of drug resistance using hierarchical clustering to determine the set of features that can best describe what features are associated with drug resistance	159	182	ANALYTICAL_METHOD
Finally, structural analysis and molecular dynamics simulation indicated that TPMT*27 was less stable than was the wild type TPMT allozyme	33	51	ANALYTICAL_METHOD
We used molecular dynamics (MD) simulation to predict the structure of the complex of human TPMT-AdoHcy(CH(2))6MP, where the sulfur atoms of AdoHcy and 6MP were linked by a CH(2) group	8	26	ANALYTICAL_METHOD
Molecular dynamics simulation (MDS) approach was conducted to investigate conformational changes in the mutant protein structure with respect to its native conformation	0	19	ANALYTICAL_METHOD
The bfPGRP1-ligand complex molecular dynamics simulation followed by free binding energy (BE) computation conceded BE values of -18	27	46	ANALYTICAL_METHOD
We had applied molecular dynamics simulation to study the possible conformational changes induced by Lys256Arg transversion on the overall structure of integrin and we have analyzed the binding affinities of natalizumab in the non-mutated and mutated structures through HINT score	15	33	ANALYTICAL_METHOD
In order to address this issue, we developed a computational pipeline of vitamin D receptor (VDR) for SNP centered study by application of elegant molecular docking and molecular dynamics simulation approaches	147	164	ANALYTICAL_METHOD
In order to address this issue, we developed a computational pipeline of vitamin D receptor (VDR) for SNP centered study by application of elegant molecular docking and molecular dynamics simulation approaches	169	187	ANALYTICAL_METHOD
Gly187Trp mutant embedded in different lipid bilayers and relaxed them for hundreds of nanoseconds by molecular dynamics simulations	102	120	ANALYTICAL_METHOD
Molecular dynamics results validated the stable conformation of oridonin docking pose on Akt kinase domain	0	18	ANALYTICAL_METHOD
Further, the mutant displayed enhanced structural flexibility particularly in the low density lipoprotein (LDL) binding domain, decreased solvent accessibility of catalytic residues-Phe274 and Ser273 and increased C\u0251 distance between Phe274 and Leu153 and large conformational entropy change as inferred from all-atom molecular dynamics (MD) simulation and essential dynamics (ED) studies	318	336	ANALYTICAL_METHOD
Further, the effect of amino acid substitutions CYP2C9 variants on the protein flexibility in the presence of tamoxifen in 4-hydroxy orientation was evaluated by molecular dynamics (MD) simulations	162	180	ANALYTICAL_METHOD
Besides, the influence of rs1065852 on the structure of CYP2D6 was further investigated via molecular dynamics simulations	92	110	ANALYTICAL_METHOD
Molecular dynamics simulations revealed higher overall flexibility, decreased intramolecular hydrogen bonds and lower content of regular secondary structures for both cancer driver variants G73W and F432S when compared to the wild-type structure	0	18	ANALYTICAL_METHOD
We previously proposed combining molecular dynamics (MD) and dynamic residue network (DRN) analysis to decipher the molecular mechanisms of missense mutations in other proteins	33	51	ANALYTICAL_METHOD
We previously proposed combining molecular dynamics (MD) and dynamic residue network (DRN) analysis to decipher the molecular mechanisms of missense mutations in other proteins	61	84	ANALYTICAL_METHOD
Five missense variants were modeled and microsecond scale molecular dynamics simulations were conducted for each, as well as for the CYP3A5 wildtype and the Y53C variant, which has a known deleterious impact on enzyme activity	58	76	ANALYTICAL_METHOD
Here we have evaluated spatio-temporal functional and molecular dynamics of five PDO models established after hepatic re-resections and neoadjuvant combination chemotherapies in a patient with microsatellite stable and KRAS mutated metastatic rectal cancer	54	72	ANALYTICAL_METHOD
We show how computational approaches such as bioinformatics tools and molecular dynamics simulations can be used to characterize the variant receptors in comparison to the wildtype receptor	70	88	ANALYTICAL_METHOD
Moreover, the stability behavior of selected docked complexes (drugs-EWS) was checked by molecular dynamics simulations	89	107	ANALYTICAL_METHOD
Finally, molecular dynamics simulations were used to investigate the stability of the best selected docked complexes	9	27	ANALYTICAL_METHOD
Further, the molecular dynamics simulations were performed to comprehend the conformational changes and stability of the targets upon binding of the selected top ranked RA drug	13	31	ANALYTICAL_METHOD
As a result, the five best flavonoid-docked complexes were selected and further evaluated by Molecular Dynamics (MD) simulation studies at 100 ns	93	111	ANALYTICAL_METHOD
<b>Results:</b> Normal mode analysis and molecular dynamics highlight the effects of known CYP missense variants on protein stability and conformational dynamics	41	59	ANALYTICAL_METHOD
Molecular dynamics simulations revealed large conformational fluctuations, confirming the predicted reduced function of <i>*86</i> and <i>*113</i> alleles	0	18	ANALYTICAL_METHOD
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	68	85	ANALYTICAL_METHOD
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	110	121	ANALYTICAL_METHOD
The progress of molecular biology with particular consideration of genotyping and DNA microarray technologies has created a basis for the dynamic progress of pharmacogenetics, allowing fast and sensitive determination of the individual pharmacogenetic profile, encompassing a large set of CYP alleles extended by allelic variants of genes encoding other enzymes participating in drug metabolism	82	96	ANALYTICAL_METHOD
Microarray-based mRNA expression profiling, COMPARE, and hierarchical cluster analyses were applied to identify which genes correlate with sensitivity or resistance to selected phytochemicals of the Korean plants	57	77	ANALYTICAL_METHOD
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel	42	72	ANALYTICAL_METHOD
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	16	50	ANALYTICAL_METHOD
DNA-binding motif analysis of the microarray-retrieved deregulated genes in the promoter region revealed NF\u03baB as potential transcription factor involved in cryptotanshinone's mode of action	0	17	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	62	76	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	127	140	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	145	158	ANALYTICAL_METHOD
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	160	176	ANALYTICAL_METHOD
To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts	163	194	ANALYTICAL_METHOD
Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	56	89	ANALYTICAL_METHOD
Study Design and Analysis: Non-concurrent cohort study; Multivariable logistic regression Setting: Hospital/integrated healthcare delivery system in northern Illinois Population Studied: 19,999 adults tracked from 2010 through 2020 who underwent testing with a 13-gene pharmacogenetic panel Outcome Measure: 90-day hospital readmission (primary outcome) Results: Univariate logistic regression analyses demonstrated that strongest associations with 90 day hospital readmissions were the number of medications prescribed within 30 days of a first hospital admission that had Clinical Pharmacogenomics Implementation Consortium (CPIC) guidance (CPIC medications) (5+ CPIC medications, odds ratio (OR) = 7	363	393	ANALYTICAL_METHOD
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	124	139	ANALYTICAL_METHOD
A Cox proportional hazards model was utilized to assess the impact of genetic markers on survival outcomes.	2	32	ANALYTICAL_METHOD
A generalized linear model (GLM) framework was employed to analyze the association between genetic variants and drug response.	2	26	ANALYTICAL_METHOD
A mixed-effects model was used to account for both fixed and random effects in the pharmacogenomic analysis.	2	21	ANALYTICAL_METHOD
A support vector machine (SVM) was utilized to classify patients based on their pharmacogenomic data.	2	24	ANALYTICAL_METHOD
Bayesian network modeling was employed to understand the probabilistic relationships between genetic variants and drug response.	0	25	ANALYTICAL_METHOD
Canonical correlation analysis (CCA) was performed to explore the relationships between genetic and clinical variables.	0	30	ANALYTICAL_METHOD
Causal inference methods were used to distinguish direct effects of genetic variants on drug response from indirect effects.	0	24	ANALYTICAL_METHOD
Conditional logistic regression was used to analyze matched case-control pharmacogenomic data.	12	31	ANALYTICAL_METHOD
Functional studies in silico, such as molecular docking, molecular dynamics, and conformational analysis, will be used to explore the impact of novel variants on protein structure and function	81	104	ANALYTICAL_METHOD
Functional studies in silico, such as molecular docking, molecular dynamics, and conformational analysis, will be used to explore the impact of novel variants on protein structure and function	38	55	ANALYTICAL_METHOD
Functional studies in silico, such as molecular docking, molecular dynamics, and conformational analysis, will be used to explore the impact of novel variants on protein structure and function	57	75	ANALYTICAL_METHOD
Gene set enrichment analysis (GSEA) was conducted to identify gene sets significantly associated with drug response.	0	28	ANALYTICAL_METHOD
Genome-wide association studies (GWAS) were performed using PLINK software to identify significant SNPs.	0	31	ANALYTICAL_METHOD
Hidden Markov models (HMM) were used to detect regions of the genome associated with drug response.	0	20	ANALYTICAL_METHOD
Hierarchical clustering was used to group patients based on their pharmacogenomic profiles.	0	23	ANALYTICAL_METHOD
Kaplan-Meier survival analysis was conducted to compare outcomes between different genotype groups.	0	30	ANALYTICAL_METHOD
Linear discriminant analysis (LDA) was employed to distinguish between responders and non-responders to treatment.	0	28	ANALYTICAL_METHOD
machine learning techniques to assess treatment prediction, prognosis prediction, diagnosis prediction, and the detection of potential biomarkers	0	27	ANALYTICAL_METHOD
Mendelian randomization analysis was used to infer causal relationships between genetic variants and drug efficacy.	0	32	ANALYTICAL_METHOD
Multivariable logistic regression models were fitted to assess the impact of multiple genetic and clinical factors.	0	40	ANALYTICAL_METHOD
Multivariate adaptive regression splines (MARS) were used to model nonlinear relationships in pharmacogenomic data.	0	40	ANALYTICAL_METHOD
Multivariate analysis of variance (MANOVA) was used to examine the interaction between multiple genetic factors and drug efficacy.	0	33	ANALYTICAL_METHOD
Network-based approaches were used to construct and analyze gene-gene interaction networks in pharmacogenomics.	0	24	ANALYTICAL_METHOD
Partial correlation analysis was performed to account for confounding variables in the genetic association study.	0	28	ANALYTICAL_METHOD
Partial least squares (PLS) regression was employed to model the relationship between genetic markers and drug efficacy.	0	21	ANALYTICAL_METHOD
Pathway enrichment analysis was conducted using DAVID to identify biological pathways affected by genetic variants.	0	27	ANALYTICAL_METHOD
Pathway-based analysis was conducted to integrate genetic data with known drug metabolism pathways.	0	22	ANALYTICAL_METHOD
Permutation-based significance testing was used to validate the robustness of the pharmacogenomic findings.	0	38	ANALYTICAL_METHOD
Principal component analysis (PCA) was conducted to reduce the dimensionality of the pharmacogenomic data.	0	28	ANALYTICAL_METHOD
Quantitative trait locus (QTL) mapping was conducted to identify loci associated with drug response traits.	0	24	ANALYTICAL_METHOD
Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive accuracy of pharmacogenomic models.	0	33	ANALYTICAL_METHOD
Survival analysis using the log-rank test was performed to compare time-to-event outcomes between genotypes.	0	17	ANALYTICAL_METHOD
The LASSO (least absolute shrinkage and selection operator) method was used to select relevant genetic predictors.	4	9	ANALYTICAL_METHOD
The Markov Chain Monte Carlo (MCMC) method was used for Bayesian inference in pharmacogenomic models.	0	28	ANALYTICAL_METHOD
The study applied Fisher's exact test to determine the association between genetic variants and adverse drug reactions.	18	37	ANALYTICAL_METHOD
The study applied stepwise regression techniques to select the most predictive genetic variables.	18	48	ANALYTICAL_METHOD
The study employed decision tree algorithms to develop clinical decision support tools based on pharmacogenomic data.	19	43	ANALYTICAL_METHOD
The study employed elastic net regression to integrate genetic and clinical data for predicting drug response.	19	41	ANALYTICAL_METHOD
The study employed machine learning algorithms, including random forests, to predict drug response based on genetic data.	19	46	ANALYTICAL_METHOD
The study employed structural equation modeling (SEM) to explore complex relationships between genetic and phenotypic variables.	19	47	ANALYTICAL_METHOD
The study used a sliding window approach to perform regional association tests in the genome.	17	40	ANALYTICAL_METHOD
The study used k-means clustering to identify subgroups of patients with similar pharmacogenomic profiles.	15	33	ANALYTICAL_METHOD
The study used Monte Carlo simulations to assess the uncertainty in pharmacogenomic predictions.	15	38	ANALYTICAL_METHOD
The study used the Bonferroni correction method to adjust for multiple testing in GWAS.	19	47	ANALYTICAL_METHOD
The study used the False Discovery Rate (FDR) approach to control for type I errors in multiple comparisons.	19	39	ANALYTICAL_METHOD
The study used the Wilcoxon rank-sum test to compare genetic variant frequencies between case and control groups.	19	41	ANALYTICAL_METHOD
The study utilized permutation testing to assess the significance of the observed associations.	19	38	ANALYTICAL_METHOD
This work proposes a machine learning approach to infer robust predictors of drug responses from patient genomic information	21	46	ANALYTICAL_METHOD
We applied logistic regression analysis to identify genetic variants associated with drug response.	11	30	ANALYTICAL_METHOD
we have provided a brief overview of the possibilities of implementing CNNs as an effective tool for analyzing one-dimensional biological data	71	75	ANALYTICAL_METHOD
we introduce an elastic-net regression methodology to compare a drug-cell line pair against an alternative pair	16	38	ANALYTICAL_METHOD
We propose to apply the principles artificial intelligence to develop a medication optimization platform to prevent, manage and treat different diseases	35	58	ANALYTICAL_METHOD
Here we present a novel machine-learning method called REGENIE for fitting a whole-genome regression model for quantitative and binary phenotypes that is substantially faster than alternatives in multi-trait analyses while maintaining statistical efficiency	24	40	ANALYTICAL_METHOD
Here we present a novel machine-learning method called REGENIE for fitting a whole-genome regression model for quantitative and binary phenotypes that is substantially faster than alternatives in multi-trait analyses while maintaining statistical efficiency	90	106	ANALYTICAL_METHOD
We explore the role of the prior distribution in whole-genome regression models for dissecting complex traits in what is now a standard situation with genomic data	62	79	ANALYTICAL_METHOD
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine.	58	81	ANALYTICAL_METHOD
We illustrate how massively parallel experimental assays, artificial intelligence (AI), and machine learning can synergize with population-scale biobank projects to facilitate the interpretation of NGS data to individualize clinical decision-making and personalized medicine.	92	108	ANALYTICAL_METHOD
in silico and large-scale functional assessment of rare variant effects on protein function are at the forefront of pharmacogenetic research to facilitate their clinical integration.	0	9	ANALYTICAL_METHOD
We propose to apply the principles artificial intelligence to develop a medication optimization platform to prevent, manage and treat different diseases.	35	58	ANALYTICAL_METHOD
The field of pharmacogenomics, comprising pharmacokinetics (PK) and pharmacodynamics (PD), has been revolutionized by computer-aided drug design (CADD) and structure-based drug design (SBDD).	156	183	ANALYTICAL_METHOD
These developments are paralleled by advances in machine learning, which have allowed us to parse the immense wealth of data and establish novel genetic markers and polygenic models for drug selection and dosing.	49	65	ANALYTICAL_METHOD
We then annotated variant call format (VCF) files using Golden Helix VarSeq 2.5.0 and employed Stargazer v2.0.2 for star allele analysis.	56	75	ANALYTICAL_METHOD
the RIKEN Center for Genomic Medicine have worked collaboratively to perform genome-wide association studies (GWAS) in women treated with both SERMs and AIs.	110	114	ANALYTICAL_METHOD
Second, there was consideration of the particular challenges of dealing with adolescent and young adult cancers, exemplified by bone sarcomas	128	143	CANCER
CD14 is a membrane glycoprotein expressed specifically on monocytes and macrophages, and its expression is markedly increased during the process of monocyte differentiation.	58	66	CELL
CD14 is a membrane glycoprotein expressed specifically on monocytes and macrophages, and its expression is markedly increased during the process of monocyte differentiation.	72	82	CELL
CD14 is a membrane glycoprotein expressed specifically on monocytes and macrophages, and its expression is markedly increased during the process of monocyte differentiation.	58	66	CELL
Even a moderate increase in the cellular cysteine supply elevates the intracellular glutathione (GSH) and glutathione disulfide (GSSG) levels and potentiates immunological functions of lymphocytes in vitro.	185	195	CELL
Because leukocyte-mediated tissue damage is an important component of the pathologic picture in ischemia/reperfusion, we have sought mechanisms by which PMNs are directed into hypoxic tissue.	153	156	CELL
Monoclonal antibodies against either monomorphic or polymorphic determinants of class I antigen induced in PBMC and highly purified T lymphocytes the nuclear activity of NF-kappa B/Rel complexes.	107	111	CELL
The induction of cytokine expression in monocytes/macrophages by bacterial endotoxin or lipopolysaccharide is a critical, highly regulated host defence response.	40	48	CELL
The induction of cytokine expression in monocytes/macrophages by bacterial endotoxin or lipopolysaccharide is a critical, highly regulated host defence response.	50	60	CELL
When monocytes are stimulated with LPS (lipopolysaccharide) repeatedly then the initially high expression of the TNF (tumor necrosis factor) gene is only very low, i.e. the cells are tolerant to LPS.	5	13	CELL
The alpha2beta1 integrin, a collagen receptor on platelets and megakaryocytes, is required for normal platelet function.	49	57	CELL
The alpha2beta1 integrin, a collagen receptor on platelets and megakaryocytes, is required for normal platelet function.	63	76	CELL
Exposing human umbilical vein endothelial cells (HUVECs) to anoxia/reoxygenation (A/R) results in an increase in polymorphonuclear leukocyte (PMN) adhesion to HUVECs.	142	145	CELL
Bacterial lipopolysaccharide (LPS)-mediated immune responses, including activation of monocytes, macrophages, and endothelial cells, play an important role in the pathogenesis of Gram-negative bacteria-induced sepsis syndrome.	86	94	CELL
Bacterial lipopolysaccharide (LPS)-mediated immune responses, including activation of monocytes, macrophages, and endothelial cells, play an important role in the pathogenesis of Gram-negative bacteria-induced sepsis syndrome.	97	107	CELL
Human peripheral blood monocytes responded to stimulation of platelet-activating factor (PAF) with up-regulation of the transcript for heparin-binding epidermal growth factor-like growth factor (HB-EGF), a potent mitogen for vascular smooth muscle cells.	23	31	CELL
An increasing body of evidence suggests that amyloid-beta (A beta) peptides and microglia are crucially involved in the pathogenesis of Alzheimer's disease.	80	89	CELL
In an effort to further elucidate the biological effects of A beta towards microglia, we investigated the ability of A beta peptides to activate nuclear factor (NF)-kappa B in the N9 murine microglial cell line.	75	84	CELL
Human neutrophils can be induced to actively transcribe a number of early-response genes, in particular those encoding cytokines, chemokines, and the high-affinity surface receptor for IgG, FcgammaRI.	6	16	CELL
In monocytes, lipopolysaccharide induces synthesis and activity of the 85-kDa cytosolic phospholipase A2.	3	11	CELL
We examined chemokine gene expression following the differentiation of a monocyte, macrophage cell lineage.	73	81	CELL
We examined chemokine gene expression following the differentiation of a monocyte, macrophage cell lineage.	83	93	CELL
The human monoblastic cell line, U937 was differentiated to macrophages by the treatment with either phorbol 12-myristate 13-acetate (PMA), retinoic acid (RA), or vitamin D3 (VitD3).	60	70	CELL
Recent studies have reported that lymphocytes produce, transport and bind dopamine present in plasma.	34	44	CELL
Infection of human monocytes with influenza A virus induces a broad range of proinflammatory cytokines and mononuclear cell attracting chemokines before the infected cells undergo apoptosis.	19	27	CELL
The responses of lymphocytes to IL-2 and IL-12, involving proliferation, differentiation, and cytokine production, are only partially overlapping, and may depend on induced differential expression of specific sets of genes.	17	27	CELL
Lipopolysaccharide (LPS) is a potent stimulator of monocytes and macrophages, causing secretion of tumor necrosis factor alpha (TNF-alpha) and other inflammatory mediators.	51	59	CELL
Lipopolysaccharide (LPS) is a potent stimulator of monocytes and macrophages, causing secretion of tumor necrosis factor alpha (TNF-alpha) and other inflammatory mediators.	65	75	CELL
The adherence of monocytes to activated endothelium is an early event in atherogenesis.	17	25	CELL
This review summarizes data on specific regulation of promoters and enhancers by nuclear trans-acting factors in lymphocytes.	113	123	CELL
Co-stimulation of T-lymphocytes by T-cell receptor (TcR) occupancy and activation of the CD28 surface molecule results in enhanced proliferation and interleukin 2 (IL-2) production.	18	30	CELL
Human monoblastic leukemia U937 cells are induced to differentiate into monocytes and macrophages by various agents.	72	80	CELL
Human monoblastic leukemia U937 cells are induced to differentiate into monocytes and macrophages by various agents.	86	96	CELL
Activation of leukocytes by proinflammatory stimuli selectively initiates intracellular signal transduction via sequential phosphorylation of kinases.	14	23	CELL
Induction of apoptosis in lymphocytes, which may account for the therapeutic effects of glucocorticoids in various diseases including leukemia, depends on the glucocorticoid receptor.	26	36	CELL
We have previously demonstrated that interaction of infected thymocytes with autologous thymic epithelial cells (TEC) is a prerequisite for a high level of human immunodeficiency virus type 1 (HIV-1) replication in thymocytes (M.Rothe, L.Chene, M.Nugeyre, F.Barre-Sinoussi, and N.Israel, J.Virol.72:5852-5861, 1998).	61	70	CELL
The expression of the hematopoietic transcription factors GATA-1, GATA-2, and GATA-3 was studied in eosinophils and basophils.	100	110	CELL
The expression of the hematopoietic transcription factors GATA-1, GATA-2, and GATA-3 was studied in eosinophils and basophils.	116	124	CELL
IL-4, a product of the T-helper 0 (Th0) and 2 (Th2) subset, was originally described as a B-cell stimulatory factor and has subsequently been found to suppress IL-1 alpha, IL-1 beta, IL-6, IL-8, and TNF-alpha gene expression in monocytes stimulated with LPS, and to upregulate IL-1 receptor antagonist (IL1-RA) gene expression.	35	38	CELL
IL-4, a product of the T-helper 0 (Th0) and 2 (Th2) subset, was originally described as a B-cell stimulatory factor and has subsequently been found to suppress IL-1 alpha, IL-1 beta, IL-6, IL-8, and TNF-alpha gene expression in monocytes stimulated with LPS, and to upregulate IL-1 receptor antagonist (IL1-RA) gene expression.	47	50	CELL
The regulation of gene expression during lymphocyte differentiation is a complex process involving interactions between multiple positive and negative transcriptional regulatory elements.	41	51	CELL
Since GH stimulates the development and function of granulocytes, we investigated the expression of GH in granulocyte subsets.	52	63	CELL
In monocytes, the nuclear factor NF-kappa B has been invoked as an important transcription factor in the expression of cytokine genes, of cell-surface receptors and in the expression of human immunodeficiency virus.	3	11	CELL
Neutrophil maturation occurs in well defined morphological stages that correlate with the acquisition of molecular markers associated with neutrophil function.	139	149	CELL
A variety of factors are known to play a role in terminal neutrophil maturation, including the vitamin A derivative, retinoic acid.	58	68	CELL
According to current models the inhibitory capacity of I(kappa)B(alpha) would be mediated through the retention of Rel/NF-kappaB proteins in the cytosol.	145	152	CELL
Peripheral blood mononuclear cells from seventeen patients with primary myelodysplastic syndromes (MDS) in advanced stage were enriched for blasts and tested for (1) karyotype, (2) genomic configuration and (3) expression of IL-3, GM-CSF, FMS and EGR-1 genes which are all located on the long arm of chromosome 5.	140	145	CELL
The nuclear factor of activated T cells (NFAT) group of transcription factors is retained in the cytoplasm of quiescent cells.	97	106	CELLULAR_COMPONENT
In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression.	88	95	CELLULAR_COMPONENT
We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei.	63	70	CELLULAR_COMPONENT
We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei.	63	70	CELLULAR_COMPONENT
However, I(kappa)B(alpha) has also been detected in the nucleus of cell lines and when overexpressed by transient transfection.	56	63	CELLULAR_COMPONENT
However, different study designs would be needed to examine common variation with minor effect sizes, or rare variation, influencing AED or LEV response or epilepsy predisposition	60	100	CHALLENGE
However, different study designs would be needed to examine common variation with minor effect sizes, or rare variation, influencing AED or LEV response or epilepsy predisposition	105	119	CHALLENGE
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	5	19	CHALLENGE
Strategies for detecting and interpreting rare variation will be critical for enabling broad application of pharmacogenetics	15	56	CHALLENGE
Delivery of proteins and peptides presents special challenges	0	33	CHALLENGE
Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries	93	131	CHALLENGE
Genomic variation among individuals and populations is a new factor that enriches and challenges our understanding of these complex relationships	0	51	CHALLENGE
Variable warfarin response during treatment initiation poses a significant challenge to providing optimal anticoagulation therapy	0	26	CHALLENGE
The challenge remains therefore, to develop more effective systemic therapies against this challenging malignancy	36	77	CHALLENGE
Despite major advancements in therapeutics, variability in drug response remains a challenge in both adults and children diagnosed with rheumatic disease	44	72	CHALLENGE
Additionally, we discuss the major challenges in translating this knowledge into a systems-level understanding of drug physiology, with the ultimate goal of developing more effective personalized clinical treatment strategies	49	110	CHALLENGE
This article will discuss the issues involved in mobilizing a PGx study during the conduct of a clinical trial, including the development of a PGx hypothesis, the identification of genetic markers for analysis, PGx platform selection and assay development, as well as challenges that arise in relation to global laws and regulations related to genetic research and logistical/timeline concerns in the execution of a PGx analysis	321	360	CHALLENGE
This article will discuss the issues involved in mobilizing a PGx study during the conduct of a clinical trial, including the development of a PGx hypothesis, the identification of genetic markers for analysis, PGx platform selection and assay development, as well as challenges that arise in relation to global laws and regulations related to genetic research and logistical/timeline concerns in the execution of a PGx analysis	305	316	CHALLENGE
In this article, which comprises a summary of discussions from the Global Cardiovascular Clinical Trialists Forum held in Paris, France, we offer a brief overview of the background and rationale for biomarker testing in heart failure, describe opportunities and challenges from a regulatory perspective, and summarize current positions from government agencies in the United States and European Union	280	302	CHALLENGE
Incidental findings have long posed challenges for healthcare providers, but the scope and scale of these challenges have increased with the introduction of new technologies	0	19	CHALLENGE
Focusing on the challenges of the incidentalome, the large set of incidental findings potentially generated through genotyping, the paper argues that provisional approaches to managing incidental findings may be implemented if necessary to allow benefits of pharmacogenomic testing to be realized in the clinical setting	34	47	CHALLENGE
In this paper, we describe studies being conducted within the eMERGE network to develop best practices for integrating genomic findings into the EHR, and the challenges associated with such work	107	148	CHALLENGE
While such cases may be rare, the clinical/genetic testing community must be aware of the challenges of CYP2D6 testing on the AmpliChip platform and implications regarding accuracy of test results	104	144	CHALLENGE
However, the challenge now in using chemotherapy to treat nonsmall-cell lung cancer is to identify more molecular markers predictive of drug sensitivity and determine the optimal drug sequences in order to tailor treatment to each patient	30	48	CHALLENGE
Previous literature has established theoretical models for PGx CDS implementation and discussed a number of anticipated real-world challenges	120	141	CHALLENGE
Anticipated challenges include data storage and management, system integration, physician acceptance, and more	31	58	CHALLENGE
Anticipated challenges include data storage and management, system integration, physician acceptance, and more	60	78	CHALLENGE
Anticipated challenges include data storage and management, system integration, physician acceptance, and more	80	100	CHALLENGE
The next-generation sequencing platforms generate huge amounts of genetic variation data and it remains a challenge to interpret the variations that are identified	66	88	CHALLENGE
Inevitably, this leads to increased diagnostic delays and challenges in the interpretation of genetic variants	76	110	CHALLENGE
Nowadays, we are experiencing the big data era with the emerging challenge of single data interpretation	78	104	CHALLENGE
Implementation challenges include the limited evidence base available to guide clinical use and the lack of data from diverse populations	38	59	CHALLENGE
Panel-based next generation sequencing (NGS) is currently preferred over whole exome sequencing (WES) for diagnosis of familial breast cancer, due to interpretation challenges caused by variants of uncertain clinical significance (VUS)	150	164	CHALLENGE
A formidable challenge is successfully integrating pharmacogenomic information into clinical practice	39	101	CHALLENGE
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	28	56	CHALLENGE
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	58	84	CHALLENGE
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	86	130	CHALLENGE
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	132	172	CHALLENGE
However, challenges such as selecting a testing platform, communicating test results, building clinical decision support processes, providing patient and provider education, and integrating methods to support the translation of emerging evidence to clinical practice are barriers to broad adoption	178	266	CHALLENGE
This article argues that increased pharmacogenetics education and system-wide implementation is necessary to overcome some of these challenges	25	61	CHALLENGE
However, efficient delivery of this information to the point of prescribing remains a significant challenge	9	47	CHALLENGE
The field of pharmacogenomics presents great challenges for researchers that are willing to make their studies reproducible and shareable	4	29	CHALLENGE
Psychiatric disorders represent one of the most difficult diagnostic challenges, given their frequent mixed nature and intrinsic variability, as in bipolar disorders and depression	0	21	CHALLENGE
Here, we detail successes, challenges, and recent advances in fibrate pharmacogenomics	62	86	CHALLENGE
Here, we provide an overview of considerations made to mitigate multiple methodological challenges that emerged during the design	64	87	CHALLENGE
Potential novel genetic treatment modalities are challenged but still in the early phase of the investigation	0	44	CHALLENGE
The issues and challenges in the diagnosis of drug allergy/hypersensitivity among children and adults in Asia are likely to be different from non-Asian countries	33	76	CHALLENGE
In this response article, we challenge a core assumption that lies at the centre of a round table discussion regarding the Pharmacogenetics to Avoid Loss of Hearing trial	125	172	CHALLENGE
Major challenges to widescale implementation of PGx include lack of physician experience or confidence in interpreting the data	60	88	CHALLENGE
Major challenges to widescale implementation of PGx include lack of physician experience or confidence in interpreting the data	92	127	CHALLENGE
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	25	88	CHALLENGE
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	90	116	CHALLENGE
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	121	144	CHALLENGE
These challenges include adapting to a constantly changing global regulatory environment, challenges in study design and clinical implementation, and the increasing concerns over patient privacy	154	194	CHALLENGE
The development of chronic kidney disease (CKD) drugs remains a challenge due to the variations in the genes	0	53	CHALLENGE
However, challenges remain and are hindering the widespread implementation of TDM in clinical practice	51	104	CHALLENGE
The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs	4	46	CHALLENGE
Precision medication of psychiatric disorders faces challenges in pharmacogenetics and pharmacodynamics research due to difficulties in recruiting human subjects because of possibility of substance abuse and relatively small sample sizes	136	161	CHALLENGE
Despite the introduction of targeted agents leading to therapeutic advances, clinical management of patients with metastatic colorectal cancer (mCRC) is still challenged by significant interindividual variability in treatment outcomes, both in terms of toxicity and therapy efficacy	173	234	CHALLENGE
These make the management of such patients a challenge	15	42	CHALLENGE
The implementation of genotyping for anti-hypertensive drugs in clinical practice remains a challenge	4	81	CHALLENGE
This dependence on intracellular activation presents novel challenges for the discovery and development of nucleoside/nucleotide analog drugs	5	43	CHALLENGE
To circumvent these challenges, deep neural models are increasingly used to improve the precision and accuracy of warfarin dose predictions	114	139	CHALLENGE
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	29	43	CHALLENGE
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	64	97	CHALLENGE
In recent decades, OS treatment has reached a plateau and drug resistance is still a major challenge	58	73	CHALLENGE
Choosing the most effective chemotherapeutic agent with safest side effect profile is a common challenge in\u00a0cancer treatment	0	50	CHALLENGE
The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education	128	133	CHALLENGE
The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education	135	146	CHALLENGE
The chapter will specifically focus on efforts to introduce pharmacogenetics in the NHS, highlighting key challenges related to scale, informatics, and education	152	161	CHALLENGE
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges	0	48	CHALLENGE
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges	50	73	CHALLENGE
Drug-induced liver injury (DILI) risk prediction, diagnosis establishment, clinical management, and all other aspects are facing great challenges	75	94	CHALLENGE
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	74	79	CHALLENGE
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	81	106	CHALLENGE
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	108	133	CHALLENGE
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	135	154	CHALLENGE
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	156	187	CHALLENGE
There are inherent challenges to enrolling a standard of care or cohorts: costs, site engagement logistics, socioeconomic variability, patient willingness, ethics of placebo interventions, cannibalizing the treatment arm population, and extending study duration	189	231	CHALLENGE
However, implementing these screening concepts in real-world settings poses challenges	9	61	CHALLENGE
The potential applications of these genetic polymorphisms as predictive indicators in clinical practice are explored, as are the challenges associated with their implementation	162	176	CHALLENGE
Bortezomib-induced neuropathic pain (BINP) poses a challenge in multiple myeloma (MM) treatment	0	35	CHALLENGE
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	11	28	CHALLENGE
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	30	40	CHALLENGE
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	42	55	CHALLENGE
Due to the limited resources, high costs, long duration, and low hit-to-lead ratio in the development of pharmacogenetics and computer technology, machine learning techniques have assisted novel drug development and have gradually received more attention by researchers	61	145	CHALLENGE
Despite advancements in machine learning and in-silico predictions, scarcity of data hampers accurate prediction of drug candidates' pharmacokinetic properties	68	84	CHALLENGE
The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye	4	36	CHALLENGE
The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye	41	56	CHALLENGE
The need to protect informed consent and confidentiality and to promote justice and equity--both nationally and globally--requires that one approach pharmacogenomics with an enthusiastic, yet critical, eye	65	80	CHALLENGE
However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research	74	123	CHALLENGE
However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research	129	175	CHALLENGE
However, the respondents had the following concerns regarding a DNA bank: the confidentiality of their personal information, the manner by which research results were utilized and simply the use of their own DNA for research	181	225	CHALLENGE
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	6	27	CHALLENGE
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	29	36	CHALLENGE
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	38	53	CHALLENGE
Then, issues of uncertainty, consent, confidentiality, and access are considered with respect to the use of DRD3 polymorphism testing in risk stratification for susceptibility to tardive dyskinesia	59	65	CHALLENGE
However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality	40	72	CHALLENGE
However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality	90	171	CHALLENGE
However, such a genomic approach brings economical and ethical questions and will require further progress in our capacity to interpret and store the personal genomic data without compromising their confidentiality	172	214	CHALLENGE
Some of these are related to the research process, for example, confidentiality and informed consent in association with human tissue sampling	64	79	CHALLENGE
Some of these are related to the research process, for example, confidentiality and informed consent in association with human tissue sampling	84	100	CHALLENGE
Concerns regarding confidentiality and discrimination were stated	19	34	CHALLENGE
Concerns regarding confidentiality and discrimination were stated	39	53	CHALLENGE
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	40	56	CHALLENGE
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	61	76	CHALLENGE
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	100	108	CHALLENGE
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	110	117	CHALLENGE
Therefore, there is a need to encourage informed consent and confidentiality, as well as to promote autonomy, justice, and equity by developing worldwide equivalent ethical, legal, and regulatory frameworks	123	129	CHALLENGE
0% of online news articles mentioned testing confidentiality and privacy protection	45	60	CHALLENGE
0% of online news articles mentioned testing confidentiality and privacy protection	65	83	CHALLENGE
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	34	41	CHALLENGE
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	43	58	CHALLENGE
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	60	68	CHALLENGE
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	70	86	CHALLENGE
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	89	113	CHALLENGE
Ethics concepts addressed include privacy, confidentiality, autonomy, informed consent, fiduciary responsibility, respect, the burden of pharmacogenomics knowledge for both the patient and healthcare provider and the pharmacist's ethical role in PGx-testing	114	121	CHALLENGE
This is an overview of drug delivery systems (DDS), starting with various routes of drug administration	23	50	CHALLENGE
Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care	35	71	CHALLENGE
Reasons for the delays include the complexity of the underlying science as well as clinical, economic, and organizational barriers to the effective delivery of personalized health care	83	184	CHALLENGE
Current research should optimise the delivery of this single-agent chemotherapy	37	79	CHALLENGE
In this age of personalized medicine, genetic and genomic testing is expected to become instrumental in health care delivery, but little is known about its actual implementation in clinical practice	130	198	CHALLENGE
Anesthesia providers strive to optimize anesthesia delivery and patient outcomes and to specifically reduce anesthesia-related risks and negative outcomes	31	59	CHALLENGE
Anesthesia providers strive to optimize anesthesia delivery and patient outcomes and to specifically reduce anesthesia-related risks and negative outcomes	101	132	CHALLENGE
Treatment of acute lymphoblastic leukemia (ALL) in adults remains a challenge, as the delivery of intensive chemotherapeutic regimens in this population is less feasible than it is in the pediatric population	0	47	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	82	125	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	127	171	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	179	202	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	203	242	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	247	330	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	338	401	CHALLENGE
To achieve demonstrated value, genomic medicine must overcome many uncertainties: the clinical relevance of genomic variation; potential variation in technical performance and/or computational analysis; management of massive information sets; and must have available clinical interventions that can be informed by genomic analysis, so as to attain more favorable cost management of healthcare delivery and demonstrate improvements in cost-effectiveness	406	452	CHALLENGE
Increased knowledge on the role of ethnicity in PD may help shed light on the symptom expression and treatment response of PD, address inequalities in health care delivery worldwide and improve the delivery of personalised medicine	134	171	CHALLENGE
Increased knowledge on the role of ethnicity in PD may help shed light on the symptom expression and treatment response of PD, address inequalities in health care delivery worldwide and improve the delivery of personalised medicine	195	232	CHALLENGE
Nevertheless, the efficacy of siRNA delivery has, so far, remained a challenging issue	14	44	CHALLENGE
This is due to their easy degradation through the circulation system and the difficulties in the intracellular delivery to specific tissues where they silence the target genes	77	119	CHALLENGE
However, efficient delivery of this information to the point of prescribing remains a significant challenge	9	47	CHALLENGE
However, integration of PGx testing may be limited as no uniform approach to delivery of tests has been established and providers are ill-prepared to integrate PGx testing into routine care	54	94	CHALLENGE
However, integration of PGx testing may be limited as no uniform approach to delivery of tests has been established and providers are ill-prepared to integrate PGx testing into routine care	120	189	CHALLENGE
Pharmacogenomics (PGx) education is crucial to support the effective delivery of PGx services in any health care system	0	32	CHALLENGE
They provide precision delivery of medications based on knowledge of pharmacogenetics, patient and family education related to the meaning of genomics, health and family assessments, and critical feedback and insights on the feasibility of implementing new technologies into clinical point-of-care or community workflows	225	297	CHALLENGE
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	64	97	CHALLENGE
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce	170	211	CHALLENGE
The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety	159	173	CHALLENGE
The incorporation of pharmacogenetic/pharmacogenomic protocols to AD research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety	195	218	CHALLENGE
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	24	58	CHALLENGE
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	106	134	CHALLENGE
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	136	181	CHALLENGE
Limitations include the optimal composition of test panels, still largely unknown, information concerning inter-individual variability, lack of analytical and quality specifications, lack of comprehensive outcome analyses to enable assessment of cost-effectiveness, lack of universal agreement related to reliable dosing algorithms and other ethical and social issues	183	221	CHALLENGE
The incorporation of pharmacogenetic/pharmacogenomic protocols into AD research and clinical practice can foster the optimization of therapeutics by helping to develop cost-effective biopharmaceuticals and improving drug efficacy and safety	160	201	CHALLENGE
The incorporation of pharmacogenetic/pharmacogenomic protocols into AD research and clinical practice can foster the optimization of therapeutics by helping to develop cost-effective biopharmaceuticals and improving drug efficacy and safety	206	240	CHALLENGE
This leads to an increase in stent thromboses and recurrent ischemic events which add to the health care costs, and increased periprocedural morbidity and mortality	93	110	CHALLENGE
alcohol intolerance), (ii) reusable graphical interfaces that reduce extension costs, and (iii) explanations of molecular and cellular drug responses	96	149	CHALLENGE
alcohol intolerance), (ii) reusable graphical interfaces that reduce extension costs, and (iii) explanations of molecular and cellular drug responses	29	86	CHALLENGE
The cost of genomic information has fallen steeply, but the clinical translation of genetic risk estimates remains unclear	60	106	CHALLENGE
Many existing algorithms do not scale up well for large sequences or databases because of their high-computational costs	28	65	CHALLENGE
Many existing algorithms do not scale up well for large sequences or databases because of their high-computational costs	96	120	CHALLENGE
With the use of molecular criteria and the diminishing cost of analytic technologies, anesthetic practice will become more individualized, and greater emphasis will be placed on the patient's genetic makeup	43	84	CHALLENGE
This leads to unnecessarily lengthy processing times and excessive data handling and storage costs	57	80	CHALLENGE
This leads to unnecessarily lengthy processing times and excessive data handling and storage costs	85	98	CHALLENGE
This leads to unnecessarily lengthy processing times and excessive data handling and storage costs	14	46	CHALLENGE
Clinical trials are ongoing to determine the clinical utility and cost-effectiveness of genotypeguided warfarin dosing	45	61	CHALLENGE
Clinical trials are ongoing to determine the clinical utility and cost-effectiveness of genotypeguided warfarin dosing	66	84	CHALLENGE
Establishment of diabetes pharmacogenetics consortia and reduction in costs of genomics might lead to some significant clinical breakthroughs in this field in a near future	57	87	CHALLENGE
The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory	72	81	CHALLENGE
The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory	83	97	CHALLENGE
The current standard method for HLA-B*57:01 screening is limited by its high-cost, time-consuming and labour-intensive procedure with the requirement of a specialized laboratory	102	118	CHALLENGE
It offers high-accuracy, cost-effective and rapid detection	10	23	CHALLENGE
It offers high-accuracy, cost-effective and rapid detection	25	39	CHALLENGE
It offers high-accuracy, cost-effective and rapid detection	44	59	CHALLENGE
Several models have been proposed to explain the immunopathogenesis of severe T cell-mediated drug HSRs, and our increased understanding of the risk factors and mechanisms involved in the development of these reactions will further the development of sensitive and specific strategies for preclinical screening that will lead to safer and more cost-effective drug design	236	310	CHALLENGE
Several models have been proposed to explain the immunopathogenesis of severe T cell-mediated drug HSRs, and our increased understanding of the risk factors and mechanisms involved in the development of these reactions will further the development of sensitive and specific strategies for preclinical screening that will lead to safer and more cost-effective drug design	329	370	CHALLENGE
This paper argues that pharmacogenomics can complement pharmacologic class effects in drug-safety management, and their use can be implemented without excessive costs or other impracticalities	86	108	CHALLENGE
This paper argues that pharmacogenomics can complement pharmacologic class effects in drug-safety management, and their use can be implemented without excessive costs or other impracticalities	128	192	CHALLENGE
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	142	176	CHALLENGE
Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs	108	155	CHALLENGE
Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs	161	181	CHALLENGE
Clinical pharmacists play an important role in designing therapeutic regimen, preventing medication errors, reducing the incidence of adverse drug reaction, and saving medical costs	79	107	CHALLENGE
Precision medicine (also called personalized, stratified, or P4 medicine) can be defined as the tailoring of preventive measures and medical treatments to the characteristics of each patient to obtain the best clinical outcome for each person while ideally also enhancing the cost-effectiveness of such interventions for patients and society	262	294	CHALLENGE
This may subsequently contribute towards significant cost-savings in the overall healthcare expenditure in the participating countries, where pharmacogenomics implementation proves to be cost-effective	53	103	CHALLENGE
In order for pharmacogenetics to reach its full potential, more cost-effective and easily accessible genotyping methods are desired	83	119	CHALLENGE
In order for pharmacogenetics to reach its full potential, more cost-effective and easily accessible genotyping methods are desired	64	78	CHALLENGE
This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment	81	110	CHALLENGE
This leads to achieving the maximal therapeutic response for each patient, while reducing adverse side effects of therapy and the cost of treatment	130	147	CHALLENGE
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	71	79	CHALLENGE
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	81	95	CHALLENGE
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	100	116	CHALLENGE
The adoption of pharmacogenetic (PGx) testing in patient care requires accurate, cost effective and rapid genotyping with clear guidance on the use of the results	123	163	CHALLENGE
The costs for both kits are not covered by the statutory health insurance and it is therefore proposed that the patients are invoiced directly in the form of individual healthcare payment	28	73	CHALLENGE
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	92	123	CHALLENGE
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	214	238	CHALLENGE
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	240	257	CHALLENGE
DNA biosensors are attractive tools for genetic analysis as there is an increasing need for rapid and low-cost DNA analysis, primarily driven by applications in personalized pharmacogenomics, clinical diagnostics, rapid pathogen detection, food traceability and forensics	262	271	CHALLENGE
Large-scale epidemiologic studies are required to demonstrate the usefulness and cost-effectiveness of screening tests because their efficacy is affected by the genetic differences among ethnicities	161	198	CHALLENGE
PGx testing that is preemptive, adaptable, current, and executable (PACE) overcomes the human and technological barriers to successful implementation, thus capitalizing on the affordable cost of such testing and clinical practice guidelines at the point of prescription ordering	124	149	CHALLENGE
Logistics and (cost-)effectiveness of pharmacogenetic (PGx)-testing may be optimized when delivered through a pre-emptive panel-based approach, within a clinical decision support system (CDSS)	0	9	CHALLENGE
Logistics and (cost-)effectiveness of pharmacogenetic (PGx)-testing may be optimized when delivered through a pre-emptive panel-based approach, within a clinical decision support system (CDSS)	14	34	CHALLENGE
This high-throughput low-cost method accurately determines CNV in the CYP2D6 gene enabling reliable estimates of disease prediction in large epidemiological samples	100	164	CHALLENGE
A sufficiently powered prospective study assessing the (cost-)effectiveness of a panel-based pharmacogenomics approach to guide pharmacotherapy is lacking	55	118	CHALLENGE
Its utility is also challenged by cost and higher reliance on conventional prescribing practices	3	39	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	84	101	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	107	129	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	146	187	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	189	210	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	214	240	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	242	260	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	262	309	CHALLENGE
Major limitations for the routine use of PGx procedures for ADRs prevention are the lack of education and training in physicians and pharmacists, poor characterization of drug-related PGx, unspecific biomarkers of drug efficacy and toxicity, cost-effectiveness, administrative problems in health organizations, and insufficient regulation for the generalized use of PGx in the clinical setting	315	369	CHALLENGE
improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic	63	101	CHALLENGE
improved safety and cost-effectiveness) and the development of efficient multi-gene genotyping panels, routine pretreatment testing for these gene-drug pairs has not been implemented widely in the clinic	104	159	CHALLENGE
The implementation of genotyping in the clinic will nonetheless be a practical challenge due to a lack of clarity about who will bear the associated costs	98	154	CHALLENGE
Numerous additional pharmacogenomic associations have been reported concerning antimicrobial-related idiosyncratic adverse drug reactions, particularly involving specific HLA alleles, but, to date, the cost-effectiveness of genotyping prior to prescription has not been confirmed	224	256	CHALLENGE
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	60	86	CHALLENGE
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	98	117	CHALLENGE
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	118	136	CHALLENGE
However, one of the barriers to effective implementation is evaluation of the evidence including clinical usefulness, cost-effectiveness, and operational requirements	143	167	CHALLENGE
The description of SNPs in pharmacogenes and the establishment of their relationship with the pharmacokinetics of an individual offer an individualized approach that allows us to reduce the unfavorable outcomes of a therapy, ensure better adherence to treatment, prevent the emergence of MDR strains, reduce the cost of treatment, and improve the quality of patients' lives	45	127	CHALLENGE
However, although such pharmacogenetic variations have been estimated to account for a considerable amount of the heritable variability in drug response and toxicity, accurate interpretation at the level of the individual patient remains challenging	167	190	CHALLENGE
While current guidelines concerning clinical implementation mostly act upon well-documented, common single nucleotide variants to guide dosing or drug selection	36	59	CHALLENGE
challenges related to accurate variant interpretation and biomarker utilization will constitute the dominant barriers to clinical use of NGS in pharmacogenomics in the future.	121	140	CHALLENGE
Ethical concerns, including violation of confidentiality, stigmatization, and social pressure to accept pharmacogenomic testing, are among the many challenges that patients face in the adoption of pharmacogenomic testing	41	56	CHALLENGE
Genotyping cost and frequency of risk alleles in the populations influence the cost-effectiveness outcome	11	15	CHALLENGE
Variants of uncertain significance (VUSs) in these genes are discovered at a rate that outpaces current ability to classify them with databases of previous cases, experimental evaluation, and computational predictors.	134	161	CHALLENGE
there are many challenges that must be overcome to apply rapidly accumulating genomic information to understand variable drug responses, including defining candidate genes and pathways	147	171	CHALLENGE
major challenges of implementation lie at the point of delivery into health-care systems	55	63	CHALLENGE
economic challenges that face developers of and payers for personalized drugs and companion diagnostics	0	8	CHALLENGE
how can we harness the data to inform clinically actionable measures and how can we use it to develop better predictive risk models	11	68	CHALLENGE
ethical considerations must inform the construction and deployment of all rare-variation triage strategies, particularly with respect to health disparities arising from unbalanced ancestry representation.	137	155	CHALLENGE
The genomic inter-individual heterogeneity remains a significant challenge for both clinical decision-making and the design of clinical trials	29	42	CHALLENGE
Despite demonstrating great value for the identification of single nucleotide variants (SNVs) and insertion/deletions (INDELs), these assays do not permit identification of large structural variants, nor do they allow unambiguous haplotype phasing for star-allele assignment.	155	198	CHALLENGE
the implementation of pharmacogenomics in routine clinical practice presents significant challenges	4	18	CHALLENGE
However, the implementation of PGx studies during clinical development presents a number of challenges	13	27	CHALLENGE
Challenges to integrating genomics-based medicine into health care systems include tumor and biologic heterogeneity	14	25	CHALLENGE
One of the major barriers to implementing clinical pharmacogenomics has been the efficient integration of rapid turnaround-time genetic testing into routine clinical practice	91	102	CHALLENGE
However, major challenges of implementation lie at the point of delivery into health-care systems, including the modification of current clinical pathways coupled with a massive knowledge gap in pharmacogenomics in the health-care workforce.	178	191	CHALLENGE
Lack of knowledge of genomics and pharmacogenomics among pharmacists was one of the most prominent findings	0	17	CHALLENGE
effective patient educational materials are limited	44	51	CHALLENGE
Nevertheless, PGx consultation prior to prescribing therapeutics is not yet mainstream.	14	86	CHALLENGE
The impact of recurrent pathogenic variants is often understood, however there is a long tail of rare genetic variants that are uncharacterized.	97	118	CHALLENGE
The problem of uncharacterized rare variation is especially acute when it occurs in genes of known clinical importance with functionally consequential variants and associated mechanisms.	31	45	CHALLENGE
Challenges related to rare-variant pharmacogenomics	22	34	CHALLENGE
Overcoming the gap between 'big data'-derived model predictions and real-world clinical outcomes arguably constitutes one of the greatest challenges of 21st century medical science	68	78	CHALLENGE
translation of the obtained genomic information into actionable clinical advice lags behind	0	11	CHALLENGE
We discuss emerging strategies and concepts to close this translational gap.	58	75	CHALLENGE
Interindividual variability in drug efficacy and toxicity is a major challenge in clinical practice	16	27	CHALLENGE
A major methodological challenge in pharmacogenomics is ascertaining the causality of identified variants	97	105	CHALLENGE
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	21	36	CHALLENGE 
This cost-effective, highly-scalable, and highly-accurate platform was created to explore rare variation in 84 key pharmacogenetic genes with strong drug phenotype associations	42	57	CHALLENGE 
The Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB; www	25	56	DATABASE
PharmGKB's website is designed to effectively disseminate knowledge to meet the needs of our users	0	8	DATABASE
In order to meet the needs of whole genome studies, PharmGKB has added new functionalities, including browsing the variant display by chromosome and cytogenetic locations, allowing the user to view variants not located within a gene	52	60	DATABASE
PharmGKB has also added functionality to accept, store, display and query high throughput SNP array data	0	8	DATABASE
The PharmGKB is a publicly available online resource that aims to facilitate understanding how genetic variation contributes to variation in drug response	4	12	DATABASE
This unit describes how to navigate the PharmGKB Web site to retrieve detailed information on genes and important variants, as well as their relationship to drugs and diseases	40	48	DATABASE
Workflow on how to use PharmGKB to facilitate design of the pharmacogenomic study is also described in this unit	23	31	DATABASE
The PharmGKB currently contains information on over 500 drugs, 500 diseases, and 700 genes with genotyped variants	4	12	DATABASE
The NIH initiated the PharmGKB in April 2000	22	30	DATABASE
PharmGKB has refocused on curating knowledge rather than housing primary genotype and phenotype data, and now, captures more complex relationships between genes, variants, drugs, diseases and pathways	0	8	DATABASE
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	88	123	DATABASE
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	131	158	DATABASE
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	166	197	DATABASE
Our own analysis shows that the overlap between important existing repositories such as Comparative Toxicogenomics Database (CTD), Therapeutic Target Database (TTD), Pharmacogenomics Knowledge Base (PharmGKB) and DrugBank as well as between our own literature mining for cancer-annotated entries is surprisingly small	213	221	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	265	270	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	272	278	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	283	296	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	148	156	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	161	170	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	202	209	DATABASE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	229	236	DATABASE
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	4	37	DATABASE
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	106	114	DATABASE
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	119	127	DATABASE
The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data from the International HapMap Project and the Singapore Genome Variation Project	181	195	DATABASE
PharmGKB is a leading resource of high quality pharmacogenomics data that provides information about how genetic variations modulate an individual's response to drugs	0	8	DATABASE
PharmGKB contains information about genetic variations, pharmacokinetic and pharmacodynamic pathways, and the effect of variations on drug-related phenotypes	0	8	DATABASE
PharmGKB provides very detailed clinical associations between genetic variants and drug response, including genotype-specific drug dosing guidelines, and this procedure will armGKB	0	8	DATABASE
Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations	77	83	DATABASE
Finally, we used the detailed drug and disease relationship information from NDF-RT and the SPLs to annotate and disambiguate the more general PharmGKB drug and disease associations	143	151	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	286	311	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	320	359	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	368	376	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	378	385	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	418	453	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	466	520	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	532	563	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	576	606	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	663	682	DATABASE
MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese	269	275	DATABASE
The PharmGKB website provides a diverse array of PGx information, from annotations of the primary literature to guidelines for adjusting drug treatment based on genetic information	4	12	DATABASE
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	181	189	DATABASE
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	175	205	DATABASE
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	207	216	DATABASE
Filtered variants were classified according to population frequency, variant type, the functional impact of the variant, pathogenicity predictions and characterization in the Pharmacogenomics Knowledgebase (PharmGKB) and ClinVar	221	228	DATABASE
Furthermore, we identified an additional 61 variants with PharmGKB 2A or 2B clinical annotations	58	66	DATABASE
In this study, we genotyped 80 VIP variants from the PharmGKB in 100 members of Blang volunteers from Yunnan province	53	61	DATABASE
State-of-the-art knowledge in PGx is mainly available in reference databases such as PharmGKB and reported in scientific biomedical literature	85	93	DATABASE
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	195	203	DATABASE
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	135	143	DATABASE
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	213	264	DATABASE
This GeneFocus provides a comprehensive overview and summary of CYP2D6 genetic variation and describes how the information provided by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC)	266	271	DATABASE
Clinical dosing guidelines for specific drug-gene interactions (DGI) are publicly available through PharmGKB	100	108	DATABASE
A total of 65 VIP variants located within 33 candidate genes were randomly selected from the PharmGKB database and genotyped using the MassARRAY (iPLEX GOLD) system	93	101	DATABASE
A total of 65 VIP variants located within 33 candidate genes were randomly selected from the PharmGKB database and genotyped using the MassARRAY (iPLEX GOLD) system	135	144	DATABASE
Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP)	72	103	DATABASE
Actionable pharmacogenetic variants were identified with a query to the Pharmacogenomics Knowledge Base (PharmGKB) database, and functional prediction using the Variant Effect Predictor (VEP)	161	185	DATABASE
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	193	201	DATABASE
In the last, a circRNA/miRNA/mRNA regulatory network was constructed, and potential compounds and drug which may have the function of anti ccRCC were forecasted by taking advantage of CMap and PharmGKB datasets	184	188	DATABASE
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	92	99	DATABASE
Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test	139	170	DATABASE
Very important pharmacogenetic (VIP) variants mean that genes or variants play important and vital roles in drug response, which have been listed in pharmacogenomics databases, such as Pharmacogenomics Knowledge Base (PharmGKB)	185	216	DATABASE
Meanwhile, we found several VIP variants that might alter the drug metabolism of cisplatin-cyclophosphamide (CYP2E1), vitamin E (CYP4F2), asthma amlodipine, chlorthalidone, and lisinopril (ACE) through PharmGKB	202	210	DATABASE
These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)	345	396	DATABASE
These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group)	407	438	DATABASE
We performed a retrospective analysis of drug plasma concentrations and treatment efficacy in patients bearing at least one relevant PharmGKB variant	133	141	DATABASE
<b>Materials & methods:</b> We selected 66 VIP variants from PharmGKB (www	61	69	DATABASE
Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases	97	105	DATABASE
Bioinformatic analyses included the identification of clinically validated variants described in PharmGKB and ClinVar databases	110	117	DATABASE
Reported associations in pharmacogenomics knowledge base PharmGKB have weak supporting evidence	25	56	DATABASE
frameshift, nonsense), and splice site variants with potential deleterious effect and B) clinically validated variants described in the PharmGKB (categories 1, 2 and 3) and/or ClinVar databases	176	183	DATABASE
0% of the individuals carried at least one high risk genotype-predicted phenotype in pharmacogenes with PharmGKB level of evidence 1A for drug interaction	104	112	DATABASE
0% of the cohort used at least one PharmGKB evidence level 1A drug, and 18	35	43	DATABASE
To examine the representation of biogeographical populations in pharmacogenomic data sets, we describe individuals involved in gene-drug response studies from PharmGKB, a leading repository of drug-gene annotations, and showcase<i>CYP2D6</i>, a gene that metabolizes approximately 25% of all prescribed drugs	159	167	DATABASE
In this guideline, we will present the genes of interest with level 1 clinical recommendations according to PharmGKB for the two major families of psychotropics: antipsychotics and antidepressants	108	116	DATABASE
Here, we used Oxford Nanopore Technologies' adaptive sampling to enrich a panel of 1,036 genes with well-documented PGx relevance extracted from the Pharmacogenomics Knowledge Base (PharmGKB)	149	180	DATABASE
We utilized PyPGx to identify star alleles (haplotype patterns) and compared allele frequencies across populations using the Pharmacogenomics Knowledgebase PharmGKB	156	164	DATABASE
54 VIP variants were selected from the Pharmacogenomics Knowledge Base (PharmGKB) and genotyped in 200 Yi individuals	39	70	DATABASE
A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided	56	64	DATABASE
A description of how haplotype information cataloged by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC) is also provided	134	185	DATABASE
Furthermore, we explored the landscape of DPWG pharmacogenes in gnomAD and our in-house cohort as well as compared bioinformatic tools for WGS-based structural variant detection in <i>CYP2D6</i>	64	70	DATABASE
We further assessed the distribution of the identified rare and common pharmacogenomics variants amongst different GnomAD subpopulations	115	121	DATABASE
Overall, our findings show that the use of publicly available sequence data, such as the DiscovEHR dataset and GnomAD, provides an opportunity for a deeper understanding of genetic variation in pharmacogenes with direct implications in clinical pharmacogenomics	89	98	DATABASE
3% of variants absent from gnomAD database	27	33	DATABASE
Here, we analyzed sequence variation data in 141,456 individuals from across eight study populations in gnomAD for 38 CYP genes to identify such variants in addition to common variants	104	110	DATABASE
Certain common functional variants including NUDT15 13:48611934 G/A (rs186364861), UGT1A1 2:234676872 C/T (rs34946978), and ALDH2 12:112241766 G/A (rs671) were population-specific for CMDB Chinese because they were absent (with a zero of variant allele frequency) or very rare in other gnomAD populations	286	292	DATABASE
Differences in variant allele frequency were observed among the populations studied and the corresponding gnomAD population for 7	106	112	DATABASE
Allelic frequencies were compared to other populations reported in the public gnomAD database	78	84	DATABASE
We compare our allelic frequencies with these from populations described in the gnomAD database	80	86	DATABASE
We demonstrate ePGA's functionality on genetic variation data from the 1000 Genomes Project	71	91	DATABASE
The 1000 Genomes Project data were analyzed to describe population genetic variation and statistics for these five genes in self-reported healthy individuals in five global super- and 26 sub-populations	4	24	DATABASE
Herein, we exploit ePGA, a web-based electronic Pharmacogenomics Assistant and publicly available genetic data from the 1000 Genomes Project to explore genotype to phenotype associations among the 1000 Genomes Project populations	120	140	DATABASE
This study aims to identify and characterize likely causal variants within well-established pharmacogenomic genes using next-generation sequencing data from the 1000 Genomes Project	161	181	DATABASE
77 M small indels, identified from 991 Chinese individuals of the Chinese Academy of Sciences Precision Medicine Initiative Project (CASPMI) and 301 Chinese individuals of the 1000 Genomes Project (1KGP)	176	196	DATABASE
This study aimed to identify the distribution differences of very important pharmacogene (VIP) variants between the Tibetan population and the other 26 populations from the 1000 Genomes project	173	193	DATABASE
To test potential associations between noncoding and coding pharmacogenetic variants, we computed a drug-level GVB for 5099 drugs from DrugBank for 2504 genomes of the 1000 Genomes Project and evaluated the correlation between the long-known noncoding variant-drug associations in PharmGKB, with functionally relevant rare and common coding variants aggregated into GVBs	168	188	DATABASE
The apparent discrepancy with our previous results for NUDT15 rs116855232 in the Ad Mixed American superpopulation of the 1000 Genomes Project is ascribed to the diversity of the Native populations of the Americas	122	142	DATABASE
Among the accuracy controls were 32 samples from the 1000 Genomes Project that were selected based on their enrichment of sequence variants included in the pharmacogenetic panel (VarCover	53	73	DATABASE
Frequency of CYP2C19*2, *3 and *17 alleles were obtained from 1000 Genomes project Phase III in line with Fort Lauderdale principles	62	82	DATABASE
In this study, we analyzed the whole-genome sequencing data from The 1000 Genomes Project (Phase 3) and the pharmacogenetic information from Drug Bank, PharmGKB, PharmaADME, and Biotransformation	69	89	DATABASE
Whole genome sequencing data from the 1000 Genomes Project and the African Genome Variation Project were mined to assess variation in <i>DPYD</i> in eight sub-Saharan African populations	38	58	DATABASE
In contrast, long-read HiFi sequencing phased all variants across the NUDT15 amplicons, including a *2/*9 diplotype that previously was characterized as *1/*2 in the 1000 Genomes Project v3 data set	166	186	DATABASE
This let us to compare the frequency of gene variants involved in response to drugs among our population and others, taking data from the 1000 Genomes Project	138	158	DATABASE
The genotype distribution data of 26 populations were downloaded from the 1000 Genomes Project and analyzed with the \u03c7<sup>2</sup> test	74	94	DATABASE
<b>Results:</b> Among the 26 populations in the 1000 Genomes Project, African Caribbeans in Barbados; Esan in Nigeria; Gambian in Western Divisions, The Gambia; Luhya in Webuye, Kenya; Yoruba in Ibadan; Finnish in Finland; Toscani in Italy\u00a0and Sri Lankan Tamil in the UK were the top eight nationalities with the most significant differences in genotype distribution from the Lisu population	48	68	DATABASE
These assessments encompass reference materials from the Genome-In-A-Bottle (GIAB), the Genetic Testing Reference Material Coordination Program (GeT-RM) projects, as well as additional samples from the 1000 Genomes project (1KGP)	202	222	DATABASE
The allele frequencies and genotype distribution data of 26 populations were obtained from the 1000 Genomes Project, followed by a comparison and statistical analysis	95	115	DATABASE
We developed a new method to construct haplogroups, representing a common ancestry structure, by iteratively excluding rare and functional variants of the 25 representative pharmacogenes using the 2504 genomes from the 1000 Genomes Project	219	239	DATABASE
We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data	177	182	DATABASE
We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data	185	189	DATABASE
We have developed new infrastructure for handling whole genome data, including increased methods for quality control and tools for comparison across other data sources, such as dbSNP, JSNP and HapMap data	193	199	DATABASE
While sequence data about genetic variation is found at databases such as dbSNP, clues about the functional and phenotypic consequences of the variations are generally found in biomedical literature	74	79	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	52	56	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	147	152	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	234	239	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	281	284	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	313	318	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	361	366	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	522	530	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	565	574	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	608	613	DATABASE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	663	682	DATABASE
While it is arguably the most comprehensive source of genetic information, the NCBI's dbSNP database (National Center for Biotechnology Information database of single nucleotide polymorphisms; http://www	86	91	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	14	20	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	47	56	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	58	65	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	67	73	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	75	80	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	82	86	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	88	96	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	98	105	DATABASE
Self-updating GenoDB contains information from NCBI Gene, Clinvar, Medgen, dbSNP, KEGG, PharmGKB, Uniprot, and Hugo Gene databases	111	120	DATABASE
We compare and report here on the observed SNP genetic variation in our sample with data on 12 world populations from dbSNP and discuss the feasibility of forecasting the pharmacokinetics of drugs utilized by migrant communities in Mersin and the Eastern Mediterranean region	118	123	DATABASE
In total, 18,245 variants were identified of which 2565 were novel variants (without rs number in dbSNP build 150) in the testing phase	98	103	DATABASE
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	210	214	DATABASE
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	185	208	DATABASE
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	117	122	DATABASE
When applied to platinum-treated patients gathered from TCGA, the model predicted treatment-specific response	56	60	DATABASE
The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network	95	118	DATABASE
The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network	120	125	DATABASE
Here, we have developed a novel computational method that allows us to impute drug response in very large clinical cancer genomics data sets, such as The Cancer Genome Atlas (TCGA)	150	173	DATABASE
Here, we have developed a novel computational method that allows us to impute drug response in very large clinical cancer genomics data sets, such as The Cancer Genome Atlas (TCGA)	175	180	DATABASE
We applied a transcriptome based drug sensitivity prediction method, to the Cancer Genome Atlas (TCGA) ovarian cancer dataset to impute patient tumor response to over 100 different drugs	76	95	DATABASE
We applied a transcriptome based drug sensitivity prediction method, to the Cancer Genome Atlas (TCGA) ovarian cancer dataset to impute patient tumor response to over 100 different drugs	97	102	DATABASE
In addition, COAC-inferred subnetworks from melanoma patients' scRNA-seq profiles are highly correlated with survival rate from The Cancer Genome Atlas (TCGA)	128	151	DATABASE
In addition, COAC-inferred subnetworks from melanoma patients' scRNA-seq profiles are highly correlated with survival rate from The Cancer Genome Atlas (TCGA)	153	158	DATABASE
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	164	169	DATABASE
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	129	134	DATABASE
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	92	127	DATABASE
Despite the availability of databases such as the Cancer Cell Line Encyclopedia (CCLE), the Cancer Therapeutics Response Portal (CTRP), and The Cancer Genome Atlas (TCGA), it is still challenging for biologists to explore the relationship between drug response and underlying genomic features due to the heterogeneity of the data	50	79	DATABASE
By comparing with the western gastric cancer patients collected from TCGA data portal, some unique characteristics for patients in QTP are suggested	69	73	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	53	76	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	84	112	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	118	171	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	182	218	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	218	223	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	225	233	DATABASE
Lung adenocarcinoma-related genes were obtained from The Cancer Genome Atlas(TCGA), Therapeutic Target Database(TTD), Pharmacogenetics and Pharmacogenomics Knowledge Base(PharmGKB), Online Mendelian Inheritance in Man(OMIM), DrugBank, and GeneCards	239	248	DATABASE
<b>Methods:</b> In the present study, we conducted a multi-omics analysis, including gene expression, methylation status, DNA alterations, pharmacogenomics, and survival status based on data from the Cancer Genome Atlas (TCGA) database to discern expression patterns and prognostic roles of BATF in tumors	221	225	DATABASE
<b>Methods:</b> In the present study, we conducted a multi-omics analysis, including gene expression, methylation status, DNA alterations, pharmacogenomics, and survival status based on data from the Cancer Genome Atlas (TCGA) database to discern expression patterns and prognostic roles of BATF in tumors	200	219	DATABASE
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	90	94	DATABASE
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	99	102	DATABASE
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	210	235	DATABASE
We conducted univariate and multivariate Cox regression analyses using publicly available TCGA and GEO datasets to investigate the impact of <i>RYK</i> gene expression status on glioma patient overall (OS) and progression-free survival (PFS)	237	241	DATABASE
Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with high <i>MKX-AS1</i> expression status had significantly worse overall survival (HR = 3	72	76	DATABASE
Further analysis of patient survival data from the Cancer Genome Atlas (TCGA) and other sources showed that patients with high <i>MKX-AS1</i> expression status had significantly worse overall survival (HR = 3	51	70	DATABASE
We applied the model to tumors in The Cancer Genome Atlas (TCGA) dataset and examined associations between predicted cell viability and mutation status or gene expression levels to understand underlying mechanisms of potential value for drug repurposing	59	63	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	99	122	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	124	129	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	131	157	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	159	164	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	166	189	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	191	195	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	205	224	DATABASE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	226	230	DATABASE
The research relied on data from the 1000 Genomes Project to assess population-specific genetic variations.	37	57	DATABASE
The Allele Frequency Aggregator (ALFA) database was utilized to explore allele frequencies of pharmacogenomic interest.	4	31	DATABASE
The study employed the Allele Frequency Net Database to assess population-level genetic variability in pharmacogenes.	23	52	DATABASE
The BioVU DNA databank was instrumental in identifying pharmacogenomic predictors of adverse drug reactions.	4	13	DATABASE
Pharmacogenomic data from the Cancer Genome Atlas (TCGA) were employed to study drug resistance mechanisms.	30	49	DATABASE
Pharmacogenomic data were sourced from public databases such as ClinVar and PharmGKB.	64	71	DATABASE
we provide a review of recent developments in computational pharmacogenomics with respect to CMap and LINCS and related applications.	93	97	DATABASE
Using the CPIC database, we correlated genetic variants with clinical dosing guidelines.	10	14	DATABASE
Clinical trial data were extracted from the dbGaP database for pharmacogenomic analysis.	44	49	DATABASE
We accessed data from the dbGAP to perform a pharmacogenomic study on drug response variability.	26	31	DATABASE
Data from the dbGaP database were analyzed to uncover genetic factors influencing drug efficacy.	14	19	DATABASE
The research utilized the dbSNP database to identify single nucleotide polymorphisms relevant to drug efficacy.	26	31	DATABASE
The NCBI dbSNP database was used to catalog single nucleotide polymorphisms relevant to drug response.	9	14	DATABASE
Data from the DME Pharmacogenomics Database were critical in analyzing drug-metabolizing enzyme variants.	14	34	DATABASE
The use of electronic health records (EHR) databases enabled large-scale pharmacogenomic studies.	11	36	DATABASE
Clinical pharmacogenomic data were retrieved from the Electronic Medical Records and Genomics (eMERGE) Network.	54	93	DATABASE
Using the eMERGE Network database, we linked electronic health record data with pharmacogenomic variants.	10	16	DATABASE
We utilized the Ensembl database to annotate genetic variants involved in drug response.	16	23	DATABASE
Genomic data from the ExAC database were utilized to investigate rare variants affecting drug metabolism.	22	26	DATABASE
Genomic variants were extracted from the ExAC database to assess their impact on drug metabolism pathways.	41	45	DATABASE
The study employed data from the FDA Adverse Event Reporting System (FAERS) database to link genetic factors with drug safety.	33	67	DATABASE
Pharmacogenomic data from the Gene Expression Omnibus (GEO) database were analyzed to identify expression patterns.	30	53	DATABASE
Data mining techniques were applied to the GWAS Catalog database to identify pharmacogenomic associations.	43	55	DATABASE
The study's findings were validated using data from the HapMap database.	56	62	DATABASE
We leveraged data from the International HapMap Project to enhance pharmacogenomic analyses.	41	47	DATABASE
Data from the Human Genome Variation Database (HGVD) were integrated into our pharmacogenomic analysis.	47	51	DATABASE
The Human Cytochrome P450 Allele Nomenclature Database provided critical data for our analysis of metabolic enzymes.	4	45	DATABASE
Data from the Human Gene Mutation Database (HGMD) were used to investigate pharmacogenomic mutations.	14	42	DATABASE
The International Warfarin Pharmacogenetics Consortium database provided data for our study on anticoagulant therapy.	4	63	DATABASE
Data from the iPGxDB database were pivotal in identifying population-specific pharmacogenomic markers.	14	20	DATABASE
Data from the International Serious Adverse Event Consortium (iSAEC) database were analyzed to investigate genetic predispositions.	62	67	DATABASE
Data from the Japanese Pharmacogenomics Data Science Consortium database were used to explore ethnic differences in drug response.	14	63	DATABASE
Large-scale perturbation databases, such as Connectivity Map (CMap) or Library of Integrated Network-based Cellular Signatures (LINCS)	0	24	DATABASE
The study leveraged the Mayo Clinic RIGHT Protocol database for pharmacogenomic implementation research.	24	51	DATABASE
relevant treatments are being discovered in precision psychiatry research by employing neuroimaging and multi-omics	104	115	DATABASE
Data from the NHGRI-EBI GWAS Catalog were integrated to identify pharmacogenomic associations with drug response.	14	28	DATABASE
We extracted pharmacogenomic data from the NIGMS Pharmacogenetics Research Network database.	43	82	DATABASE
The study used the Population Architecture using Genomics and Epidemiology (PAGE) database to investigate diverse population groups.	76	80	DATABASE
The PGRNseq dataset provided essential pharmacogenomic variant information for our analysis.	4	11	DATABASE
Data from the Pharmacogenomics Research Network (PGRN) were essential for our study.	14	47	DATABASE
Data were retrieved from the PharmGKB database to analyze genetic variants associated with drug metabolism.	29	37	DATABASE
The pharmacogenomic data were sourced from the PharmGKB database, focusing on gene-drug interaction profiles.	47	55	DATABASE
The study utilized the PharmGKB database to compile comprehensive drug-gene interaction data.	23	31	DATABASE
Data from the PharmacoGenomics Knowledge Base (PharmGKB) were used to annotate clinically relevant genetic variants.	47	55	DATABASE
Data from the PharmVar database were analyzed to study allelic variations in pharmacogenes.	14	22	DATABASE
The Personalized Medicine Research Project (PMRP) database provided crucial data for our pharmacogenomic study.	44	48	DATABASE
We utilized the Stanford University Biobank to validate pharmacogenomic findings in a clinical cohort.	16	43	DATABASE
We utilized the TCGA database to correlate genomic alterations with therapeutic outcomes.	16	20	DATABASE
We accessed the TCGA database to examine the association between somatic mutations and chemotherapy response.	16	20	DATABASE
The study integrated pharmacogenomic data from the UGT Alleles Nomenclature Database to investigate glucuronidation processes.	51	84	DATABASE
Genetic data from the UK Biobank were analyzed to explore pharmacogenomic implications in a large cohort.	22	32	DATABASE
The Utah Population Database provided valuable pharmacogenomic data for our study on familial drug responses.	4	28	DATABASE
The current version also supports summary analysis on differentially expressed genes between the HapMap samples of European and African ancestry	97	103	DATABASE
The CPNDS database consisted of 93,974 reports of medication use, including 10,475 reports of ADRs, of which 72.6% occurred in pediatric patients (≤21 years old).	4	18	DATABASE
The CPNDS database is a valuable resource to identify clinical and genomic predictors of ADRs.	4	18	DATABASE
CellMinerCDB: NCATS comprises 183 cancer cell lines, with 72 unique to NCATS, including some from previously understudied tissues of origin.	0	12	DATABASE
Clear easy-to-follow instructions are given on how to use big data technologies and public health databases in day-to-day clinical practice.	84	107	DATABASE
This study analyzed 942 whole-genome sequences from the Electricity Generating Authority of Thailand (EGAT) cohort to establish a population-specific pharmacogenomic database (TPGxD-1) in the Thai population.	176	183	DATABASE
Mental health problems are the leading cause of disability in Canadian workers.	0	13	DISEASE
Tacrolimus is metabolised in the liver and intestine by the cytochrome P450 3A (CYP3A) isoforms CYP3A4 and CYP3A5.	60	78	DISEASE
Osteoporosis is the most frequent metabolic bone	0	12	DISEASE
Although tuberculosis is largely a curable disease	9	21	DISEASE
A machine learning model was trained to predict the genome-wide chromatin accessibility from transcriptome data using the paired expression and chromatin accessibility data collected from ENCODE and ROADMAP	188	194	ENCODE
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	78	100	TECHNIQUE
In addition to high-density experimental microarrays, low-density, gel-based biochip technology represents a versatile platform for translation of research into clinical practice	67	84	TECHNIQUE
Whole blood was used to identify SNPs in ABCB1, MRP2, CYP2B6, CYP2A6, UGT2B7, NR1I2 (PXR), NR1I3 (CAR) and HNF4\u03b1 by real-time PCR	41	46	GENE_OR_GENE_PRODUCT
The anaphylatoxin C3a has been reported to have immunomodulatory effects on a number of different cell types.	18	21	GENE_OR_GENE_PRODUCT
CD14 is a membrane glycoprotein expressed specifically on monocytes and macrophages, and its expression is markedly increased during the process of monocyte differentiation.	0	4	GENE_OR_GENE_PRODUCT
CD14, a glycosylphosphatidylinositol-linked antigen, functions as an LPS signaling receptor.	0	4	GENE_OR_GENE_PRODUCT
A critical issue concerns the mechanism by which CD14, which has no transmembrane domain, transduces its signal following LPS binding.	49	53	GENE_OR_GENE_PRODUCT
Recently, investigators have hypothesized that CD14-mediated signaling is effected through a receptor-associated tyrosine kinase (TK), suggesting a multicomponent receptor model of LPS signaling.	47	51	GENE_OR_GENE_PRODUCT
The role of interleukin-11 (IL-11) was evaluated in the IgG immune complex model of acute lung injury in rats.	12	26	GENE_OR_GENE_PRODUCT
The role of interleukin-11 (IL-11) was evaluated in the IgG immune complex model of acute lung injury in rats.	28	33	GENE_OR_GENE_PRODUCT
The T cell surface molecule CD28 binds to ligands on accessory cells and APCs, playing an important costimulatory role in the response of T cells to Ags.	28	32	GENE_OR_GENE_PRODUCT
NF-IL6 is an important transcriptional regulator of genes induced in activated monocytes/macrophages, and NF-IL6 is the only CCAAT/enhancer-binding protein (C/EBP) family member whose steady-state mRNA levels increase upon activation of monocytes (1).	0	6	GENE_OR_GENE_PRODUCT
Recently NF-kappaB has been shown to have both proapoptotic and antiapoptotic functions.	9	18	GENE_OR_GENE_PRODUCT
Here we show that blockade of NF-kappaB activity, using a dominant negative IkappaBalpha, has opposite effects on these two apoptotic signals.	30	39	GENE_OR_GENE_PRODUCT
IFN-gamma has potent antiproliferative and apoptotic effects in T cells that are important in determining T cell development and polarized differentiation.	0	9	GENE_OR_GENE_PRODUCT
We have examined the effect of cytokines on IL-2 deprivation-induced apoptosis of human antigen-specific T helper clones with different cytokine production profiles.	44	48	GENE_OR_GENE_PRODUCT
We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones.	14	18	GENE_OR_GENE_PRODUCT
We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones.	20	36	GENE_OR_GENE_PRODUCT
We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones.	38	47	GENE_OR_GENE_PRODUCT
We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones.	54	62	GENE_OR_GENE_PRODUCT
We found that IL-2, interferon-alpha (IFN-alpha), and IFN-beta inhibited IL-2 deprivation apoptosis in Th0, Th1, and Th2 clones.	14	18	GENE_OR_GENE_PRODUCT
We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins.	19	23	GENE_OR_GENE_PRODUCT
We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins.	19	23	GENE_OR_GENE_PRODUCT
We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins.	140	143	GENE_OR_GENE_PRODUCT
We also found that IL-2 protects T cell clones from IL-2 deprivation apoptosis accompanying active proliferation and enhanced expression of P53, Rb and Bcl-xL proteins.	145	147	GENE_OR_GENE_PRODUCT
IL-8, a potent chemotactic factor for neutrophil granulocytes and lymphocytes, is a proinflammatory cytokine secreted by a variety of cell types, including T cells.	0	4	GENE_OR_GENE_PRODUCT
Interleukin-5 (IL-5), which is produced by CD4(+) T helper 2 (Th2) cells, but not by Th1 cells, plays a key role in the development of eosinophilia in asthma.	0	13	GENE_OR_GENE_PRODUCT
Interleukin-5 (IL-5), which is produced by CD4(+) T helper 2 (Th2) cells, but not by Th1 cells, plays a key role in the development of eosinophilia in asthma.	15	19	GENE_OR_GENE_PRODUCT
CIITA is a positive regulator of class II major histocompatibility complex gene transcription that has been found to be defective in one of the five complementation groups of class II major histocompatibility complex-negative cell lines.	0	5	GENE_OR_GENE_PRODUCT
CD3, CD2, and CD28 are functionally distinct receptors on T lymphocytes.	0	3	GENE_OR_GENE_PRODUCT
CD3, CD2, and CD28 are functionally distinct receptors on T lymphocytes.	5	8	GENE_OR_GENE_PRODUCT
CD3, CD2, and CD28 are functionally distinct receptors on T lymphocytes.	14	18	GENE_OR_GENE_PRODUCT
Tissue-specific expression of interleukin-3 (IL-3) is mediated via cis-acting elements located within 315 base pairs of the transcription start.	30	43	GENE_OR_GENE_PRODUCT
Tissue-specific expression of interleukin-3 (IL-3) is mediated via cis-acting elements located within 315 base pairs of the transcription start.	45	49	GENE_OR_GENE_PRODUCT
CD30 is a recently described member of the tumor necrosis factor/nerve growth factor receptor superfamily.	0	4	GENE_OR_GENE_PRODUCT
The highly specific granulomonocyte-associated lysosomal proteins myeloperoxidase (MPO) and lysozyme (LZ), as well as the transcription factor PU.1, were already detectable in the most immature CD34+Thy-1+ subset.	66	81	GENE_OR_GENE_PRODUCT
The highly specific granulomonocyte-associated lysosomal proteins myeloperoxidase (MPO) and lysozyme (LZ), as well as the transcription factor PU.1, were already detectable in the most immature CD34+Thy-1+ subset.	83	86	GENE_OR_GENE_PRODUCT
The highly specific granulomonocyte-associated lysosomal proteins myeloperoxidase (MPO) and lysozyme (LZ), as well as the transcription factor PU.1, were already detectable in the most immature CD34+Thy-1+ subset.	92	100	GENE_OR_GENE_PRODUCT
The highly specific granulomonocyte-associated lysosomal proteins myeloperoxidase (MPO) and lysozyme (LZ), as well as the transcription factor PU.1, were already detectable in the most immature CD34+Thy-1+ subset.	102	104	GENE_OR_GENE_PRODUCT
The highly specific granulomonocyte-associated lysosomal proteins myeloperoxidase (MPO) and lysozyme (LZ), as well as the transcription factor PU.1, were already detectable in the most immature CD34+Thy-1+ subset.	143	147	GENE_OR_GENE_PRODUCT
The chemokine receptor, BLR1, is a major regulator of the microenvironmental homing of B cells in lymphoid organs.	24	28	GENE_OR_GENE_PRODUCT
The therapeutic potential of drugs that block the induction of cyclooxygenase-2 has been emphasized.	63	79	GENE_OR_GENE_PRODUCT
Jagged1 belongs to the DSL family of ligands for Notch receptors that control the proliferation and differentiation of various cell lineages.	0	7	GENE_OR_GENE_PRODUCT
Interleukin-10 (IL-10) is a potent monocyte regulatory cytokine that inhibits gene expression of proinflammatory mediators.	0	14	GENE_OR_GENE_PRODUCT
Interleukin-10 (IL-10) is a potent monocyte regulatory cytokine that inhibits gene expression of proinflammatory mediators.	16	21	GENE_OR_GENE_PRODUCT
PU.1 is a hematopoietic transcription factor belonging to the Ets-family.	0	4	GENE_OR_GENE_PRODUCT
In order to understand the role of NF-kappaB in EBV transformation we have established stably transfected IkappaBalpha into lymphoblastoid cells.	35	44	GENE_OR_GENE_PRODUCT
Using the coiled-coil region of Stat5b as the bait in a yeast two-hybrid screen, we identified the association of Nmi, a protein of unknown function previously reported as an N-Myc interactor.	32	38	GENE_OR_GENE_PRODUCT
Using the coiled-coil region of Stat5b as the bait in a yeast two-hybrid screen, we identified the association of Nmi, a protein of unknown function previously reported as an N-Myc interactor.	114	117	GENE_OR_GENE_PRODUCT
In vitro labeled receptors were incubated with various synthetic or natural agonists or antagonists and submitted to trypsin digestion.	117	124	GENE_OR_GENE_PRODUCT
The amount of trypsin-resistant fragments was proportional to receptor occupancy by the ligand, and allowed the determination of dissociation constants (kDa).	14	21	GENE_OR_GENE_PRODUCT
The human autosomal recessive disease, xeroderma pigmentosum (XP), can result from mutations in any one of seven genes, designated XPA through XPG.	131	134	GENE_OR_GENE_PRODUCT
The human autosomal recessive disease, xeroderma pigmentosum (XP), can result from mutations in any one of seven genes, designated XPA through XPG.	143	146	GENE_OR_GENE_PRODUCT
Most erythroleukemic cell lines established in vitro coexpress erythrocytic and megakaryocytic markers that often are associated with expression of Spi-1 and/or Fli-1 transcription factors known as transactivators of megakaryocyte-specific promoters.	148	153	GENE_OR_GENE_PRODUCT
Most erythroleukemic cell lines established in vitro coexpress erythrocytic and megakaryocytic markers that often are associated with expression of Spi-1 and/or Fli-1 transcription factors known as transactivators of megakaryocyte-specific promoters.	161	166	GENE_OR_GENE_PRODUCT
Interstitial collagenase (MMP-1), a metalloproteinase produced by resident and inflammatory cells during connective tissue turnover, cleaves type I collagen fibrils.	13	24	GENE_OR_GENE_PRODUCT
Interstitial collagenase (MMP-1), a metalloproteinase produced by resident and inflammatory cells during connective tissue turnover, cleaves type I collagen fibrils.	26	31	GENE_OR_GENE_PRODUCT
We have examined binding of the nuclear protein HMG-I to the human gamma-globin promoter.	48	53	GENE_OR_GENE_PRODUCT
The anaphylatoxins C5a and C3a are involved in the regulation of cytokine production.	19	22	GENE_OR_GENE_PRODUCT
The anaphylatoxins C5a and C3a are involved in the regulation of cytokine production.	27	30	GENE_OR_GENE_PRODUCT
In this study the capability of C5a and C3a to induce transcription factor activation was examined.	32	35	GENE_OR_GENE_PRODUCT
In this study the capability of C5a and C3a to induce transcription factor activation was examined.	40	43	GENE_OR_GENE_PRODUCT
The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells.	69	82	GENE_OR_GENE_PRODUCT
The development of chronic eosinophilic inflammation is dependent on interleukin-5 (IL-5), a selective eosinophil-activating factor, produced by helper T cells.	84	88	GENE_OR_GENE_PRODUCT
LMP-1, an Epstein-Barr virus membrane protein expressed during latent infection, has oncogenic properties, as judged from its ability to transform B lymphocytes and rodent fibroblasts.	0	5	GENE_OR_GENE_PRODUCT
CD40 activation of B cells is strongly influenced by the presence of cytokines.	0	4	GENE_OR_GENE_PRODUCT
Proteins of the ATF/CREB class of transcription factors stimulate gene expression of several cell growth-related genes through protein kinase A-related cAMP response elements.	20	24	GENE_OR_GENE_PRODUCT
The lineage-restricted transcription factor GATA-1 is required for differentiation of erythroid and megakaryocytic cells.	44	50	GENE_OR_GENE_PRODUCT
The molecular mechanism underlying IL-2 transcriptional blockade in anergic T cell clones is not fully understood.	35	39	GENE_OR_GENE_PRODUCT
We analyzed the activity of the enhancer, the promoter and the silencer of the human CD4 gene during T cell development using transgenic mice.	32	40	GENE_OR_GENE_PRODUCT
We analyzed the activity of the enhancer, the promoter and the silencer of the human CD4 gene during T cell development using transgenic mice.	46	54	GENE_OR_GENE_PRODUCT
We analyzed the activity of the enhancer, the promoter and the silencer of the human CD4 gene during T cell development using transgenic mice.	63	71	GENE_OR_GENE_PRODUCT
Induction of NFkappaB is a highly regulated process requiring phosphorylation, ubiquitination, and proteasome-mediated degradation of the cytosolic inhibitor IkappaBalpha.	13	21	GENE_OR_GENE_PRODUCT
Induction of NFkappaB is a highly regulated process requiring phosphorylation, ubiquitination, and proteasome-mediated degradation of the cytosolic inhibitor IkappaBalpha.	99	109	GENE_OR_GENE_PRODUCT
Induction of NFkappaB is a highly regulated process requiring phosphorylation, ubiquitination, and proteasome-mediated degradation of the cytosolic inhibitor IkappaBalpha.	158	170	GENE_OR_GENE_PRODUCT
Analyses of the regulation of IkappaBalpha in TNF-alpha-treated T lymphocytes from young and elderly donors revealed severely compromised degradation of IkappaBalpha in T cells from the elderly.	30	42	GENE_OR_GENE_PRODUCT
We investigated the functional role of Itk, a member of the cytoplasmic tyrosine kinase Tec family, in T cell activation.	39	42	GENE_OR_GENE_PRODUCT
CD40/CD40 ligand interactions play a key role in the immune responses of B lymphocytes, monocytes, and dendritic cells.	0	4	GENE_OR_GENE_PRODUCT
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity.	97	102	GENE_OR_GENE_PRODUCT
Recent biochemical and genetic studies indicate that in addition to the octamer-binding proteins Oct-1 and Oct-2, other B cell components are required for lymphoid-restricted, octamer site-mediated immunoglobulin gene promoter activity.	107	112	GENE_OR_GENE_PRODUCT
The activation of transcriptional factor c-Fos/c-Jun AP-1 is essential for normal T cell responsiveness and is often impaired in T cells during aging.	53	57	GENE_OR_GENE_PRODUCT
A major obstacle in understanding the signaling events that follow CD28 receptor ligation arises from the fact that CD28 acts as a costimulus to TCR engagement, making it difficult to assess the relative contribution of CD28 signals as distinct from those of the TCR.	67	71	GENE_OR_GENE_PRODUCT
A major obstacle in understanding the signaling events that follow CD28 receptor ligation arises from the fact that CD28 acts as a costimulus to TCR engagement, making it difficult to assess the relative contribution of CD28 signals as distinct from those of the TCR.	67	71	GENE_OR_GENE_PRODUCT
A major obstacle in understanding the signaling events that follow CD28 receptor ligation arises from the fact that CD28 acts as a costimulus to TCR engagement, making it difficult to assess the relative contribution of CD28 signals as distinct from those of the TCR.	67	71	GENE_OR_GENE_PRODUCT
The viral encoded protein tax, is thought to play an important role in oncogenesis.	26	29	GENE_OR_GENE_PRODUCT
Our previous data obtained from a tax transgenic mouse model revealed that tax transforms mouse fibroblasts but not thymocytes, despite comparable levels of tax expression in both tissues.	34	37	GENE_OR_GENE_PRODUCT
Our previous data obtained from a tax transgenic mouse model revealed that tax transforms mouse fibroblasts but not thymocytes, despite comparable levels of tax expression in both tissues.	34	37	GENE_OR_GENE_PRODUCT
Initiation binding repressor [corrected] (IBR) is a chicken erythrocyte factor (apparent molecular mass, 70 to 73 kDa) that binds to the sequences spanning the transcription initiation site of the histone h5 gene, repressing its transcription.	42	45	GENE_OR_GENE_PRODUCT
Although the role of CD28 in T cell costimulation is firmly established, the mechanisms by which it exerts its costimulatory actions are less clear.	21	25	GENE_OR_GENE_PRODUCT
Resolution of whole cell extract through two chromatographic steps yields a single protein fraction requiring only the addition of TFIID for the initiation of transcription at RNA polymerase II promoters.	131	136	GENE_OR_GENE_PRODUCT
The immunomodulatory cytokine IL-4 affects cells of most hemopoietic lineages.	30	34	GENE_OR_GENE_PRODUCT
RelA (p65) functions as the critical transactivating component of the heterodimeric p50-p65 NF-kappa B complex and contains a high-affinity binding site for its cytoplasmic inhibitor, I kappa B alpha.	0	4	GENE_OR_GENE_PRODUCT
RelA (p65) functions as the critical transactivating component of the heterodimeric p50-p65 NF-kappa B complex and contains a high-affinity binding site for its cytoplasmic inhibitor, I kappa B alpha.	6	9	GENE_OR_GENE_PRODUCT
The B cell-specific cell surface molecule CD19 is expressed at all stages of B cell development, including normal plasma cells, and mediates signal transduction via interaction with cytoplasmic effector proteins.	42	46	GENE_OR_GENE_PRODUCT
Tax corresponds to a 40-kDa transforming protein from the pathogenic retrovirus human T-cell leukemia virus type 1 (HTLV-1) that activates nuclear expression of the NF-kappaB/Rel family of transcription factors by an unknown mechanism.	0	3	GENE_OR_GENE_PRODUCT
IL-10 markedly reduces nuclear factor (NF)-kappa B/Rel nuclear activity induced in PBMC by stimulation with the anti-CD3 mAb OKT3.	0	5	GENE_OR_GENE_PRODUCT
The nuclear factor of kappaB (NF-kappaB) is a ubiquitous transcription factor that is key in the regulation of the immune response and inflammation.	30	39	GENE_OR_GENE_PRODUCT
T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha.	74	83	GENE_OR_GENE_PRODUCT
T cell receptor (TCR) cross-linking is in part required for activation of NF-kappaB, which is dependent on the phosphorylation and degradation of IkappaBalpha.	146	158	GENE_OR_GENE_PRODUCT
The role of the transcription factor NF-kappaB in the pathogenesis of rheumatoid arthritis has long been a subject of controversy.	37	46	GENE_OR_GENE_PRODUCT
We used an adenoviral technique of blocking NF-kappaB through overexpression of the inhibitory subunit IkappaBalpha, which has the advantage that it can be used in the diseased tissue itself, with >90% of the synovial macrophages, fibroblasts, and T cells infected.	44	53	GENE_OR_GENE_PRODUCT
We examined chemokine gene expression following the differentiation of a monocyte, macrophage cell lineage.	12	21	GENE_OR_GENE_PRODUCT
The promoter of the human major histocompatibility complex class II-associated invariant-chain gene (Ii) contains two NF-kappa B/Rel binding sites located at -109 to -118 (Ii kappa B-1) and -163 to -172 (Ii kappa B-2) from the transcription start site.	4	12	GENE_OR_GENE_PRODUCT
Interferons (IFNs) inhibit induction by IL-4 of multiple genes in human monocytes.	40	44	GENE_OR_GENE_PRODUCT
Increased oxidative stress and subsequent activation of the transcription factor NF-kappaB has been linked to the development of late diabetic complications.	81	90	GENE_OR_GENE_PRODUCT
To determine whether oxidative stress dependent NF-kappaB activation is evident in patients with diabetic nephropathy we used an Electrophoretic Mobility Shift Assay based semiquantitative detection system which enabled us to determine NF-kappaB activation in ex vivo isolated peripheral blood mononuclear cells.	48	57	GENE_OR_GENE_PRODUCT
To determine whether oxidative stress dependent NF-kappaB activation is evident in patients with diabetic nephropathy we used an Electrophoretic Mobility Shift Assay based semiquantitative detection system which enabled us to determine NF-kappaB activation in ex vivo isolated peripheral blood mononuclear cells.	48	57	GENE_OR_GENE_PRODUCT
Interleukin-3 (IL-3) is exclusively expressed by activated T and natural killer cells, a function that is tightly controlled both in a lineage-specific and in a stimulation-dependent manner.	0	13	GENE_OR_GENE_PRODUCT
Interleukin-3 (IL-3) is exclusively expressed by activated T and natural killer cells, a function that is tightly controlled both in a lineage-specific and in a stimulation-dependent manner.	15	19	GENE_OR_GENE_PRODUCT
IL-10 is a well-known immunosuppressive and/or anti-inflammatory cytokine.	0	5	GENE_OR_GENE_PRODUCT
However, we report in vitro experimental studies in which IL-10 primed leukocytes and led to an enhanced production of tumor necrosis factor (TNF) upon further stimulation by lipopolysaccharide (LPS).	58	63	GENE_OR_GENE_PRODUCT
Anergic CD4+ Th cells do not produce IL-2 when challenged with Ag-pulsed accessory cells because of a transcriptional defect.	37	41	GENE_OR_GENE_PRODUCT
We have previously described a mutant B lymphoblastoid cell line, Clone-13, that expresses HLA-DQ in the absence of HLA-DR and -DP.	91	97	GENE_OR_GENE_PRODUCT
Fas-mediated apoptosis plays an important role in regulating the immune response in peripheral T cells.	0	3	GENE_OR_GENE_PRODUCT
CD44 is a ubiquitous molecule also known as hyaluronic acid or homing receptor.	0	4	GENE_OR_GENE_PRODUCT
Nuclear factor of activated T cells (NFAT) is a transcriptional activator that binds to sequences in the interleukin-2 (IL-2) promoter and is thought to be largely responsible for the T cell-specific inducibility of IL-2 expression.	37	41	GENE_OR_GENE_PRODUCT
C5a, a potent peptide chemoattractant, stimulates interleukin-8 (IL-8) secretion from peripheral blood mononuclear cells (PBMC).	50	63	GENE_OR_GENE_PRODUCT
C5a, a potent peptide chemoattractant, stimulates interleukin-8 (IL-8) secretion from peripheral blood mononuclear cells (PBMC).	65	69	GENE_OR_GENE_PRODUCT
IL-2-mediated T cell proliferation is a critical early event in the inflammatory process.	0	4	GENE_OR_GENE_PRODUCT
Tax1, a transcriptional trans-activator of the Human T-cell leukemia virus type I (HTLV-I), induces the expression of many cellular genes through interaction with at least three distinct cellular transcription factors; CREB/ATF, NF-kappaB, and SRF.	0	4	GENE_OR_GENE_PRODUCT
IL-10 is a potent mediator of human B cell growth and plasma cell formation.	0	5	GENE_OR_GENE_PRODUCT
We demonstrate that JunD, a component of the AP-1 transcription factor complex, activates transcription of the human proenkephalin gene in a fashion that is completely dependent upon the cAMP-dependent protein kinase, protein kinase A.	20	24	GENE_OR_GENE_PRODUCT
FGF-1 is abundantly expressed in the synovium in rheumatoid arthritis and in rejecting allografts, sites of chronic immune-mediated inflammation.	0	5	GENE_OR_GENE_PRODUCT
A novel member of the tumor necrosis factor (TNF) receptor family, designated TRAMP, has been identified.	78	83	GENE_OR_GENE_PRODUCT
Cytokines, IL-2, IL-4, IL-6, IL-7, IL-12, and IL-15 are key regulators of human peripheral blood T and NK cell activation and differentiation but the precise mechanisms that give rise to their differential activities within these cells are not clear.	11	15	GENE_OR_GENE_PRODUCT
Cytokines, IL-2, IL-4, IL-6, IL-7, IL-12, and IL-15 are key regulators of human peripheral blood T and NK cell activation and differentiation but the precise mechanisms that give rise to their differential activities within these cells are not clear.	17	21	GENE_OR_GENE_PRODUCT
Cytokines, IL-2, IL-4, IL-6, IL-7, IL-12, and IL-15 are key regulators of human peripheral blood T and NK cell activation and differentiation but the precise mechanisms that give rise to their differential activities within these cells are not clear.	23	27	GENE_OR_GENE_PRODUCT
Cytokines, IL-2, IL-4, IL-6, IL-7, IL-12, and IL-15 are key regulators of human peripheral blood T and NK cell activation and differentiation but the precise mechanisms that give rise to their differential activities within these cells are not clear.	29	33	GENE_OR_GENE_PRODUCT
Cytokines, IL-2, IL-4, IL-6, IL-7, IL-12, and IL-15 are key regulators of human peripheral blood T and NK cell activation and differentiation but the precise mechanisms that give rise to their differential activities within these cells are not clear.	35	40	GENE_OR_GENE_PRODUCT
Cytokines, IL-2, IL-4, IL-6, IL-7, IL-12, and IL-15 are key regulators of human peripheral blood T and NK cell activation and differentiation but the precise mechanisms that give rise to their differential activities within these cells are not clear.	46	51	GENE_OR_GENE_PRODUCT
Accumulating data from a number of laboratories have recently indicated that the response of transcription factor NF-kappaB to alterations in the redox homeostasis of cells may play an important role in modulating immune function.	114	123	GENE_OR_GENE_PRODUCT
The activation of NF-kappaB has been recognized to regulate a number of genes necessary for normal T cell responses including IL-2, IL-6, IL-8, and several T cell surface receptors.	18	27	GENE_OR_GENE_PRODUCT
CD40 is a receptor that is critical for the survival, growth, differentiation, and isotype switching of B lymphocytes.	0	4	GENE_OR_GENE_PRODUCT
Enforced expression of Id3, which has the capacity to inhibit many basic helix-loop-helix (bHLH) transcription factors, in human CD34(+) hematopoietic progenitor cells that have not undergone T cell receptor (TCR) gene rearrangements inhibits development of the transduced cells into TCRalpha beta and gamma delta cells in a fetal thymic organ culture (FTOC).	23	26	GENE_OR_GENE_PRODUCT
The Ca(2+)-dependent phosphatase calcineurin, a target of FK506 and CsA, synergizes with PKC-induced activation of nuclear factor (NF)-kappa B in T cell lines.	33	44	GENE_OR_GENE_PRODUCT
The Ca(2+)-dependent phosphatase calcineurin, a target of FK506 and CsA, synergizes with PKC-induced activation of nuclear factor (NF)-kappa B in T cell lines.	89	92	GENE_OR_GENE_PRODUCT
Nuclear factor of activated T cells-family proteins (NFAT1/NFATp, NFATc, NFAT3, and NFAT4/NFATx/NFATc3) play a key role in the transcription of cytokine genes and other genes during the immune response.	53	64	GENE_OR_GENE_PRODUCT
Nuclear factor of activated T cells-family proteins (NFAT1/NFATp, NFATc, NFAT3, and NFAT4/NFATx/NFATc3) play a key role in the transcription of cytokine genes and other genes during the immune response.	59	64	GENE_OR_GENE_PRODUCT
Nuclear factor of activated T cells-family proteins (NFAT1/NFATp, NFATc, NFAT3, and NFAT4/NFATx/NFATc3) play a key role in the transcription of cytokine genes and other genes during the immune response.	66	71	GENE_OR_GENE_PRODUCT
Nuclear factor of activated T cells-family proteins (NFAT1/NFATp, NFATc, NFAT3, and NFAT4/NFATx/NFATc3) play a key role in the transcription of cytokine genes and other genes during the immune response.	73	78	GENE_OR_GENE_PRODUCT
Nuclear factor of activated T cells-family proteins (NFAT1/NFATp, NFATc, NFAT3, and NFAT4/NFATx/NFATc3) play a key role in the transcription of cytokine genes and other genes during the immune response.	84	102	GENE_OR_GENE_PRODUCT
BACKGROUND: IL-5 is fundamentally involved in eosinophilic inflammation.	12	16	GENE_OR_GENE_PRODUCT
Control of IL-5 production may be effective for the management of allergic diseases.	11	15	GENE_OR_GENE_PRODUCT
OBJECTIVE: We aimed to find the transcriptional mechanisms that regulate the IL-5 gene to selectively control IL-5 synthesis.	77	81	GENE_OR_GENE_PRODUCT
OBJECTIVE: We aimed to find the transcriptional mechanisms that regulate the IL-5 gene to selectively control IL-5 synthesis.	77	81	GENE_OR_GENE_PRODUCT
TCR engagement stimulates the activation of the protein kinase Raf-1.	63	68	GENE_OR_GENE_PRODUCT
Active Raf-1 phosphorylates and activates the mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase kinase 1 (MEK1), which in turn phosphorylates and activates the MAP kinases/extracellular signal regulated kinases, ERK1 and ERK2.	7	12	GENE_OR_GENE_PRODUCT
Here we show that the lymphoid lineage-determining factors Ikaros and Aiolos can function as strong transcriptional repressors.	59	65	GENE_OR_GENE_PRODUCT
Here we show that the lymphoid lineage-determining factors Ikaros and Aiolos can function as strong transcriptional repressors.	70	76	GENE_OR_GENE_PRODUCT
RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted) is a chemoattractant cytokine (chemokine) important in the generation of inflammatory infiltrate and human immunodeficiency virus entry into immune cells.	0	6	GENE_OR_GENE_PRODUCT
We previously reported that dexamethasone (DEX), a synthetic glucocorticoid, causes apoptosis in mature Th cell lines, and that this induction of cell death is prevented by specific cytokines, namely, by IL-2 in Th1 cells and by IL-4 in Th2 cells.	204	208	GENE_OR_GENE_PRODUCT
The transcription factor GATA-1 is expressed in a subset of hemopoietic cells, where it mediates the cell-type specific expression of several genes.	25	31	GENE_OR_GENE_PRODUCT
To elucidate the roles of individual GATA factors in erythropoiesis, conditional alleles of GATA-1, GATA-2, and GATA-3 were prepared by fusing each of the factors to the hormone-binding domain of the human estrogen receptor (ER).	92	98	GENE_OR_GENE_PRODUCT
To elucidate the roles of individual GATA factors in erythropoiesis, conditional alleles of GATA-1, GATA-2, and GATA-3 were prepared by fusing each of the factors to the hormone-binding domain of the human estrogen receptor (ER).	100	106	GENE_OR_GENE_PRODUCT
To elucidate the roles of individual GATA factors in erythropoiesis, conditional alleles of GATA-1, GATA-2, and GATA-3 were prepared by fusing each of the factors to the hormone-binding domain of the human estrogen receptor (ER).	112	118	GENE_OR_GENE_PRODUCT
SLP-76 and Vav, two hematopoietic cell specific molecules, are critical for T cell development and activation.	0	6	GENE_OR_GENE_PRODUCT
SLP-76 and Vav, two hematopoietic cell specific molecules, are critical for T cell development and activation.	11	14	GENE_OR_GENE_PRODUCT
NF-kappaB is a potent cellular activator of HIV-1 gene expression.	0	9	GENE_OR_GENE_PRODUCT
The effect of constitutive Tax expression on the interaction of NF-kappa B with its recognition sequence and on NF-kappa B-dependent gene expression was examined in T lymphoid Jurkat cell lines (19D and 9J) stably transformed with a Tax expression vector.	27	30	GENE_OR_GENE_PRODUCT
The responses of lymphocytes to IL-2 and IL-12, involving proliferation, differentiation, and cytokine production, are only partially overlapping, and may depend on induced differential expression of specific sets of genes.	32	36	GENE_OR_GENE_PRODUCT
The responses of lymphocytes to IL-2 and IL-12, involving proliferation, differentiation, and cytokine production, are only partially overlapping, and may depend on induced differential expression of specific sets of genes.	41	46	GENE_OR_GENE_PRODUCT
Using reverse-transcription PCR differential display, we isolated an mRNA species expressed in IL-2- but not IL-12-stimulated NK cells.	95	99	GENE_OR_GENE_PRODUCT
Using reverse-transcription PCR differential display, we isolated an mRNA species expressed in IL-2- but not IL-12-stimulated NK cells.	109	114	GENE_OR_GENE_PRODUCT
One gene encodes a protein, RFX5, that is a member of the RFX family of DNA binding proteins.	28	32	GENE_OR_GENE_PRODUCT
The other, CIITA, encodes a large protein with a defined acidic transcriptional activation domain; this protein does not interact with DNA.	11	16	GENE_OR_GENE_PRODUCT
Regulation of the transcription factor NF-kappaB involves proteasome-mediated processing of the NF-kappaB1 p105 precursor protein, which generates the p50 subunit of NF-kappaB.	39	48	GENE_OR_GENE_PRODUCT
PU.1 is a hematopoietic-specific Ets family transcription factor that is required for development of some lymphoid and myeloid lineages.	0	4	GENE_OR_GENE_PRODUCT
The cell cycle-dependent transcription factor, E2F-1, regulates the cyclin-like species of the DNA repair enzyme uracil-DNA glycosylase (UDG) gene in human osteosarcoma (Saos-2) cells.	47	52	GENE_OR_GENE_PRODUCT
Activation of the CD28 surface receptor provides a major costimulatory signal for T cell activation resulting in enhanced production of interleukin-2 (IL-2) and cell proliferation.	18	22	GENE_OR_GENE_PRODUCT
Effects of oxidative stress on stimulation-dependent signal transduction, leading to IL-2 expression, were studied.	85	89	GENE_OR_GENE_PRODUCT
MNDA (myeloid cell nuclear differentiation antigen) is an interferon alpha regulated nuclear protein expressed only in cells of the human myelomonocytic lineage.	0	4	GENE_OR_GENE_PRODUCT
MyD88, originally isolated as a myeloid differentiation primary response gene, is shown to act as an adaptor in interleukin-1 (IL-1) signaling by interacting with both the IL-1 receptor complex and IL-1 receptor-associated kinase (IRAK).	0	5	GENE_OR_GENE_PRODUCT
Activation of expression of genes encoding transcription factors: c-fos and c-jun and formation of AP1 transcriptional complex in human monocytes was investigated.	28	32	GENE_OR_GENE_PRODUCT
Activation of expression of genes encoding transcription factors: c-fos and c-jun and formation of AP1 transcriptional complex in human monocytes was investigated.	66	71	GENE_OR_GENE_PRODUCT
Activation of expression of genes encoding transcription factors: c-fos and c-jun and formation of AP1 transcriptional complex in human monocytes was investigated.	76	81	GENE_OR_GENE_PRODUCT
In this study, the IFN-gamma induction of MHC class II gene expression in primary cultures of thymic epithelial cells (TEC) was analyzed.	19	28	GENE_OR_GENE_PRODUCT
The binding of interleukin-2 (IL-2) to its receptor on normal T cells induces nuclear expression of nuclear factor kappaB (NF-kappaB), activation of the IL-2 receptor (IL-2R) alpha chain gene, and cell proliferation.	15	28	GENE_OR_GENE_PRODUCT
The binding of interleukin-2 (IL-2) to its receptor on normal T cells induces nuclear expression of nuclear factor kappaB (NF-kappaB), activation of the IL-2 receptor (IL-2R) alpha chain gene, and cell proliferation.	30	34	GENE_OR_GENE_PRODUCT
The region downstream of the enhancer (DEN) of the long terminal repeat of the mink cell focus-forming murine leukemia virus is important for viral pathogenicity.	29	37	GENE_OR_GENE_PRODUCT
The region downstream of the enhancer (DEN) of the long terminal repeat of the mink cell focus-forming murine leukemia virus is important for viral pathogenicity.	39	42	GENE_OR_GENE_PRODUCT
Expression studies as well as the use of transgenic animals have demonstrated that the A-MYB transcription factor plays central and specific role in the regulation of mature B cell proliferation and/or differentiation.	87	92	GENE_OR_GENE_PRODUCT
PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages.	0	4	GENE_OR_GENE_PRODUCT
PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages.	6	11	GENE_OR_GENE_PRODUCT
Among host immune factors, the cytokine TNF-alpha has previously been shown to increase HIV-1 replication in various monocyte and T cell model systems.	40	49	GENE_OR_GENE_PRODUCT
The t(17;19) translocation in acute lymphoblastic leukemias results in creation of E2A-hepatic leukemia factor (HLF) chimeric proteins that contain the DNA-binding and protein dimerization domains of the basic leucine zipper (bZIP) protein HLF fused to a portion of E2A proteins with transcriptional activation properties.	4	12	GENE_OR_GENE_PRODUCT
We have studied the effects of prednisone (PDN), deflazacort (DFC), and dexamethasone (DXM) on the production of cytokines (IL-2, IL-6, TNF-alpha, IL-10) by peripheral T lymphocytes, and the effects on the inhibition of NF-kB DNA binding activity by activated Jurkat cell line.	124	128	GENE_OR_GENE_PRODUCT
We have studied the effects of prednisone (PDN), deflazacort (DFC), and dexamethasone (DXM) on the production of cytokines (IL-2, IL-6, TNF-alpha, IL-10) by peripheral T lymphocytes, and the effects on the inhibition of NF-kB DNA binding activity by activated Jurkat cell line.	130	134	GENE_OR_GENE_PRODUCT
We have studied the effects of prednisone (PDN), deflazacort (DFC), and dexamethasone (DXM) on the production of cytokines (IL-2, IL-6, TNF-alpha, IL-10) by peripheral T lymphocytes, and the effects on the inhibition of NF-kB DNA binding activity by activated Jurkat cell line.	136	145	GENE_OR_GENE_PRODUCT
We have studied the effects of prednisone (PDN), deflazacort (DFC), and dexamethasone (DXM) on the production of cytokines (IL-2, IL-6, TNF-alpha, IL-10) by peripheral T lymphocytes, and the effects on the inhibition of NF-kB DNA binding activity by activated Jurkat cell line.	147	152	GENE_OR_GENE_PRODUCT
The protein products of the c-fos (p62c-fos) and c-jun (p39c-jun) genes are members of the AP-1 transcription factor family and are thought to play important roles in the regulation of gene expression during the cell cycle.	28	33	GENE_OR_GENE_PRODUCT
The protein products of the c-fos (p62c-fos) and c-jun (p39c-jun) genes are members of the AP-1 transcription factor family and are thought to play important roles in the regulation of gene expression during the cell cycle.	35	43	GENE_OR_GENE_PRODUCT
The protein products of the c-fos (p62c-fos) and c-jun (p39c-jun) genes are members of the AP-1 transcription factor family and are thought to play important roles in the regulation of gene expression during the cell cycle.	49	54	GENE_OR_GENE_PRODUCT
The protein products of the c-fos (p62c-fos) and c-jun (p39c-jun) genes are members of the AP-1 transcription factor family and are thought to play important roles in the regulation of gene expression during the cell cycle.	56	64	GENE_OR_GENE_PRODUCT
The protein products of the c-fos (p62c-fos) and c-jun (p39c-jun) genes are members of the AP-1 transcription factor family and are thought to play important roles in the regulation of gene expression during the cell cycle.	91	95	GENE_OR_GENE_PRODUCT
To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments.	63	80	GENE_OR_GENE_PRODUCT
To investigate the mechanisms of transcriptional activation of interleukin-1beta (IL-1beta) in non-monocytic cells, we constructed a series of reporter plasmids with the bacterial chloramphenicol acetyltransferase gene linked to various parts of the human IL-1beta promoter and performed transient transfection experiments.	82	90	GENE_OR_GENE_PRODUCT
The Rho family of small GTP-binding proteins is involved in the regulation of cytoskeletal structure, gene transcription, specific cell fate development, and transformation.	4	7	GENE_OR_GENE_PRODUCT
The lymphoid-specific transcription factor Oct-2a is implicated in B cell-specific transcriptional activity via the octamer motif.	43	49	GENE_OR_GENE_PRODUCT
Structure/function analysis of various Oct-2a effector regions in the context of the GAL4 DNA-binding domain revealed that Oct-2a contains two functionally different activation domains at the N and the C termini.	39	45	GENE_OR_GENE_PRODUCT
Structure/function analysis of various Oct-2a effector regions in the context of the GAL4 DNA-binding domain revealed that Oct-2a contains two functionally different activation domains at the N and the C termini.	39	45	GENE_OR_GENE_PRODUCT
Recently, we have identified a repression domain located within the N terminus of Oct-2a (amino acids 2-99).	82	88	GENE_OR_GENE_PRODUCT
The class II trans- activator (CIITA) is the main transcriptional co-activator for the expression of MHC class II proteins.	31	36	GENE_OR_GENE_PRODUCT
Expression of a highly specific protein inhibitor for cyclic AMP-dependent protein kinases in interleukin-1 (IL-1)-responsive cells blocked IL-1-induced gene transcription that was driven by the kappa immunoglobulin enhancer or the human immunodeficiency virus long terminal repeat.	94	107	GENE_OR_GENE_PRODUCT
We investigated the molecular basis of the synergistic induction by interferon-gamma (IFN-gamma)/tumor necrosis factor-alpha (TNF-alpha) of human interleukin-6 (IL-6) gene in THP-1 monocytic cells, and compared it with the basis of this induction by lipopolysaccharide (LPS).	68	84	GENE_OR_GENE_PRODUCT
We investigated the molecular basis of the synergistic induction by interferon-gamma (IFN-gamma)/tumor necrosis factor-alpha (TNF-alpha) of human interleukin-6 (IL-6) gene in THP-1 monocytic cells, and compared it with the basis of this induction by lipopolysaccharide (LPS).	86	95	GENE_OR_GENE_PRODUCT
IL-10 is elevated in HIV-1-infected individuals and has been implicated in disease progression.	0	5	GENE_OR_GENE_PRODUCT
p21ras is activated by the T cell antigen receptor (TCR) and then co-ordinates important signaling pathways for T lymphocyte activation.	0	6	GENE_OR_GENE_PRODUCT
The transcription factor AP-1 is an important human mediator of the cellular response to serum, growth factors, and phorbol esters such as 12-O-tetradecanoyl-phorbol-13 acetate (TPA).	25	29	GENE_OR_GENE_PRODUCT
CD40 signaling to B cells is important for generating an effective humoral immune response.	0	4	GENE_OR_GENE_PRODUCT
Elf-1 is a lymphoid-specific transcription factor that belongs to the ETS protein family.	0	5	GENE_OR_GENE_PRODUCT
Here, we report the functional expression of CD40 on human malignant melanomas (MMs).	45	49	GENE_OR_GENE_PRODUCT
Comparison of tumor specimen from MM precursor lesions, primary tumors, and metastases revealed that CD40 surface expression is down-regulated during tumor progression.	101	105	GENE_OR_GENE_PRODUCT
CD40 expression was confirmed in 7 human MM cell lines established from immunogenic primary tumors or metastases, whereas 11 cell lines established from advanced stages were CD40 negative.	0	4	GENE_OR_GENE_PRODUCT
CD40 expression was confirmed in 7 human MM cell lines established from immunogenic primary tumors or metastases, whereas 11 cell lines established from advanced stages were CD40 negative.	0	4	GENE_OR_GENE_PRODUCT
CD40 expression could be enhanced in CD40-positive MM by stimulation with IFN-gamma and tumor necrosis factor-alpha but not by interleukin (IL)-1beta or CD40 triggering.	0	4	GENE_OR_GENE_PRODUCT
CD40 expression could be enhanced in CD40-positive MM by stimulation with IFN-gamma and tumor necrosis factor-alpha but not by interleukin (IL)-1beta or CD40 triggering.	0	4	GENE_OR_GENE_PRODUCT
CD40 expression could be enhanced in CD40-positive MM by stimulation with IFN-gamma and tumor necrosis factor-alpha but not by interleukin (IL)-1beta or CD40 triggering.	74	83	GENE_OR_GENE_PRODUCT
This review summarizes data on specific regulation of promoters and enhancers by nuclear trans-acting factors in lymphocytes.	54	62	GENE_OR_GENE_PRODUCT
This review summarizes data on specific regulation of promoters and enhancers by nuclear trans-acting factors in lymphocytes.	68	76	GENE_OR_GENE_PRODUCT
Furthermore, the most important trans-acting factors of T and B lymphocytes (e.g. NF-kB, NF-AT and STAT families) and their functional importance are described.	82	87	GENE_OR_GENE_PRODUCT
Furthermore, the most important trans-acting factors of T and B lymphocytes (e.g. NF-kB, NF-AT and STAT families) and their functional importance are described.	89	94	GENE_OR_GENE_PRODUCT
IL-4 secreted by activated T cells is a pleiotropic cytokine affecting growth and differentiation of diverse cell types such as T cells, B cells, and mast cells.	0	4	GENE_OR_GENE_PRODUCT
Fas (CD95) and Fas ligand (CD95L) are an interacting receptor-ligand pair required for immune homeostasis.	0	3	GENE_OR_GENE_PRODUCT
Fas (CD95) and Fas ligand (CD95L) are an interacting receptor-ligand pair required for immune homeostasis.	5	9	GENE_OR_GENE_PRODUCT
The transcription factor, NF-kappaB, is important for T-cell activation, B-cell maturation, and human immunodeficiency virus transcription and plays a role in alternatively mediating and protecting against apoptosis in a variety of cell types.	26	35	GENE_OR_GENE_PRODUCT
Previously, we have shown that TAL1 and the LIM-only protein gene (LMO) are regularly coactivated in T-cell acute lymphoblastic leukemia (T-ALL).	31	35	GENE_OR_GENE_PRODUCT
CD30 is a cell-surface receptor that can augment lymphocyte activation and survival through its ability to induce the transcription factor NF-kappaB.	0	4	GENE_OR_GENE_PRODUCT
Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids.	0	5	GENE_OR_GENE_PRODUCT
CTCF is a transcriptional repressor of the c-myc gene.	0	4	GENE_OR_GENE_PRODUCT
Spi-B is an Ets transcription factor related to the oncoprotein Spi-1/PU.1 and highly expressed in B lymphoid cells.	0	5	GENE_OR_GENE_PRODUCT
Spi-B is an Ets transcription factor related to the oncoprotein Spi-1/PU.1 and highly expressed in B lymphoid cells.	64	74	GENE_OR_GENE_PRODUCT
Retinoid-like receptors play a central role in hormonal responses by forming heterodimers with other nuclear hormone receptors.	77	88	GENE_OR_GENE_PRODUCT
We have shown that interleukin-1 (IL-1) and IL-2 control IL-2 receptor alpha (IL-2R alpha) gene transcription in CD4-CD8- murine T lymphocyte precursors.	19	32	GENE_OR_GENE_PRODUCT
We have shown that interleukin-1 (IL-1) and IL-2 control IL-2 receptor alpha (IL-2R alpha) gene transcription in CD4-CD8- murine T lymphocyte precursors.	34	38	GENE_OR_GENE_PRODUCT
We have shown that interleukin-1 (IL-1) and IL-2 control IL-2 receptor alpha (IL-2R alpha) gene transcription in CD4-CD8- murine T lymphocyte precursors.	44	48	GENE_OR_GENE_PRODUCT
AML1 plays a critical role during hematopoiesis and chromosomal translocations involving AML1 are commonly associated with different forms of leukemia, including pre-B acute lymphoblastic leukemia.	0	4	GENE_OR_GENE_PRODUCT
AML1 plays a critical role during hematopoiesis and chromosomal translocations involving AML1 are commonly associated with different forms of leukemia, including pre-B acute lymphoblastic leukemia.	0	4	GENE_OR_GENE_PRODUCT
To understand the function of AML1 during B cell differentiation, we analyzed regulatory regions of B cell-specific genes for potential AML1-binding sites and have identified a putative AML1-binding site in the promoter of the B cell-specific tyrosine kinase gene, blk.	30	34	GENE_OR_GENE_PRODUCT
CD36 is a cell surface glycoprotein composed of a single polypeptide chain, which interacts with thrombospondin, collagens type I and IV, oxidized low density lipoprotein, fatty acids, anionic phospholipids, and erythrocytes parasitized with Plasmodium falciparum.	0	4	GENE_OR_GENE_PRODUCT
CD36 is a cell surface glycoprotein composed of a single polypeptide chain, which interacts with thrombospondin, collagens type I and IV, oxidized low density lipoprotein, fatty acids, anionic phospholipids, and erythrocytes parasitized with Plasmodium falciparum.	23	35	GENE_OR_GENE_PRODUCT
CD36 is a cell surface glycoprotein composed of a single polypeptide chain, which interacts with thrombospondin, collagens type I and IV, oxidized low density lipoprotein, fatty acids, anionic phospholipids, and erythrocytes parasitized with Plasmodium falciparum.	97	111	GENE_OR_GENE_PRODUCT
CTLA-4 engagement by mAbs inhibits, while CD28 enhances, IL-2 production and proliferation upon T cell activation.	0	6	GENE_OR_GENE_PRODUCT
CTLA-4 engagement by mAbs inhibits, while CD28 enhances, IL-2 production and proliferation upon T cell activation.	42	46	GENE_OR_GENE_PRODUCT
CTLA-4 engagement by mAbs inhibits, while CD28 enhances, IL-2 production and proliferation upon T cell activation.	57	61	GENE_OR_GENE_PRODUCT
The transcription factor HIV-TF1, which binds to a region about 60 bp upstream from the enhancer of the human immunodeficiency virus-1 (HIV-1), was purified from human B cells.	25	32	GENE_OR_GENE_PRODUCT
In the examination of the induction of autoimmunity in transgenic mice, evidence has been obtained further implicating the lymphokine interferon-gamma in the etiology of autoimmunity.	134	150	GENE_OR_GENE_PRODUCT
IL-12 is a critical immunoregulatory cytokine that promotes cell-mediated immune responses and the differentiation of naive CD4+ cells to Th1 cells; however, relatively few IL-12 target genes have been identified.	0	5	GENE_OR_GENE_PRODUCT
Tat is an essential regulatory protein for the replication of human immunodeficiency virus (HIV).	0	3	GENE_OR_GENE_PRODUCT
Although much is understood about the induction of genes expressed early (within 24 h) after T-cell activation, little is known about the regulation of expression of genes expressed 'late' (three or more days) post-stimulation.	51	55	GENE_OR_GENE_PRODUCT
TRAF2 is a signal transducing adaptor molecule which binds to the CD40 cytoplasmic domain.	0	5	GENE_OR_GENE_PRODUCT
Activation of CD40 is essential for thymus-dependent humoral immune responses and rescuing B cells from apoptosis.	14	18	GENE_OR_GENE_PRODUCT
Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA).	10	14	GENE_OR_GENE_PRODUCT
Few known genes (IL-2, members of the IL-8 family, interferon-gamma) are induced in T cells only through the combined effect of phorbol myristic acetate (PMA) and a Ca(2+)-ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A (CyA).	17	21	GENE_OR_GENE_PRODUCT
"Application of a ""formamide free"" and thus ""material preserving"" in situ hybridization technique using the cDNA of the myf3 gene revealed the following results: Human rhabdomyosarcoma cells, characterized by a high expression of myf3 show intensive hybridization signals in their interphase."	107	111	GENE_OR_GENE_PRODUCT
Activation through the Ca2+/calcineurin pathway is essential to the transcription of many cytokine genes.	28	39	GENE_OR_GENE_PRODUCT
The molecular mechanisms of the effects of IL-4 and IL-13 on HIV infection in human monocytes as they matured into monocyte-derived macrophages over 7 days were investigated using HIV-1(BaL), and low passage clinical strains.	43	47	GENE_OR_GENE_PRODUCT
The molecular mechanisms of the effects of IL-4 and IL-13 on HIV infection in human monocytes as they matured into monocyte-derived macrophages over 7 days were investigated using HIV-1(BaL), and low passage clinical strains.	52	57	GENE_OR_GENE_PRODUCT
AP-1, the polypeptide product of c-jun, recognizes and binds to specific DNA sequences and stimulates transcription of genes responsive to certain growth factors and phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA).	0	4	GENE_OR_GENE_PRODUCT
AP-1, the polypeptide product of c-jun, recognizes and binds to specific DNA sequences and stimulates transcription of genes responsive to certain growth factors and phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA).	33	38	GENE_OR_GENE_PRODUCT
AP-1, the polypeptide product of c-jun, recognizes and binds to specific DNA sequences and stimulates transcription of genes responsive to certain growth factors and phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate (TPA).	119	123	GENE_OR_GENE_PRODUCT
Binding of type I interferon (IFN-alpha/beta) to specific receptors results in the rapid transcriptional activation, independent of protein synthesis, of IFN-alpha-stimulated genes (ISGs) in human fibroblasts and HeLa and Daudi cell lines.	30	44	GENE_OR_GENE_PRODUCT
The expression of the hematopoietic transcription factors GATA-1, GATA-2, and GATA-3 was studied in eosinophils and basophils.	58	64	GENE_OR_GENE_PRODUCT
The expression of the hematopoietic transcription factors GATA-1, GATA-2, and GATA-3 was studied in eosinophils and basophils.	66	72	GENE_OR_GENE_PRODUCT
The expression of the hematopoietic transcription factors GATA-1, GATA-2, and GATA-3 was studied in eosinophils and basophils.	78	84	GENE_OR_GENE_PRODUCT
The zinc finger transcription factor GATA-1 is a major regulator of gene expression in erythroid, megakaryocyte, and mast cell lineages.	37	43	GENE_OR_GENE_PRODUCT
GATA-1 binds to WGATAR consensus motifs in the regulatory regions of virtually all erythroid cell-specific genes.	0	6	GENE_OR_GENE_PRODUCT
A group of coordinately induced protooncogenes, cytoskeletal, and extracellular matrix genes have been termed immediate early response genes, and their induction has been associated with growth factor-stimulated cell proliferation.	32	45	GENE_OR_GENE_PRODUCT
CD14, a monocyte/macrophage receptor for the complex of LPS and LPS binding protein, is a differentiation marker for the monocyte/macrophage lineage.	0	4	GENE_OR_GENE_PRODUCT
CD40 is an important signaling and activation Ag found on certain bone marrow-derived cells.	0	4	GENE_OR_GENE_PRODUCT
The IL-2 growth hormone is the major growth factor of activated T lymphocytes during a developing immune response.	4	8	GENE_OR_GENE_PRODUCT
This study evaluates (i) constitutive levels of oncogene and p53 transcripts in chronic phase CML patients and (ii) their modulations subsequent to in vivo therapy with rIFN-alpha 2c.	48	56	GENE_OR_GENE_PRODUCT
XPB is a subunit of the basal transcription factor TFIIH, which is also involved in nucleotide excision repair (NER) and potentially in cell cycle regulation.	0	3	GENE_OR_GENE_PRODUCT
XPB is a subunit of the basal transcription factor TFIIH, which is also involved in nucleotide excision repair (NER) and potentially in cell cycle regulation.	51	56	GENE_OR_GENE_PRODUCT
TSC2 is a gene on chromosome 16p13.3 associated with the autosomal dominant neurocutaneous disorder, tuberous sclerosis complex (TSC).	0	4	GENE_OR_GENE_PRODUCT
The renin-angiotensin system may contribute to the pathogenesis of atherosclerosis.	4	9	GENE_OR_GENE_PRODUCT
IL-4, a product of the T-helper 0 (Th0) and 2 (Th2) subset, was originally described as a B-cell stimulatory factor and has subsequently been found to suppress IL-1 alpha, IL-1 beta, IL-6, IL-8, and TNF-alpha gene expression in monocytes stimulated with LPS, and to upregulate IL-1 receptor antagonist (IL1-RA) gene expression.	0	4	GENE_OR_GENE_PRODUCT
Cell cycle progression initiated by interleukin-2 (IL-2) in T cells is critical for lymphoproliferation and an immune response.	36	49	GENE_OR_GENE_PRODUCT
Cell cycle progression initiated by interleukin-2 (IL-2) in T cells is critical for lymphoproliferation and an immune response.	51	55	GENE_OR_GENE_PRODUCT
Since GH stimulates the development and function of granulocytes, we investigated the expression of GH in granulocyte subsets.	6	8	GENE_OR_GENE_PRODUCT
Since GH stimulates the development and function of granulocytes, we investigated the expression of GH in granulocyte subsets.	6	8	GENE_OR_GENE_PRODUCT
Previous cotransfection experiments had demonstrated that ectopic expression of the lymphocyte-specific transcription factor Oct2 could efficiently activate a promoter containing an octamer motif.	125	129	GENE_OR_GENE_PRODUCT
BOB.1/OBF.1 is a transcriptional coactivator that is constitutively expressed in B cells and interacts with the Oct1 and Oct2 transcription factors.	0	11	GENE_OR_GENE_PRODUCT
G0S3 is a member of a set of putative G0/G1 switch regulatory genes (G0S genes) selected by screening cDNA libraries prepared from human blood mononuclear cells cultured for 2 hr with lectin and cycloheximide.	0	4	GENE_OR_GENE_PRODUCT
IL-12 is a 75-kDa heterodimeric cytokine composed of two covalently linked p35 and p40 chains.	0	5	GENE_OR_GENE_PRODUCT
The NF-kappaB family of transcription factors regulates the inducible expression of a variety of genes.	4	13	GENE_OR_GENE_PRODUCT
BACKGROUND: IL-5 controls development of eosinophilia and has been shown to be involved in the pathogenesis of allergic diseases.	12	16	GENE_OR_GENE_PRODUCT
In both atopic and nonatopic asthma, elevated IL-5 has been detected in peripheral blood and the airways.	46	50	GENE_OR_GENE_PRODUCT
IL-5 is produced mainly by activated T cells, and its expression is regulated at the transcriptional level.	0	4	GENE_OR_GENE_PRODUCT
Oct-2 is a transcription factor that binds specifically to octamer DNA motifs in the promoters of immunoglobulin and interleukin-2 genes.	0	5	GENE_OR_GENE_PRODUCT
In 1991, we demonstrated, using electrophoretic mobility shift assays, that 3 different factors (termed B1, B2 and B3) with affinity for the KB-enhancer target sequence were specifically detected in nuclear extracts from HIV1-infected monocytes and macrophages.	104	106	GENE_OR_GENE_PRODUCT
In 1991, we demonstrated, using electrophoretic mobility shift assays, that 3 different factors (termed B1, B2 and B3) with affinity for the KB-enhancer target sequence were specifically detected in nuclear extracts from HIV1-infected monocytes and macrophages.	108	110	GENE_OR_GENE_PRODUCT
In 1991, we demonstrated, using electrophoretic mobility shift assays, that 3 different factors (termed B1, B2 and B3) with affinity for the KB-enhancer target sequence were specifically detected in nuclear extracts from HIV1-infected monocytes and macrophages.	115	117	GENE_OR_GENE_PRODUCT
The proto-oncogene products c-Fos and c-Jun heterodimerize through their leucine zippers to form the AP-1 transcription factor.	28	33	GENE_OR_GENE_PRODUCT
The proto-oncogene products c-Fos and c-Jun heterodimerize through their leucine zippers to form the AP-1 transcription factor.	38	43	GENE_OR_GENE_PRODUCT
Trapoxin is a microbially derived cyclotetrapeptide that inhibits histone deacetylation in vivo and causes mammalian cells to arrest in the cell cycle.	66	73	GENE_OR_GENE_PRODUCT
Our investigations have focused on localizing cis-elements responsible for the down regulation of the adult beta-like globin genes (delta and beta) in immature, or primitive erythroid tissues.	46	57	GENE_OR_GENE_PRODUCT
The promoters and enhancers of cell type-specific genes are often conserved in evolution, and hence one might expect that a given enhancer has evolved to work best with its own promoter.	4	12	GENE_OR_GENE_PRODUCT
The promoters and enhancers of cell type-specific genes are often conserved in evolution, and hence one might expect that a given enhancer has evolved to work best with its own promoter.	18	26	GENE_OR_GENE_PRODUCT
The promoters and enhancers of cell type-specific genes are often conserved in evolution, and hence one might expect that a given enhancer has evolved to work best with its own promoter.	18	26	GENE_OR_GENE_PRODUCT
This study was designed to determine the potential cis-elements involved in transcriptional regulation of the mouse perforin gene.	51	62	GENE_OR_GENE_PRODUCT
In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression.	56	68	GENE_OR_GENE_PRODUCT
The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown.	24	36	GENE_OR_GENE_PRODUCT
We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei.	25	37	GENE_OR_GENE_PRODUCT
We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin.	43	55	GENE_OR_GENE_PRODUCT
We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin.	57	64	GENE_OR_GENE_PRODUCT
We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin.	91	96	GENE_OR_GENE_PRODUCT
We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin.	98	108	GENE_OR_GENE_PRODUCT
We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin.	114	117	GENE_OR_GENE_PRODUCT
We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin.	126	130	GENE_OR_GENE_PRODUCT
Constitutive expression of IFN-alpha5 and IFN-beta was detected in different lymphoid cells including peripheral blood mononuclear cells from normal individuals following amplification of IFN mRNA by reverse transcriptase-polymerase chain reaction and direct sequencing of the amplified product.	27	37	GENE_OR_GENE_PRODUCT
Constitutive expression of IFN-alpha5 and IFN-beta was detected in different lymphoid cells including peripheral blood mononuclear cells from normal individuals following amplification of IFN mRNA by reverse transcriptase-polymerase chain reaction and direct sequencing of the amplified product.	42	50	GENE_OR_GENE_PRODUCT
The HIV-1 accessory gene product Vpr can influence viral pathogenesis by affecting viral replication as well as host cell transcription and proliferation.	33	36	GENE_OR_GENE_PRODUCT
We investigated the mechanisms by which proinflammatory mediator, thrombin, released during intravascular coagulation and tissue injury, induces ICAM-1 (CD54) expression in endothelial cells.	66	74	GENE_OR_GENE_PRODUCT
We investigated the mechanisms by which proinflammatory mediator, thrombin, released during intravascular coagulation and tissue injury, induces ICAM-1 (CD54) expression in endothelial cells.	145	151	GENE_OR_GENE_PRODUCT
We investigated the mechanisms by which proinflammatory mediator, thrombin, released during intravascular coagulation and tissue injury, induces ICAM-1 (CD54) expression in endothelial cells.	153	157	GENE_OR_GENE_PRODUCT
The POU transcription factors Oct-1 and Oct-2 regulate the activity of octamer-dependent promoters, including those that direct transcription from rearranged immunoglobulin genes.	30	35	GENE_OR_GENE_PRODUCT
The POU transcription factors Oct-1 and Oct-2 regulate the activity of octamer-dependent promoters, including those that direct transcription from rearranged immunoglobulin genes.	40	45	GENE_OR_GENE_PRODUCT
The transcription factor GATA-1 is essential for normal erythropoiesis.	25	31	GENE_OR_GENE_PRODUCT
GATA3, a member of the GATA family that is abundantly expressed in the T-lymphocyte lineage, is thought to participate in T-cell receptor gene activation through binding to enhancers.	0	5	GENE_OR_GENE_PRODUCT
CD30, a member of the tumor necrosis factor (TNF) receptor family, is expressed constitutively on the surface of the human T cell line ACH-2, which is chronically infected with human immunodeficiency virus type-1 (HIV)-1.	0	4	GENE_OR_GENE_PRODUCT
Even with a therapy as specific as anti-TNF antibody, it is not clear if the benefit is attributable to simple binding and clearance of TNF-alpha or to binding on the cell surface and subsequent deletion of the activated macrophage.	136	145	GENE_OR_GENE_PRODUCT
MZF-1 is a C2H2 zinc finger gene encoding a putative transcriptional regulator of myeloid differentiation.	0	5	GENE_OR_GENE_PRODUCT
NF-kB is a eukaryotic transcription regulatory factor.	0	5	GENE_OR_GENE_PRODUCT
We have cloned a group of cDNAs representing mRNAs that are rapidly induced following adherence of human monocytes.	26	30	GENE_OR_GENE_PRODUCT
The Th2-type cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), induce expression of a distinct subset of genes in human monocytes, including FcepsilonRIIb (CD23), 15-lipoxygenase, IL-1 receptor antagonist (IL-1ra), and type I and type II IL-1 receptors (IL-1R).	24	37	GENE_OR_GENE_PRODUCT
The Th2-type cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), induce expression of a distinct subset of genes in human monocytes, including FcepsilonRIIb (CD23), 15-lipoxygenase, IL-1 receptor antagonist (IL-1ra), and type I and type II IL-1 receptors (IL-1R).	39	43	GENE_OR_GENE_PRODUCT
The Th2-type cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), induce expression of a distinct subset of genes in human monocytes, including FcepsilonRIIb (CD23), 15-lipoxygenase, IL-1 receptor antagonist (IL-1ra), and type I and type II IL-1 receptors (IL-1R).	49	63	GENE_OR_GENE_PRODUCT
The Th2-type cytokines, interleukin-4 (IL-4) and interleukin-13 (IL-13), induce expression of a distinct subset of genes in human monocytes, including FcepsilonRIIb (CD23), 15-lipoxygenase, IL-1 receptor antagonist (IL-1ra), and type I and type II IL-1 receptors (IL-1R).	65	70	GENE_OR_GENE_PRODUCT
According to current models the inhibitory capacity of I(kappa)B(alpha) would be mediated through the retention of Rel/NF-kappaB proteins in the cytosol.	55	71	GENE_OR_GENE_PRODUCT
However, I(kappa)B(alpha) has also been detected in the nucleus of cell lines and when overexpressed by transient transfection.	9	25	GENE_OR_GENE_PRODUCT
CD28 is an important costimulatory molecule in the activation of human T cells.	0	4	GENE_OR_GENE_PRODUCT
DNA-binding motif analysis of the microarray-retrieved deregulated genes in the promoter region revealed NF\u03baB as potential transcription factor involved in cryptotanshinone's mode of action	34	45	TECHNIQUE
Here, we describe a user-friendly web-based software package, named Drug-SNPing, which provides a platform for the integration of drug information (DrugBank and PharmGKB), protein-protein interactions (STRING), tagSNP selection (HapMap) and genotyping information (dbSNP, REBASE and SNP500Cancer)	68	79	NO_ENTITY
PharmGKB-based inputs include the following: (i) gene name (HUGO), (ii) drug name and (iii) disease-related keywords	0	8	NO_ENTITY
Positive-pressure mechanical ventilation supports gas exchange in patients with respiratory failure but is also responsible for significant lung injury.	140	144	ORGAN
Irrespective of the etiology, many kidney diseases result in inflammation and fibrosis of the tubulointerstitium, with the subsequent loss of renal function.	35	41	ORGAN
Coordination of the immune response to injury or disease in the brain is postulated to involve bi-directional discourse between the immune system and the central nervous system.	64	69	ORGAN
CD4+ macrophages in tissues such as lung, skin, and lymph nodes, promyelocytic cells in bone marrow, and peripheral blood monocytes serve as important targets and reservoirs for human immunodeficiency virus type 1 (HIV-1) replication.	36	40	ORGAN
CD4+ macrophages in tissues such as lung, skin, and lymph nodes, promyelocytic cells in bone marrow, and peripheral blood monocytes serve as important targets and reservoirs for human immunodeficiency virus type 1 (HIV-1) replication.	42	46	ORGAN
In both atopic and nonatopic asthma, elevated IL-5 has been detected in peripheral blood and the airways.	97	103	ORGAN
Positive-pressure mechanical ventilation supports gas exchange in patients with respiratory failure but is also responsible for significant lung injury.	66	73	ORGANISM
A family of transcriptional activators has recently been identified in chickens; these transcriptional activators recognize a common consensus motif (WGATAR) through a conserved C4 zinc finger DNA-binding domain.	71	78	ORGANISM
High-dose estrogen administration induces anemia in mammals.	52	58	ORGANISM
Using the coiled-coil region of Stat5b as the bait in a yeast two-hybrid screen, we identified the association of Nmi, a protein of unknown function previously reported as an N-Myc interactor.	56	61	ORGANISM
HTLV-1 infection causes an adult T cell leukemia in humans.	0	6	ORGANISM
HTLV-1 infection causes an adult T cell leukemia in humans.	52	57	ORGANISM
Molecular, biochemical and epidemiological evidence implicate HTLV-I as an etiologic agent of adult T cell leukemia (ATL).	62	68	ORGANISM
To determine whether oxidative stress dependent NF-kappaB activation is evident in patients with diabetic nephropathy we used an Electrophoretic Mobility Shift Assay based semiquantitative detection system which enabled us to determine NF-kappaB activation in ex vivo isolated peripheral blood mononuclear cells.	83	90	ORGANISM
HTLV-I is the etiologic agent of adult T-cell leukemia/lymphoma and is associated with tropical spastic paraparesis/HTLV-I-associated myelopathy.	0	6	ORGANISM
HTLV-I is the etiologic agent of adult T-cell leukemia/lymphoma and is associated with tropical spastic paraparesis/HTLV-I-associated myelopathy.	0	6	ORGANISM
Uncontrolled replication of a virus, which is harmful to the host is also disadvantageous to the virus.	30	35	ORGANISM
Most viruses cannot compete with the various immune mechanisms and become eliminated in the course of infection.	5	10	ORGANISM
A few viruses, like the Herpesviruses or the papillomaviruses, however, have developed a sophisticated strategy for persisting lifelong, usually asymptomatically in the host, hiding from the immune system and producing infectious progeny at the same time.	24	35	ORGANISM
A few viruses, like the Herpesviruses or the papillomaviruses, however, have developed a sophisticated strategy for persisting lifelong, usually asymptomatically in the host, hiding from the immune system and producing infectious progeny at the same time.	45	59	ORGANISM
Three molecular clones of HIV-1, derived from a single isolate (AL1), exhibited distinct replicative and cytopathic properties during propagation in a human T cell line.	26	31	ORGANISM
Three molecular clones of HIV-1, derived from a single isolate (AL1), exhibited distinct replicative and cytopathic properties during propagation in a human T cell line.	64	67	ORGANISM
The GATA factors are a family of transcriptional regulatory proteins in eukaryotes that share extensive homology in their DNA-binding domains.	72	81	ORGANISM
Because candidiasis and cryptococcosis are common in human immunodeficiency virus (HIV)-infected persons, the effect of Cryptococcus neoformans and Candida albicans on HIV expression in monocytic cells was examined.	8	19	ORGANISM
Because candidiasis and cryptococcosis are common in human immunodeficiency virus (HIV)-infected persons, the effect of Cryptococcus neoformans and Candida albicans on HIV expression in monocytic cells was examined.	24	38	ORGANISM
We introduce a new experimental system combining adenovirus-mediated gene transfer and fetal thymic organ culture (FTOC).	49	59	ORGANISM
The level of ongoing HIV-1 replication within an individual is critical to HIV-1 pathogenesis.	21	26	ORGANISM
The level of ongoing HIV-1 replication within an individual is critical to HIV-1 pathogenesis.	21	26	ORGANISM
Among host immune factors, the cytokine TNF-alpha has previously been shown to increase HIV-1 replication in various monocyte and T cell model systems.	88	93	ORGANISM
Numerous cellular and biochemical abnormalities in immune regulation have been described in patients with systemic lupus erythematosus (SLE), including surface Ag receptor-initiated signaling events and lymphokine production.	92	99	ORGANISM
We have demonstrated that native envelope glycoproteins of HIV-1, gp160 can induce activation of the transcription factor, NF-kappa B.	59	64	ORGANISM
We have demonstrated that native envelope glycoproteins of HIV-1, gp160 can induce activation of the transcription factor, NF-kappa B.	66	71	ORGANISM
Studies of these females show that the XIST locus on their tiny ring X chromosomes is either not present or not expressed.	17	23	ORGANISM
The generation of genomic diversity during the course of infection has the potential to affect all aspects of HIV-1 replication, including expression of the proviral genome.	110	115	ORGANISM
Permissiveness to replication of human immunodeficiency virus (HIV) differs in T lymphocytes and macrophages.	63	66	ORGANISM
Recent evidence indicates that the rate of progression of the HIV-1 disease is significantly reduced in thalassaemia major patients upon treatment with high doses of desferrioxamine (DFX).	62	67	ORGANISM
Recent evidence indicates that the rate of progression of the HIV-1 disease is significantly reduced in thalassaemia major patients upon treatment with high doses of desferrioxamine (DFX).	123	130	ORGANISM
J delta K cells were isolated as a chronically infected survivor cell line, following infection of Jurkat CD4+ T cells with dl-NF, a mutated strain of human immunodeficiency virus type 1 (HIV-1) containing a deletion of the long terminal repeat (LTR) NF-kappa B sites.	124	129	ORGANISM
The HIV-1 accessory gene product Vpr can influence viral pathogenesis by affecting viral replication as well as host cell transcription and proliferation.	4	9	ORGANISM
Tuberculosis has emerged as an epidemic, extended by the large number of individuals infected with human immunodeficiency virus type 1 (HIV-1).	0	12	ORGANISM
HIV-1 infects resting peripheral blood mononuclear cells (PBMCs) but remains inactive state until subsequent cell activation.	0	5	ORGANISM
CD30, a member of the tumor necrosis factor (TNF) receptor family, is expressed constitutively on the surface of the human T cell line ACH-2, which is chronically infected with human immunodeficiency virus type-1 (HIV)-1.	214	217	ORGANISM
Peripheral blood mononuclear cells from seventeen patients with primary myelodysplastic syndromes (MDS) in advanced stage were enriched for blasts and tested for (1) karyotype, (2) genomic configuration and (3) expression of IL-3, GM-CSF, FMS and EGR-1 genes which are all located on the long arm of chromosome 5.	50	57	ORGANISM
Four selected 3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in <i>GATA4</i>, <i>VKORC1</i>, <i>CALU</i> and <i>GGCX</i> genes, respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method	320	329	TECHNIQUE
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	78	87	DATABASE
A machine learning model was trained to predict the genome-wide chromatin accessibility from transcriptome data using the paired expression and chromatin accessibility data collected from ENCODE and ROADMAP	199	206	ROADMAP
All of the 32 samples that were positive by HC2 were also positive by RT-PCR, however 21 samples that were positive by RT-PCR were negative by HC2 test	119	125	TECHNIQUE
They are rapidly activated by various cytokines, hormones, and growth factors.	49	56	SIMPLE_CHEMICAL
In vitro labeled receptors were incubated with various synthetic or natural agonists or antagonists and submitted to trypsin digestion.	88	98	SIMPLE_CHEMICAL
In a previous study, we demonstrated that bufalin, which is an active principle of Chinese medicine, chan'su, caused apoptosis in human leukemia U937 cells by anomalous activation of mitogen-activated protein kinase (MAPK) via the signaling pathway of Ras, Raf-1, and MAPK kinase-1.	42	49	SIMPLE_CHEMICAL
The purpose of this study was to examine the effects of bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane (YM-268), a thiazolidinedione derivative, on glucose uptake, adipocyte differentiation through peroxisome proliferator-activated receptor gamma(PPARgamma), and phosphatidylinositol 3-kinase (PI 3-kinase) activity in cultured cells.	56	110	SIMPLE_CHEMICAL
The purpose of this study was to examine the effects of bis[4-[2,4-dioxo-5-thiazolidinyl)methyl]phenyl]methane (YM-268), a thiazolidinedione derivative, on glucose uptake, adipocyte differentiation through peroxisome proliferator-activated receptor gamma(PPARgamma), and phosphatidylinositol 3-kinase (PI 3-kinase) activity in cultured cells.	112	118	SIMPLE_CHEMICAL
Previously we reported that 3-deazaadenosine (DZA), a potent inhibitor and substrate for S-adenosylhomocysteine hydrolase inhibits bacterial lipopolysaccharide-induced transcription of tumor necrosis factor-alpha and interleukin-1beta in mouse macrophage RAW 264.7 cells.	28	44	SIMPLE_CHEMICAL
Recent studies have reported that lymphocytes produce, transport and bind dopamine present in plasma.	74	82	SIMPLE_CHEMICAL
However, the action of dopamine on HIV-1 gene expression in cells of the immune system has not yet been examined.	23	31	SIMPLE_CHEMICAL
Terminal differentiation of the leukemic cell lines U-937 and HL-60 by 12-O-tetradecanoylphorbol-13-acetate is accompanied by marked changes in gene expression.	71	107	SIMPLE_CHEMICAL
The Ca(2+)-dependent phosphatase calcineurin, a target of FK506 and CsA, synergizes with PKC-induced activation of nuclear factor (NF)-kappa B in T cell lines.	4	10	SIMPLE_CHEMICAL
The Ca(2+)-dependent phosphatase calcineurin, a target of FK506 and CsA, synergizes with PKC-induced activation of nuclear factor (NF)-kappa B in T cell lines.	58	63	SIMPLE_CHEMICAL
The Ca(2+)-dependent phosphatase calcineurin, a target of FK506 and CsA, synergizes with PKC-induced activation of nuclear factor (NF)-kappa B in T cell lines.	68	71	SIMPLE_CHEMICAL
Glucocorticoid-induced apoptosis was investigated in glucocorticoid-sensitive 6TG1.1 and resistant ICR27TK.3 human leukemic T cells.	53	67	SIMPLE_CHEMICAL
1. Bioactivation of sulphamethoxazole (SMX) to chemically-reactive metabolites and subsequent protein conjugation is thought to be involved in SMX hypersensitivity.	20	37	SIMPLE_CHEMICAL
1. Bioactivation of sulphamethoxazole (SMX) to chemically-reactive metabolites and subsequent protein conjugation is thought to be involved in SMX hypersensitivity.	39	42	SIMPLE_CHEMICAL
1. Bioactivation of sulphamethoxazole (SMX) to chemically-reactive metabolites and subsequent protein conjugation is thought to be involved in SMX hypersensitivity.	67	77	SIMPLE_CHEMICAL
1. Bioactivation of sulphamethoxazole (SMX) to chemically-reactive metabolites and subsequent protein conjugation is thought to be involved in SMX hypersensitivity.	39	42	SIMPLE_CHEMICAL
We have therefore examined the cellular metabolism, disposition and conjugation of SMX and its metabolites in vitro.	83	86	SIMPLE_CHEMICAL
We have therefore examined the cellular metabolism, disposition and conjugation of SMX and its metabolites in vitro.	95	105	SIMPLE_CHEMICAL
2. Flow cytometry revealed binding of N-hydroxy (SMX-NHOH) and nitroso (SMX-NO) metabolites of SMX, but not of SMX itself, to the surface of viable white blood cells.	38	58	SIMPLE_CHEMICAL
2. Flow cytometry revealed binding of N-hydroxy (SMX-NHOH) and nitroso (SMX-NO) metabolites of SMX, but not of SMX itself, to the surface of viable white blood cells.	63	79	SIMPLE_CHEMICAL
The first product of ascorbate oxidation, the ascorbate free radical (AFR), acts in biological systems mainly as an oxidant, and through its role in the plasma membrane redox system exerts different effects on the cell.	21	30	SIMPLE_CHEMICAL
1. In this study we hypothesized that in individuals with certain genetic makeup, MTBE, benzene or their metabolites act as adducts and may induce programmed cell death.	82	86	SIMPLE_CHEMICAL
1. In this study we hypothesized that in individuals with certain genetic makeup, MTBE, benzene or their metabolites act as adducts and may induce programmed cell death.	88	95	SIMPLE_CHEMICAL
Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC).	113	129	SIMPLE_CHEMICAL
Because antioxidants have been considered to be of antiatherosclerotic potential, we investigated the effects of alpha-tocopherol (TCP) and its acetate and succinate esters on monocyte adhesion to cytokine-stimulated human umbilical vein endothelial cells (HUVEC).	131	134	SIMPLE_CHEMICAL
Flavonoids are a group of naturally-occurring phenolic compounds in the plant kingdom, and many flavonoids are found with vascular protective properties.	96	105	SIMPLE_CHEMICAL
PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties.	0	5	SIMPLE_CHEMICAL
PG490 (triptolide) is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties.	7	17	SIMPLE_CHEMICAL
Toremifene exerts multiple and varied effects on the gene expression of human peripheral mononuclear cells.	0	10	SIMPLE_CHEMICAL
We have shown that 1-(5-chloronaphthalene-1-sulfonyl)-1H-hexahydro-1,4-diazepine hydrochloride (ML-9), an inhibitor of myosin light chain kinase, induces differentiation of monocytoid leukemia cell lines U937 and THP-1 but not of myeloblastic leukemic ML-1 cell or erythroleukemia K562 cells.	96	100	SIMPLE_CHEMICAL
FK506, an immunosuppressant, inhibits the production of several cytokines in T lymphocytes.	0	5	SIMPLE_CHEMICAL
We had previously shown that the drug undecylprodigiosin (UP) blocks human lymphocyte proliferation in vitro.	38	56	SIMPLE_CHEMICAL
We had previously shown that the drug undecylprodigiosin (UP) blocks human lymphocyte proliferation in vitro.	58	60	SIMPLE_CHEMICAL
Some antioxidants, including butylated hydroxyanisole (BHA), tetrahydropapaveroline (THP), nordihydroguiauretic acid, and 10,11-dihydroxyaporphine (DHA), were found to be potent inhibitors of the production of tumor necrosis factor (TNF)-alpha, IL-1 beta, and IL-6 by human peripheral blood mononuclear cells (PBMC) stimulated by lipopolysaccharide (LPS) (IC50s in the low micromolar range).	5	17	SIMPLE_CHEMICAL
Activation through the Ca2+/calcineurin pathway is essential to the transcription of many cytokine genes.	23	27	SIMPLE_CHEMICAL
Retinoic acid (RA), a vitamin A derivative, exerts a wide range of biological effects related to cell proliferation and differentiation.	15	17	SIMPLE_CHEMICAL
A human T lymphoid cell line, PEER, dies by apoptosis in the presence of PMA and calcium ionophore.	73	76	SIMPLE_CHEMICAL
Recent evidence indicates that the rate of progression of the HIV-1 disease is significantly reduced in thalassaemia major patients upon treatment with high doses of desferrioxamine (DFX).	166	181	SIMPLE_CHEMICAL
1. Administration of danazol for over one month reduced the levels of estrogen receptor (ER) and its mRNA to approximately 50 and 20%, respectively in monocytes.	21	28	SIMPLE_CHEMICAL
Potential explanations for low replication rate include differences in microarray platforms, statistical modeling, covariates considered and origin and collection procedures of tissues	93	113	ANALYTICAL_METHOD
Large-scale whole genome and exome resequencing studies have revealed that humans have a high level of deleterious rare variation, which has important implications for the design of future pharmacogenetics studies	0	24	TECHNIQUE
Large-scale whole genome and exome resequencing studies have revealed that humans have a high level of deleterious rare variation, which has important implications for the design of future pharmacogenetics studies	29	47	TECHNIQUE
Genotypic variants of CYP3A4, CYP3A5, CYP2C8, NR1I2-206, ABCB1, ERCC1, and ERCC2 were analyzed by pyrosequencing or by PCR restriction fragment length polymorphism	119	122	TECHNIQUE
Here we developed a novel, rapid Allele-Specific PCR method for CDA rs2072671 genotyping	49	52	TECHNIQUE
A total of 332 Romanian individuals were genotyped for the CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms using the PCR-RFLP technique	123	131	TECHNIQUE
Furthermore, genotyping for CYP3A5*3 and CYP3A5*6 was performed by PCR-RFLP	67	75	TECHNIQUE
The SmartAmp method enables us to detect genetic polymorphisms or mutations in target genes within 30-40 min without DNA isolation and PCR amplification	135	138	TECHNIQUE
Differing from the widely used PCR, the SmartAmp reaction is an isothermal DNA amplification, where the initial step of copying a target sequence from the template DNA is critically important	31	34	TECHNIQUE
The present study examined two polymorphisms of GRIN1, rs11146020 (G1001C) and rs1126442 (G2108A), in 100 male Thai METH-dependent patients and 103 healthy controls using PCR-RFLP techniques	171	179	TECHNIQUE
Using a PCR array for 84 apoptosis genes, cantharidin treatment upregulated gene expression of caspase-1 and nerve growth factor receptor, but downregulated mRNA expression of Bcl-2 like protein 10, Fas ligand, and tumor necrosis factor-\u03b1	8	11	TECHNIQUE
RT-PCR analysis also confirmed the down-regulation of SKA2 and BUB1B, and the up-regulation of PPP1R15A, SQSTM1, HSPA1B, and DDIT4 by OGE treatment	0	6	TECHNIQUE
DNA extraction was performed using phenol chloroform extraction procedure and genotyping by standard Taqman based RT-PCR method	114	120	TECHNIQUE
Major CYP2D6 alleles of *1, *3, *4, *5, and *6 were genotyped for 30 responsive and 60 non-responsive FMF patients by multiplex PCR-based reverse-hybridization StripAssay and real-time PCR methods	128	131	TECHNIQUE
Here we developed a modified PR-PCR method using a ddNTP-blocked primer and a mixture of DNA polymerases with and without the 3'-5' proofreading function	29	35	TECHNIQUE
The modified PR-PCR method is quite capable of detecting various mutation types, including point mutations and insertions/deletions (indels), and allows discrimination amplification when the mismatch is located within the last eight nucleotides from the 3'-end of the ddNTP-blocked primer	13	19	TECHNIQUE
Current technologies for detecting the variants of these genes are mainly based on real-time PCR	93	96	TECHNIQUE
521T>C) SNP was performed with allele-specific polymerase chain reaction, whilst polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) was used for genotyping the SLCO1B1 rs2306283 (c	149	157	TECHNIQUE
Whole blood was used to identify SNPs in ABCB1, MRP2, CYP2B6, CYP2A6, UGT2B7, NR1I2 (PXR), NR1I3 (CAR) and HNF4\u03b1 by real-time PCR	116	129	TECHNIQUE
In the second part of the study, consensus real-time polymerase chain reaction (RT-PCR) (Takara Bio Inc	80	86	TECHNIQUE
All of the 32 samples that were positive by HC2 were also positive by RT-PCR, however 21 samples that were positive by RT-PCR were negative by HC2 test	70	76	TECHNIQUE
In addition, a significant degree of concordance was detected between HC2 and concensus RT-PCR methods (Cohen's kappa: 0	88	94	TECHNIQUE
Finally, the newly predicted miRNAs for tamoxifen and metformin were experimentally validated in MCF-7 and MDA-MB-231 breast cancer cell lines via qRT-PCR assays	147	154	TECHNIQUE
TPMT activity was measured by using a non-extraction HPLC method and genotype for the C3435T polymorphism of MDR1 gene was determined in 215 unrelated IBD patients including of 85 males and 130 females and 212 unrelated healthy individuals consisted of 96 males and 116 females as control group by PCR-RFLP in Iran's western population	38	57	TECHNIQUE
The device combines a blood lysis chamber, a cross-flow filter, a T-junction mixer, and a microreactor for quantitative polymerase chain reaction (qPCR)	147	151	TECHNIQUE
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	66	82	TECHNIQUE
Genotyping was conducted by the QuantStudio 12K Flex Real-Time PCR System using a custom open array chip with metabolism, transport, and transcription factor polymorphisms of interest to cisplatin disposition and toxicity	32	73	TECHNIQUE
Frequency distribution of SULT1A1 copy number (CN) in 157 healthy Indian individuals was assessed using florescent-based quantitative PCR assay	134	143	TECHNIQUE
Genotyping was performed by TaqMan real-time polymerase chain reaction (PCR) (pharmacokinetics genes: cytochrome P450 2D6 (CYP2D6) *4 (rs3892097), *5 (gene deletion), *10 (rs1065852) and *41 (rs28371725), ATP-binding cassette transporter B1 (ABCB1) 2677\u00a0G>T/A (rs2032582) and 3435C>T (rs1045642) and pharmacodynamics genes: dopamine receptor D2 (DRD2) Tag-SNP (C>T) (rs4436578), DRD2 Tag1A (C>T) (rs1800497), leptin gene (LEP) -2548G>A (rs7799039), ghrelin gene (GHRL) -604G>A (rs27647) and brain-derived neurotrophic factor (BDNF) 196G>A (rs6265))	28	70	TECHNIQUE
PCR and direct sequencing revealed a total of 32 polymorphisms, of which 5 novel mutations were presented	0	3	TECHNIQUE
PCR and direct sequencing revealed a total of 32 polymorphisms, of which 5 novel mutations were presented	8	25	TECHNIQUE
DNA was extracted from buccal swabs obtained from 636 non-related Southeastern European Caucasian individuals and was analyzed by real-time PCR	130	143	TECHNIQUE
Polymorphism genotypes were determined by real-time PCR using validated assays	42	55	TECHNIQUE
Genotypes were determined by means of Taq Man probes (qPCR)	38	52	TECHNIQUE
Genotypes were determined by means of Taq Man probes (qPCR)	54	59	TECHNIQUE
Real Time PCR (Melting Curve Analysis) followed DNA extraction from buccal swabs and statistical analysis of the results was performed	0	13	TECHNIQUE
Variants in OPRM1 (A118G), ABCB1 (C3435T), COMT (G472A), OPRD1 (T921C) and ARRB2 (C8622T) genes were tested by real-time PCR	111	124	TECHNIQUE
Allelic discrimination was performed by real-time PCR	40	53	TECHNIQUE
Four selected 3'-UTR SNPs (rs12458, rs7294, rs1868774 and rs34669593 located in <i>GATA4</i>, <i>VKORC1</i>, <i>CALU</i> and <i>GGCX</i> genes, respectively) with the potential to disrupt/eliminate or enhance/create microRNA-binding site were genotyped using a simple PCR-based restriction fragment length polymorphism (PCR-RFLP) method	261	271	TECHNIQUE
PCR and next generation sequencing were used for the analysis	0	3	TECHNIQUE
PCR and next generation sequencing were used for the analysis	8	34	TECHNIQUE
Significant pairs were prioritized based on strength of association and <i>in-silico</i> miRNA target prediction analyses to select candidates for validation with qRT-PCR	163	170	TECHNIQUE
<i>CYP1A2*1F</i> (163C>A; rs762551); <i>CYP2C9*3</i> (1075A>C; rs1057910); and <i>CYP3A5*3</i> (6986A>G; rs776746) polymorphisms were investigated through real-time PCR using TaqMan probes	155	168	TECHNIQUE
<i>CYP1A2*1F</i> (163C>A; rs762551); <i>CYP2C9*3</i> (1075A>C; rs1057910); and <i>CYP3A5*3</i> (6986A>G; rs776746) polymorphisms were investigated through real-time PCR using TaqMan probes	175	188	TECHNIQUE
Eleven variants in the thymidylate synthetase (<i>TYMS</i>), methylenetetrahydrofolate reductase (<i>MTHFR</i>)<i>,</i> dihydrofolate reductase (<i>DHFR</i>), <i>SLC19A1</i> and <i>SLCO1B</i> genes were analyzed in 148 patients, using PCR- and sequencing-based methodology	235	238	TECHNIQUE
Genomic DNA was extracted from blood samples, and PCR and DNA sequencing were performed to identify genetic variations in the different study groups	50	53	TECHNIQUE
Genomic DNA was extracted from blood samples, and PCR and DNA sequencing were performed to identify genetic variations in the different study groups	58	72	TECHNIQUE
NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively	159	167	TECHNIQUE
NPC1L1 rs2073548, p53 rs1042522, VKORC1 rs9923231 and CYP2C9*1/*3 polymorphisms were genotyped by polymerase chain reaction-restriction fragment polymorphism (PCR-RFLP) or Sanger sequencing, respectively	172	189	TECHNIQUE
Genotyping of SOD2 (rs4880), PNPL3 (rs738409) and ABCC1 (rs4148350), CBR1 (rs9024) and ABCG2 (rs2231142) was performed by Tetra-ARMS PCR-based technique to evaluate the genotype-phenotype correlation	122	136	TECHNIQUE
The patients were genotyped for <i>CYP3A5</i>*3, <i>CYP3A4</i>*1B, <i>CYP3A4</i>*1G, <i>ABCB1</i> G2677T, and <i>ABCB1</i> C3435T polymorphisms by the PCR-RFLP method	151	159	TECHNIQUE
Here, we present two simple novel approaches for the identification of samples carrying either deletions or duplications of the <i>CYP2D6</i> gene; by relative quantification using a singleplex 5'nuclease real-time PCR assay, and by high-resolution melting of PCR products	183	224	TECHNIQUE
Drug levels were analyzed using liquid chromatography at different days of therapy, whereas variants in genes encoding transporters and nuclear factors were investigated using real-time PCR	176	189	TECHNIQUE
Allelic discrimination analysis was performed using a step one real-time PCR machine	63	76	TECHNIQUE
Here, we present a new method for polymerase chain reaction (PCR) melting curve analysis using one fluorescent probe to discriminate the UGT1A1*1 [(TA)<sub>6</sub> ] and *28 [(TA)<sub>7</sub> ] genotypes	61	64	TECHNIQUE
Genotypes of 10 SNPs from four different genes were analyzed using the allelic discrimination PCR technique	94	97	TECHNIQUE
Genotyping was performed using real-time PCR and long-range PCR	31	44	TECHNIQUE
Genotyping was performed using real-time PCR and long-range PCR	49	63	TECHNIQUE
Five single-nucleotide polymorphisms were genotyped by real-time PCR assays: prostaglandin-F2\u03b1 receptor (rs3766355, rs3753380); cytochrome-P450 2D6 (rs16947, rs769258); and beta-2-adrenergic receptor (rs1042714)	56	68	TECHNIQUE
In this study, we evaluated TaqMan PCR for detection of the NUDT15 single-nucleotide polymorphisms (SNPs) and examined the clinical impact of Arg139His on thiopurine-induced leukopenia	28	39	TECHNIQUE
First, we demonstrated that a TaqMan PCR assay successfully detected the Arg139His polymorphism of NUDT15 in clinical samples	30	40	TECHNIQUE
Next, the NUDT15 gene polymorphisms (Arg139Cys and Arg139His) were separately analyzed by TaqMan Real-Time PCR in 189 patients from August 2018 to July 2019	90	111	TECHNIQUE
719A>G were detected by PCR-restriction fragment length polymorphism assay and c	24	68	TECHNIQUE
The expression of 32 target genes in 80 paired specimens (pre-chemotherapeutic primary tumor, post-chemotherapeutic primary tumor and pulmonary metastasis) obtained from 33 patients diagnosed with OS were analyzed by the real-time PCR methodology	221	234	TECHNIQUE
Genotyping was performed using PCR-RFLP and direct Sanger sequencing	31	39	TECHNIQUE
Genotyping was performed using PCR-RFLP and direct Sanger sequencing	51	68	TECHNIQUE
However, an imbalance in the PCR amplification of different haplotypes could affect the accuracy of typing results	29	46	TECHNIQUE
<i>IL5RA</i> mRNA expression level was analyzed in different groups of patients by performing qPCR assays	94	105	TECHNIQUE
SNPs were analyzed using real-time PCR with TaqMan<sup>\u00ae</sup> probes	25	39	TECHNIQUE
<i>Results</i>: Based on the analysis of melt profile data for each PCR product, the identification of polymorphisms was carried out	68	71	TECHNIQUE
In this context, there is reported a case in which a routine PCR-SS approach for genotyping <i>DPYD</i> SNP rs55886062 failed in a proband of African descent	61	67	TECHNIQUE
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	19	42	TECHNIQUE
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	44	48	TECHNIQUE
The enforcement of whole genome sequencing (WGS) approach led to the identification of two adenine (A) insertions near the PCR primers annealing regions in the proband, responsible for a sequence frameshift and a genotyping error for rs55886062	123	126	TECHNIQUE
This preventive measure is essential to avoid sequence frameshifts or primer misalignments arising from SNP occurrences in the genome, which can compromise PCR-SS and lead to genotyping failures	156	162	TECHNIQUE
We also built the Library of Knowledge Integration (LOKI), a repository of data assembled from public databases, which contains resources such as: dbSNP and gene Entrez database information from the National Center for Biotechnology (NCBI), pathway information from Gene Ontology (GO), Protein families database (Pfam), Kyoto Encyclopedia of Genes and Genomes (KEGG), Reactome, NetPath - signal transduction pathways, Open Regulatory Annotation Database (ORegAnno), Biological General Repository for Interaction Datasets (BioGrid), Pharmacogenomics Knowledge Base (PharmGKB), Molecular INTeraction database (MINT), and evolutionary conserved regions (ECRs) from UCSC Genome Browser	266	279	TECHNIQUE
To date, at least 244 pharmacogenes identified have been associated with ADRs of 176 clinically used drugs based on PharmGKB	116	124	TECHNIQUE
In this study, we recruited 100 unrelated, healthy Deng people and genotyped them with respect to 76 different single-nucleotide polymorphisms by the PharmGKB database	150	158	TECHNIQUE
MATERIAL AND METHODS In this study, we genotyped 66 Very Important Pharmacogene (VIP) variants selected from PharmGKB in 98 unrelated, healthy Miao individuals from the Guizhou province and compared our data with 12 other populations, including 11 populations from the HapMap data set and Xi'an Han Chinese	109	117	TECHNIQUE
Coding and regulatory regions of 509 genes, selected from PharmGKB and Phenopedia, were sequenced using massive parallel sequencing in blood DNA from 105 breast cancer patients in the testing phase	58	66	TECHNIQUE
Indeed, among the 94 PGx-based drug dosing guidelines currently published by the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group on PharmGKB web site, 81 (86%) are associated with the genotype determination of either a metabolizing enzyme or a membrane drug transporter, whereas only 13 (14%) are associated with the genotype determination of a pharmacodynamics (PD)-associated gene	81	132	TECHNIQUE
In the first of a series of PharmGKB tutorials, we introduce the PharmGKB coronavirus disease 2019 (COVID-19) portal and, using examples of drugs found in the portal, demonstrate some of the main features of PharmGKB	65	73	TECHNIQUE
We screened 4306 DLs applying natural language processing focusing on drug metabolism (pharmacokinetics) and we assigned PGx levels following the classification system of PharmGKB	171	179	TECHNIQUE
Filtering the variants according to Pharmacogenomics Knowledge Base (PharmGKB) annotations identified 27 diplotypes and 26 variants with an evident clinical relevance	36	67	TECHNIQUE
By further comparison with data from two PGx-specific databases (PharmVar and PharmGKB) and ClinVar, we identified 234 missense variants in 35 CYP genes, of which 107 were unknown to these databases	65	73	TECHNIQUE
Evidence from the pharmacogenomic literature is curated into PharmGKB as variant annotations, which can be used to create new clinical annotations or added to existing clinical annotations	61	69	TECHNIQUE
As more evidence is curated into PharmGKB, the task of maintaining consistency when assessing all the available evidence and assigning an LOE becomes increasingly difficult	33	41	TECHNIQUE
In combination with increased standardization of how clinical annotations are written, use of this scoring system helps to ensure that PharmGKB clinical annotations continue to be a robust source of pharmacogenomic information	135	143	TECHNIQUE
"Based on PharmGKB expert guidelines we identified at least one \""actionable\"" variant in all 135 (100%) tested patients"	9	17	TECHNIQUE
Targeted variant CPGx tests found in the Genetic Testing Registry (GTR), gene selection information, and diplotype frequency data from the Pharmacogenomics Knowledge Base (PharmGKB) were used to determine the detection rate of each CPGx test	41	65	TECHNIQUE
For another pharmacogenetic hurdle, the speed by which a pharmacogenetic profile for a certain drug can be obtained in an individual patient, there has been a revolution in molecular genetics through the introduction of next generation sequencing (NGS), making it possible to sequence a large number of genes up to the complete genome in a single reaction	220	246	TECHNIQUE
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \""post-genomic era\"	40	50	TECHNIQUE
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \""post-genomic era\"	67	97	TECHNIQUE
"Modern genetic analysis methods such as DNA arrays (gene chips) or high-throughput DNA sequencing of the next generation (Next Generation Sequencing, NGS) have once again accelerated the pace of innovation that has been powered by genome research over the past 10 years of the \""post-genomic era\"	122	148	TECHNIQUE
However, with the rise of new technologies, as next generation sequencing, allowing to obtain pre-emptive genetic information, one must be aware that the question will no longer be whether to genotype or not but rather whether or not to use the information already there	47	73	TECHNIQUE
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	196	222	TECHNIQUE
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	230	236	TECHNIQUE
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	242	252	TECHNIQUE
Results from the initial next generation sequencing studies indicate an enrichment of rare variants in pathways and genes that were previously found to be associated with BD	25	51	TECHNIQUE
Furthermore, the development of next generation sequencing technology and non-invasive approaches to analyze circulating tumor DNA will make real-time monitoring of the tumor pharmacogenomic markers possible in the clinical routine, rendering precision medicine available to every patient	32	58	TECHNIQUE
In the current study, the mRNA and microRNA (miRNA) expression profiles derived from next generation sequencing data for APAP-treated (5 and 10\u00a0mM) HepaRG cells and controls were analyzed systematically	85	111	TECHNIQUE
With the advancement of next generation sequencing technology, researchers are now able to identify important variants and structural changes in DNA and RNA in cancer patient samples	24	50	TECHNIQUE
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	116	142	TECHNIQUE
To make concrete the goal of personalized medicine, it is necessary to employ high-throughput methodologies such as Next Generation Sequencing (NGS), Genome-Wide Association Studies (GWAS), Mass Spectrometry or Microarrays, that are able to investigate a single disease from a broader perspective	212	223	TECHNIQUE
Recent progress in Next Generation Sequencing (NGS) technologies has for the first time allowed to comprehensively map the genetic landscape of human pharmacogenes	19	45	TECHNIQUE
Extraordinary advances in high throughput next generation sequencing (NGS) technology and bioinformatics are the main thrust that transforms the current state of healthcare into the era of precision medicine where clinical practice takes individual variability into account	42	68	TECHNIQUE
"The manuscripts in following categories are welcome, but not limited to: Application of next generation sequencing in clinical diagnosis, including but not limited to rare genetic disease, complex inherited disease, prenatal/perinatal screening, oncology, organ transplantation and pathogen identification; Novel bioinformatics approaches in human genomics; Single cell sequencing, liquid biopsy and other emerging genomic assays in molecular genetics, pharmacogenomics, oncology and immuno-oncology; Integration of genomics with other \""omics\"" technology in genetic medicine"	88	114	TECHNIQUE
High-throughput next generation sequencing (NGS) is a shotgun approach applied in a parallel fashion by which the genome is fragmented and sequenced through small pieces and then analyzed either by aligning to a known reference genome or by de novo assembly without reference genome	16	42	TECHNIQUE
Next generation sequencing (NGS) is a cost-effective option for genotyping patients at many pharmacogenomic loci simultaneously, and guidelines for implementation of these data are available from organizations such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG)	0	26	TECHNIQUE
It also plays a fundamental role in nucleic acid sequencing applications, including Next Generation Sequencing (NGS)-based ones	84	110	TECHNIQUE
PCR and next generation sequencing were used for the analysis	0	3	TECHNIQUE
PCR and next generation sequencing were used for the analysis	8	34	TECHNIQUE
In this study we used next generation sequencing to measure genome-wide miRNA expression in lymphoblastoid cell lines from BD patients excellent responders (ER, <i>n</i> = 12) and non-responders (NR, <i>n</i> = 12) to lithium	21	48	TECHNIQUE
In this study we used next generation sequencing to measure genome-wide miRNA expression in lymphoblastoid cell lines from BD patients excellent responders (ER, <i>n</i> = 12) and non-responders (NR, <i>n</i> = 12) to lithium	60	88	TECHNIQUE
For the advances of pediatric oncology next generation sequencing (NGS) research to equitably benefit all children, a diverse and representative sample of participants is needed	39	65	TECHNIQUE
The rapid clinical implementation of next generation sequencing techniques\u00a0is\u00a0 due to its ability to sequence a large number of genetic regions at\u00a0lower costs\u00a0 than conventional techniques	37	63	TECHNIQUE
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	40	43	TECHNIQUE
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	45	54	TECHNIQUE
Samples from patients were genotyped by PCR, MassArray, and targeted next generation sequencing	60	95	TECHNIQUE
Here, we report on the development of a cost-effective next generation sequencing-based pain-genotyping assay comprising the development of a customized AmpliSeq\u2122 panel and bioinformatics approaches that condensate the genetic information of pain by identifying the most representative genes	55	81	TECHNIQUE
<b>Conclusion:</b> The implementation of Precision Medicine by using tools such as Next Generation Sequencing and TDM led to diagnose and select a targeted therapy for the treatment of a KCNT1-related epilepsy in a patient presented with EIMFS in early infancy and poor response to antiepileptic drugs	83	109	TECHNIQUE
The increasing availability of next generation sequencing (NGS) for personal genomics could promote pharmacogenomics (PGx) discovery and application	31	57	TECHNIQUE
Nowadays, a plethora of studies implement next generation sequencing to capture rare and novel pharmacogenomic (PGx) variants that influence drug response	42	68	TECHNIQUE
To assess whether the specific population history of Roma, characterized by constant migrations and endogamy, influenced the distribution of alleles and thus phenotypes, the CYP2D6 gene was sequenced using NGS (Next Generation Sequencing) method-targeted sequencing in three groups of Croatian Roma (N = 323) and results were compared to European and Asian populations	206	209	TECHNIQUE
To assess whether the specific population history of Roma, characterized by constant migrations and endogamy, influenced the distribution of alleles and thus phenotypes, the CYP2D6 gene was sequenced using NGS (Next Generation Sequencing) method-targeted sequencing in three groups of Croatian Roma (N = 323) and results were compared to European and Asian populations	211	238	TECHNIQUE
An innovative multimodal targeted next generation sequencing (mmNGS) approach with custom primers designed for the most commonly reported SNPs of genes belonging to DNA repair, CDDP transport or detoxification, or associated with CDPP-related toxicity was applied	25	60	TECHNIQUE
Massively parallel, next generation sequencing (NGS), has allowed pharmacogenetics to be subsumed by pharmacogenomics with respect to the identification of variants associated with responders and non-responders, optimal drug response, and adverse drug reactions	20	46	TECHNIQUE
In the near future, we envision a shift toward long-read sequencing as the predominant method for gene diagnostics and pharmacogenetic profiling, providing unprecedented data quality and improving patient care	47	67	TECHNIQUE
Here, we show the utility of long-read sequencing to resolve complex pharmacogenes by analyzing a well-characterised sample	29	49	TECHNIQUE
Together, these findings suggest that long-read sequencing data offers promising opportunities in elucidating complex pharmacogenes and haplotype phasing while maintaining accurate variant calling	38	58	TECHNIQUE
Long-read sequencing, on the other hand, has been shown to be able to resolve complex (pharmaco) genes	0	20	TECHNIQUE
In this study we aimed to assess the value of long-read sequencing for research and clinical PGx focusing on the important and highly polymorphic <i>CYP2C19</i> gene	46	66	TECHNIQUE
<b>Methods and Results:</b> With a capture-based long-read sequencing panel we were able to characterize the entire region and assign variants to their allele of origin (phasing), resulting in the identification of 813 unique variants in 37 samples	49	69	TECHNIQUE
To improve <i>CYP2D6</i> genotyping accuracy, we developed a PCR-free CRISPR-Cas9 based enrichment method for targeted long-read sequencing that fully characterizes the entire <i>CYP2D6-CYP2D7-CYP2D8</i> loci	61	81	TECHNIQUE
To improve <i>CYP2D6</i> genotyping accuracy, we developed a PCR-free CRISPR-Cas9 based enrichment method for targeted long-read sequencing that fully characterizes the entire <i>CYP2D6-CYP2D7-CYP2D8</i> loci	110	139	TECHNIQUE
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	139	159	TECHNIQUE
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	161	181	TECHNIQUE
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	187	206	TECHNIQUE
In this study, we employed long-read sequencing technology, extensively utilized in studying complex genomic regions, to characterize genetic alterations, including short variants (single nucleotide variants and short insertions and deletions) and copy number variations, in 370 CMRGs across 41 individuals from 19 global populations	27	47	TECHNIQUE
Our results demonstrate that nanopore sequencing is an emerging standalone technology with potential utility in a clinical environment to aid in medical decision-making	29	48	TECHNIQUE
We have established methods for sequencing and haplotyping of the whole <i>CYP2D6</i> gene using nanopore sequencing	97	116	TECHNIQUE
The MinION nanopore sequencing device opens the opportunity to cost-effective and point-of-care DNA sequencing	4	30	TECHNIQUE
We carried out long PCR to isolate the <i>CYP2D6</i> region before performing nanopore sequencing to identify all variants and alleles in these samples	15	23	TECHNIQUE
We carried out long PCR to isolate the <i>CYP2D6</i> region before performing nanopore sequencing to identify all variants and alleles in these samples	79	98	TECHNIQUE
Nanopore sequencing has been examined as a method for rapid and high-resolution human leukocyte antigen (HLA) typing in recent years	0	19	TECHNIQUE
This work advances the use of nanopore sequencing in clinical PGx settings	30	49	TECHNIQUE
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	139	159	TECHNIQUE
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	161	181	TECHNIQUE
Further technological development of sequencing technologies has led to the birth of third and fourth-generation sequencing, which include long-read sequencing, single-cell genomics, and nanopore sequencing	187	206	TECHNIQUE
<b>Objectives:</b> We sought to develop a Nanopore sequencing panel and validate its performance in patients with active tuberculosis (TB) to personalize treatment dosing	42	61	TECHNIQUE
<b>Methods:</b> We developed a Nanopore sequencing panel targeting 15 SNPs in five genes affecting the metabolism of antitubercular drugs	31	50	TECHNIQUE
In the past decade, pharmacogenomics and microarrays are considered two of the most important scientific breakthroughs for detection and treatment of diseases with many other applications	41	52	TECHNIQUE
The IC50 values for miltirone of 60 National Cancer Institute cell lines were associated with the microarray-based expression of 9,706 genes	98	108	TECHNIQUE
The results obtained from microarray were further validated by real-time reverse transcription-PCR	26	36	TECHNIQUE
The pharmacogenomic effects of a corticosteroid (CS) were assessed in rat skeletal muscle using microarrays	96	107	TECHNIQUE
These technologies include target therapies, toxicogenomics, nanomedicine, pharmacogenetics and pharmacogenomics, with a particular focus on microarray technology	141	151	TECHNIQUE
Improvements in the sensitivity and precision of DNA microarrays permit a detailed and accurate scrutiny of the human genome	49	64	TECHNIQUE
Genome-wide gene-expression data from DNA-microarray technology and molecular-network data from computational text-mining have led to a paradigm shift in biological research	38	52	TECHNIQUE
However, the comprehensive study of pharmacoepigenomics awaits the advent of genome-wide analysis of DNA methylation using microarrays and next-generation sequencers	101	134	TECHNIQUE
However, the comprehensive study of pharmacoepigenomics awaits the advent of genome-wide analysis of DNA methylation using microarrays and next-generation sequencers	140	166	TECHNIQUE
Novel multistranded and alternative DNA, RNA and plasmid microarrays (transitional structural nucleic acid microarrays) have been developed that allows for the immobilization of intact, nondenatured, double-stranded DNA, double-stranded RNA, and alternative and multistranded nucleic acids	41	68	TECHNIQUE
This technology represents the next generation of microarrays, which will aid in the characterization of nucleic acid structure and function, and accelerate the discovery of drugs that bind to nucleic acids	50	61	TECHNIQUE
These novel nucleic acid microarrays, together with pharmacogenomics, can be used to improve the study of DNA and RNA structure, gene expression, drug development and treatment of various diseases	12	36	TECHNIQUE
It is suggested that a systems biology approach employing microarray analyses of gene expression and methylation patterns can lead to a better understanding of long-term side-effects of drugs, and that in the future, epigenetic assays should be incorporated into the safety assessment of all pharmaceutical drugs	58	68	TECHNIQUE
In addition to high-density experimental microarrays, low-density, gel-based biochip technology represents a versatile platform for translation of research into clinical practice	41	52	TECHNIQUE
Gel-based microarrays (biochips) consist of nanoliter gel drops on a hydrophobic surface with different immobilized biopolymers (primarily nucleic acids and proteins)	0	21	TECHNIQUE
In addition to tubulin as primary target, microarray-based mRNA signatures of responsiveness of these compounds have been identified by COMPARE and signaling pathway profiling	42	63	TECHNIQUE
Research into gene diversity through single-nucleotide polymorphisms (SNPs) by means of microarray systems, allows the detailed analysis of gene factors associated to a given disease	88	98	TECHNIQUE
Screening of microarray data revealed paraoxonases PON1 and PON3 among 17 candidate esterases	13	23	TECHNIQUE
Potential explanations for low replication rate include differences in microarray platforms, statistical modeling, covariates considered and origin and collection procedures of tissues	71	81	TECHNIQUE
The advent of microarrays over the past decade has transformed the way genome-wide studies are designed and conducted, leading to an unprecedented speed of acquisition and amount of new knowledge	14	26	TECHNIQUE
Microarray data have led to the identification of molecular subclasses of solid tumors characterized by distinct oncogenic pathways, as well as the development of multigene prognostic or predictive models equivalent or superior to those of established clinical parameters	0	10	TECHNIQUE
Herein, we present a summary of the main applications of whole-genome expression microarrays in the field of molecular-targeted therapies for solid tumors and we discuss their potential in the clinical setting	81	92	TECHNIQUE
Increasing numbers of clinically useful DNA microarrays are in the development stage, including a simplified procedure for genotyping patients for CYP2D6, which metabolizes a high proportion of the currently prescribed antidepressants and antipsychotics	40	55	TECHNIQUE
We investigated the association of genetic polymorphisms in drug metabolizing enzymes (DMEs) and transporters in patients with docetaxel-induced febrile neutropenia, by a new high-throughput DMEs and transporters (DMETPlus) microarray platform, characterizing 1936 single nucleotide polymorphisms (SNPs) in 225 genes	200	234	TECHNIQUE
We investigated the association of genetic polymorphisms in drug metabolizing enzymes (DMEs) and transporters in patients with docetaxel-induced febrile neutropenia, by a new high-throughput DMEs and transporters (DMETPlus) microarray platform, characterizing 1936 single nucleotide polymorphisms (SNPs) in 225 genes	175	190	TECHNIQUE
Microarray-based mRNA expression profiling, COMPARE, and hierarchical cluster analyses were applied to identify which genes correlate with sensitivity or resistance to selected phytochemicals of the Korean plants	0	42	TECHNIQUE
Selected phytochemicals from Korean plants were analyzed in more detail using microarray-based mRNA expression profiles and molecular docking to VEGFR1 and VEGFR2	78	119	TECHNIQUE
By using COMPARE analysis of microarray-based transcriptome-wide mRNA expressions, 21 genes were found to significantly correlate with response of 60 tumor cell lines to cantharidin	29	81	TECHNIQUE
For this reason, we performed COMPARE and hierarchical cluster analyses of the transcriptome-wide microarray-based mRNA expression of the NCI cell panel	79	130	TECHNIQUE
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	65	77	TECHNIQUE
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	33	64	TECHNIQUE
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	79	90	TECHNIQUE
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	92	118	TECHNIQUE
With genomic techniques, such as real-time reverse transcriptase PCR (RT-PCR), microarrays, next-generation sequencing, and whole-exome sequencing, breast cancer diagnostics is going through a significant evolution	124	146	TECHNIQUE
We conducted an expression quantitative trait loci (eQTL) analysis using >300 expression microarrays (from 117 lymphoblastoid cell lines) in corticosteroid (dexamethasone) treated and untreated cells derived from asthmatic subjects in the Childhood Asthma Management Program (CAMP) clinical trial	52	57	TECHNIQUE
cDNA microarray assay demonstrated that the expression of cell cycle regulators, apoptosis-related factors and cell proliferation markers were all modified by OGE treatment	0	21	TECHNIQUE
The surface of the microarray is functionalized with self-assembled monolayers of mercaptoundodecanoic acid or thiolated DNA	19	29	TECHNIQUE
To develop a gold nanoparticle-based visual DNA microarray for simple and rapid screening of EGFR gene mutations	44	58	TECHNIQUE
The progress of molecular biology tools (microarrays, proteomics and nanotechnology) have revolutionised the field of the biomarker discovery	41	52	TECHNIQUE
Understanding the process microarray testing provides a framework for understanding pharmacogenetic testing	26	36	TECHNIQUE
The progress of molecular biology tools (microarrays, proteomics, and epigenetics) have progressed the field of the genetic markers discovery	41	52	TECHNIQUE
Transcriptomic data were obtained from these samples using Illumina HumanHT-12 v4 Expression BeadChip microarrays	82	113	TECHNIQUE
Validation of expression of selected candidate genes was determined by evaluating an independent microarray expression data set	97	118	TECHNIQUE
This study presents two rapid and affordable microarray-based strategies to discriminate three clinically important SNPs in genes ADRA2A, SL6CA2, and OPRM1 (rs1800544, rs5569, and rs1799971, respectively)	45	55	TECHNIQUE
Previous studies have relied primarily on microarrays to understand gene expression differences, or have focused on a single tissue or small number of samples	42	53	TECHNIQUE
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	230	236	TECHNIQUE
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	242	252	TECHNIQUE
org ), a comprehensive and easy-to-apply gene set analysis tool for rapid contextualization of expression patterns and functional signatures embedded in the postgenomics Big Data domains, such as Next Generation Sequencing (NGS), RNAseq, and microarray experiments	196	222	TECHNIQUE
Genotyping was performed using the DMET Plus microarray platform	35	55	TECHNIQUE
Beg P132 Association of HCV nucleotide polymorphism in the development of hepatocellular carcinoma Mohd Suhail, Abid Qureshi, Adil Jamal, Peter Natesan Pushparaj, Mohammad Al-Qahtani, Ishtiaq Qadri P133 Gene expression profiling by DNA microarrays in colon cancer treated with chelidonine alkaloid Mahmoud Z El-Readi, Safaa Y Eid, Michael Wink P134 Successful <i>in vitro</i> fertilization after eight failed trials Ahmed M	232	247	TECHNIQUE
Recent growth in the area of toxicogenomics and pharmacogenomics has provided with a vast amount of drug expression microarray data	116	126	TECHNIQUE
Therefore, the miRNA-mRNA interactions and drug toxicity were investigated in silico using available microarray data	101	111	TECHNIQUE
As recognised by the National Institutes of Health (NIH) Precision Medicine Initiative (PMI), microarray technology currently provides a rapid, inexpensive means of identifying large numbers of known genomic variants or gene transcripts in experimental and clinical settings	94	104	TECHNIQUE
Microarrays presently remain the technology of choice in applications that require fast, cost-effective genome-wide screening of variants of known importance, particularly for large sample sizes	0	11	TECHNIQUE
Recently, the Affymetrix DMET (Drug Metabolizing Enzymes and Transporters) microarray platform has offered the possibility to determine the ADME (absorption, distribution, metabolism, and excretion) gene variants of a patient and to correlate them with drug-dependent adverse events	75	85	TECHNIQUE
Gene expression profiles predicting sensitivity and resistance of tumor cells to induction by curcumin and AA were determined by microarray-based mRNA expressions, COMPARE, and hierarchical cluster analyses	129	150	TECHNIQUE
SULT1A1 mRNA and protein levels were quantified using microarray data and Western blot analysis, respectively	54	64	TECHNIQUE
COMPARE analyses of the NCI microarray database for 60 cell lines showed that several genes, including those involved in lipid metabolism, correlated with cellular responsiveness to niclosamide	28	38	TECHNIQUE
Forty genes determining cellular responsiveness to As<sub>2</sub>O<sub>3</sub> were identified by microarray and COMPARE analyses in 58 cell lines of the NCI panel	98	108	TECHNIQUE
This paper presents the design and the experimentation of a comprehensive software pipeline, named microPipe, for the preprocessing, annotation and analysis of microarray-based Single Nucleotide Polymorphism (SNP) genotyping data	160	170	TECHNIQUE
Microarrays and mass spectrometry-based proteomics were employed to quantify hepatic transcript and protein dynamics	0	11	TECHNIQUE
Microarrays and mass spectrometry-based proteomics were employed to quantify hepatic transcript and protein dynamics	16	34	TECHNIQUE
The pharmacogenomics screening was performed from whole blood samples using the Affymetrix DMET (Drug-Metabolizing Enzymes and Transporters) Plus microarray, and confirmation of genetic variants was performed using real-time polymerase chain reaction	146	156	TECHNIQUE
The optical sensing method in a DNA microarray format was optimized and evaluated for the simultaneous identification of 28 polymorphisms associated with psychiatric pharmacogenomics	32	46	TECHNIQUE
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	80	92	TECHNIQUE
Differential gene expression analysis was conducted using the Linear Models for Microarray and RNA-Seq (limma) package and the Decision Tree and Random Forest machine learning algorithms in R	96	103	TECHNIQUE
Correlation to transcript microarray expression levels for identical genes and identical cell lines across CellMinerCDB demonstrates the high quality of these new RNA-seq data	15	47	TECHNIQUE
Correlation to transcript microarray expression levels for identical genes and identical cell lines across CellMinerCDB demonstrates the high quality of these new RNA-seq data	163	175	TECHNIQUE
33 region was interrogated across deidentified clinical chromosomal microarray (CMA) data from 20,642 patients tested at two academic medical centers	68	78	TECHNIQUE
Fourteen patients with chronic ITP were studied by means of microarrays before and during eltrombopag treatment	60	71	TECHNIQUE
The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling	284	287	TECHNIQUE
The implementation of PGx requires: (i) education of physicians and all other parties involved in the use and benefits of PGx; (ii) prospective studies to demonstrate the benefits of PGx genotyping; (iii) standardization of PGx procedures and development of clinical guidelines; (iv) NGS and microarrays to cover genes with high PGx potential; and (v) new regulations for PGx-related drug development and PGx drug labelling	292	303	TECHNIQUE
To explore the pharmacogenomic markers that affect the platinum-based chemotherapy response in non-small-cell lung carcinoma (NSCLC), we performed a two-cohort of genome-wide association studies (GWAS), including 34 for WES-based and 433 for microarray-based analyses, as well as two independent validation cohorts	242	252	TECHNIQUE
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	120	130	TECHNIQUE
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	132	144	TECHNIQUE
The verification test exhibited good concordance with the results analyzed using the other standard genotyping methods (microarray, TaqMan assay, or another mass spectrometry-based commercial kit)	158	175	TECHNIQUE
In this work, we studied the effect of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in HCC by constructing tissue microarrays (TAMs) from 90 HCC cases and corresponding para-cancerous tissues	131	142	TECHNIQUE
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	59	69	TECHNIQUE
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	71	96	TECHNIQUE
Current targeted PGx testing platforms are mainly based on microarray, polymerase chain reaction, or short-read sequencing	101	122	TECHNIQUE
PK and PGx were evaluated using tandem mass spectrometry and PharmacoScan\u2122 microarray (including <i>CYP3A5*3</i> , <i>*6</i> , and <i>*7</i> )	32	56	TECHNIQUE
PK and PGx were evaluated using tandem mass spectrometry and PharmacoScan\u2122 microarray (including <i>CYP3A5*3</i> , <i>*6</i> , and <i>*7</i> )	62	86	TECHNIQUE
Here, we sequenced the exomes of 25 bladder cancer (BCa) cell lines and compared mutations, copy number alterations (CNAs), gene expression and drug response to BCa patient profiles in The Cancer Genome Atlas (TCGA)	92	115	TECHNIQUE
The miRNA and mRNA expression profiles derived from data for normal and solid tumor tissues in The Cancer Genome Atlas (TCGA) Research Network	14	38	TECHNIQUE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	277	303	TECHNIQUE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	305	315	TECHNIQUE
<b>Materials and Methods:</b> We meticulously sourced BRCA data from renowned repositories such as The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Gene Expression Omnibus (GEO), and the Human Protein Atlas (HPA), leveraging cutting-edge techniques including single-cell RNA-sequencing (scRNA-seq), spatial transcriptomics, and pharmacogenomics	317	340	TECHNIQUE
Applying genome editing techniques like TALENs, we generated precise modifications in the model organism's genome.	9	34	TECHNIQUE
Applying single-cell DNA sequencing, we uncovered genomic heterogeneity within tumor samples, offering insights into cancer evolution.	9	35	TECHNIQUE
Applying synthetic lethality screens, we identified gene interactions that are critical for cancer cell viability, opening new avenues for targeted therapy.	9	36	TECHNIQUE
ChIP-seq was utilized to identify the binding sites of transcription factors across the genome, revealing key regulatory elements involved in gene expression.	0	8	TECHNIQUE
Compared with current genomic testing strategies, largely focused on small number of genes tested individually or targeted panels, whole-genome and transcriptome sequencing (WGTS) provides novel opportunities to identify and report a potentially much larger number of actionable alterations with diagnostic, prognostic, and/or predictive impact.	148	172	TECHNIQUE
Compared with current genomic testing strategies, largely focused on small number of genes tested individually or targeted panels, whole-genome and transcriptome sequencing (WGTS) provides novel opportunities to identify and report a potentially much larger number of actionable alterations with diagnostic, prognostic, and/or predictive impact.	174	178	TECHNIQUE
DNA methylation profile and differential expression of circulating non-coding RNAs (miRNAs and lncRNAs) will be analyzed in FH patients and normolipidemic subjects (control group)	0	15	TECHNIQUE
First, mESCs were differentiated into epiblast stem cells (EpiSCs) to enhance the PP differentiation rate	59	65	TECHNIQUE
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	200	225	TECHNIQUE
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	131	158	TECHNIQUE
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	88	125	TECHNIQUE
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	164	190	TECHNIQUE
Five pharmacogenetic tests are reviewed in detail: the Roche AmpliChip CYP450 Test, the Luminex Tag-It Mutation Detection Kit, the LGC clozapine response test, the PGxPredict: Clozapine test, and the Genomas PhyzioType system.	55	70	TECHNIQUE
For further mechanistic validation, Molecular Dynamics simulations were performed, which revealed that certain mismatches showed elevated root mean square deviation (RMSD) values that can be attributed to conformational instability within the RNA-DNA duplex	36	66	TECHNIQUE
High-throughput molecular profiling of tumors is a fundamental aspect of precision oncology, enabling the identification of genomic alterations	16	35	TECHNIQUE
In the Neocent study, paired tumour whole exome sequence data was available before and after 21 weeks neoadjuvant therapy and bioinformatics approaches were used to compare exome profiles. Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from in these patients. A related study in patients with metastatic breast cancer (MBC) evaluated NGS analysis of specific mutations using the Oncomine breast cancer cfDNA assay and results were compared with detection of SCNA by sWGS	222	226	TECHNIQUE
In the Neocent study, paired tumour whole exome sequence data was available before and after 21 weeks neoadjuvant therapy and bioinformatics approaches were used to compare exome profiles. Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from in these patients. A related study in patients with metastatic breast cancer (MBC) evaluated NGS analysis of specific mutations using the Oncomine breast cancer cfDNA assay and results were compared with detection of SCNA by sWGS	531	535	TECHNIQUE
In the Neocent study, paired tumour whole exome sequence data was available before and after 21 weeks neoadjuvant therapy and bioinformatics approaches were used to compare exome profiles. Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from in these patients. A related study in patients with metastatic breast cancer (MBC) evaluated NGS analysis of specific mutations using the Oncomine breast cancer cfDNA assay and results were compared with detection of SCNA by sWGS	197	220	TECHNIQUE
In this paper, we establish a multi-stage fiber amplifier with pseudo-random binary sequence (PRBS) phase modulation	94	98	TECHNIQUE
In this paper, we establish a multi-stage fiber amplifier with pseudo-random binary sequence (PRBS) phase modulation	63	92	TECHNIQUE
Microarray analysis was performed to assess the gene expression changes in response to environmental stress, offering a high-throughput approach to study transcriptional regulation.	0	19	TECHNIQUE
Microarray analysis was performed using plasma from six patients without anemia and six patients with anemia, and nine miRNAs were differentially expressed.	0	10	TECHNIQUE
miR-1273g-3p, miR-3613-5p and miR-455-3p, identified using microarray, were assessed using qPCR in 20 patients without anemia and 26 patients with anemia.	91	95	TECHNIQUE
Molecular profiling of tumor samples has acquired importance in cancer research, but currently also plays an important role in the clinical management of cancer patients. Rapid identification of genomic aberrations improves diagnosis, prognosis and effective therapy selection.	0	19	TECHNIQUE
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries.	0	26	TECHNIQUE
Next-generation sequencing (NGS) is progressively being used in clinical practice. However, several barriers preclude using this technology for precision oncology in most Latin American countries.	28	31	TECHNIQUE
Next-generation sequencing (NGS) is used increasingly in hereditary cancer patients' (HCP) management	0	26	TECHNIQUE
Next-generation sequencing (NGS) is used increasingly in hereditary cancer patients' (HCP) management	28	31	TECHNIQUE
Next-generation sequencing (NGS) represents a rapid, relatively inexpensive, large-scale DNA sequencing technology with potential relevance as a comprehensive pharmacogenetic genotyping platform to identify genetic variation related to drug therapy.	0	26	TECHNIQUE
Our research applied whole-genome sequencing to identify novel genetic variants linked to Alzheimer's disease, highlighting the potential of comprehensive genomic approaches.	21	44	TECHNIQUE
Sequencing of circulating tumor DNA (ctDNA) in blood samples provided a non-invasive method for monitoring cancer progression.	14	35	TECHNIQUE
Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from these patients.	33	37	TECHNIQUE
Shallow whole genome sequencing (sWGS) was also used to explore somatic copy number alterations (SCNA) in ctDNA from these patients.	8	31	TECHNIQUE
Since the days of Sanger sequencing, next-generation sequencing technologies have significantly evolved to provide increased data output, efficiencies, and applications	37	76	TECHNIQUE
Since the days of Sanger sequencing, next-generation sequencing technologies have significantly evolved to provide increased data output, efficiencies, and applications	18	35	TECHNIQUE
Single-cell multi-omics approaches combined RNA sequencing and epigenetic profiling to provide a comprehensive view of cellular states.	0	23	TECHNIQUE
Single-cell RNA sequencing analysis revealed a larger endocrine population within the PP + MP aggregates, as compared to PPs alone or PPs in Matrigel aggregates	0	26	TECHNIQUE
The application of single-cell ATAC-seq allowed for the profiling of chromatin accessibility at a single-cell level, providing insights into gene regulatory networks.	19	39	TECHNIQUE
"The development of next-generation-sequencing (NGS) techniques, commercially available since 2006, allowed for a cost- and time-effective sequencing of tumor DNA, leading to a ""genomic era""of cancer research and treatment."	19	45	TECHNIQUE
The last decade has seen rapid progress in the use of genomic tests, including gene panels, whole-exome sequencing , and whole-genome sequencing, in research and clinical cancer	92	114	TECHNIQUE
The NeuroIDgenetix® test uses a genetic variant panel of ten genes, along with concomitant medications, to make medication management recommendations based on gene-drug and drug-drug interactions for over 40 medications used in the treatment of depression and anxiety	4	18	TECHNIQUE
The stimulated Brillouin gain spectra of the main amplifier with both the unmodulated and pseudo-random binary sequence phase modulated configuration are measured (with corresponding output power)	90	119	TECHNIQUE
The stimulated Brillouin gain spectra of the main amplifier with both the unmodulated and pseudo-random binary sequence phase modulated configuration are measured (with corresponding output power)	4	37	TECHNIQUE
The stimulated Brillouin scattering reflectivity is below 0.01% at 3.05 kW at 13.7 GHz, which indicates that stimulated Brillouin scattering can be suppressed efficiently at this power and linewidth level	4	48	TECHNIQUE
The study employed amplicon sequencing to analyze the diversity of microbial communities in environmental samples.	19	38	TECHNIQUE
The therapeutic application of CRISPR-Cas9 is limited due to its off-target activity	31	42	TECHNIQUE
The utilization of CRISPR activation (CRISPRa) enabled the upregulation of target gene expression, facilitating functional genomic studies.	19	25	TECHNIQUE
The utilization of CRISPR activation (CRISPRa) enabled the upregulation of target gene expression, facilitating functional genomic studies.	38	44	TECHNIQUE
This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels.	52	78	TECHNIQUE
This can be attributed mainly to the development of next-generation sequencing (NGS) methods, especially targeted DNA panels.	80	83	TECHNIQUE
This review provides an overview of these technologies as two paradigms: short-read, or “second-generation,” technologies, and long-read, or “third-generation,” technologies	73	83	TECHNIQUE
This study employs CRISPR-Cas9 to investigate the functional roles of candidate genes in cancer cells, demonstrating the utility of gene editing technologies.	19	25	TECHNIQUE
This study provides clinicians and researchers with an informed choice between current commercially available targeted sequencing panels and exome sequencing panels in the context of pan-cancer pharmacogenetics.	141	157	TECHNIQUE
Through exome sequencing, we focused on the protein-coding regions of the genome to identify deleterious mutations associated with rare genetic disorders.	8	24	TECHNIQUE
Using clustered regularly interspaced short palindromic repeats interference (CRISPRi), we achieved targeted gene repression in mammalian cells.	78	85	TECHNIQUE
Using high-throughput CRISPR screens, we identified essential genes for cancer cell survival, highlighting potential therapeutic targets.	22	28	TECHNIQUE
Using methylation sequencing, we mapped the DNA methylation landscape in cancer tissues, uncovering epigenetic modifications linked to tumorigenesis.	6	28	TECHNIQUE
Utilizing digital droplet PCR, we achieved highly sensitive quantification of rare genetic mutations in liquid biopsy samples.	10	29	TECHNIQUE
Utilizing RNA-seq, we quantified the differential gene expression profiles of treated versus untreated cells, providing insights into the molecular mechanisms of drug response.	10	17	TECHNIQUE
Utilizing whole-exome sequencing, we pinpointed mutations in the coding regions that are responsible for monogenic disorders, aiding in the diagnosis and treatment.	10	32	TECHNIQUE
We demonstrated that INTERSTELLAR successfully extracted information from a range of short- and long-read sequencing reads and translated those of single-cell (sc)RNA-seq, scATAC-seq, and spatial transcriptomics to be analyzed by different software tools that have been developed for conceptually the same types of experiments	172	182	TECHNIQUE
We demonstrated that INTERSTELLAR successfully extracted information from a range of short- and long-read sequencing reads and translated those of single-cell (sc)RNA-seq, scATAC-seq, and spatial transcriptomics to be analyzed by different software tools that have been developed for conceptually the same types of experiments	196	211	TECHNIQUE
We employed polymerase chain reaction (PCR) to amplify specific DNA fragments, facilitating the detection of pathogen presence in clinical samples.	12	37	TECHNIQUE
We further conducted RNA sequencing analysis to clarify the potential underlying mechanism of the anti-depressive effect of 1-MT in HFD-induced depressive mice	21	44	TECHNIQUE
We performed integrative genomic analysis combining whole-genome sequencing and transcriptomics to uncover regulatory mechanisms in disease.	13	41	TECHNIQUE
We used single-cell ATAC-seq to profile chromatin accessibility in individual cells, shedding light on gene regulatory mechanisms.	8	28	TECHNIQUE
We utilized bioinformatics tools to analyze the high-throughput sequencing data, providing insights into the genetic architecture of the population.	12	32	TECHNIQUE
With the availability of whole-genome single-nucleotide polymorphism (SNP) maps, it will soon be possible to create an SNP profile for patients who experience adverse events (AEs) or who respond clinically to the medicine (efficacy).	25	37	TECHNIQUE
Recent advances in next-generation sequencing (NGS) have resulted in the identification of tens of thousands of rare pharmacogenetic variations with unknown functional effects.	47	50	TECHNIQUE
Recent advances in next-generation sequencing (NGS) have resulted in the identification of tens of thousands of rare pharmacogenetic variations with unknown functional effects.	19	45	TECHNIQUE
Genome sequencing is enabling precision medicine—tailoring treatment to the unique constellation of variants in an individual’s genome.	0	17	TECHNIQUE
St Catherine Specialty Hospital in Zagreb/Zabok, Croatia has implemented a personalized patient approach using the RightMed® Comprehensive PGx panel of 25 pharmacogenes plus Facor V Leiden, Factor II and MTHFR genes, which is interpreted by a special counseling team to offer the best quality of care.	139	148	TECHNIQUE
This work advances the use of nanopore sequencing in clinical PGx settings.	30	49	TECHNIQUE
Differing from the widely used PCR, the SmartAmp reaction is an isothermal DNA amplification, where the initial step of copying a target sequence from the template DNA is critically important	40	57	TECHNIQUE 
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	89	100	TECHNIQUE 
Multiple technologies exist to determine these variants, like the AmpliChip CYP450 test, Taqman qPCR, or Second-Generation Sequencing, however, sequence homology between cytochrome P450 genes and pseudogene CYP2D7 impairs reliable CYP2D6 genotyping, and variant phasing cannot accurately be determined using these assays	105	133	TECHNIQUE 
SULT1A1 mRNA and protein levels were quantified using microarray data and Western blot analysis, respectively	74	86	TECHNIQUE
